document incorporate reference document proxy statement annual meeting iii shareholder hold file securities exchange commission day close fiscal year cover reporttable content item business item risk factor cautionary factor affect future result item b unresolved staff comment item property item legal proceeding executive officer registrant item reserve ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum financial statement note consolidated financial statement report independent register public accounting firm b supplementary datum item change disagreement accountant account financial disclosure item control procedure management report item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule signature consent independent register public accounting firm independent auditor consent ex ex ex ex ex ex ex ex ex ex ex ex ex ex ex ex instance document ex schema document ex calculation linkbase document ex label linkbase document ex presentation linkbase document ex definition linkbase documenttable content item business november merck co inc old merck scheringplough corporation scheringplough complete previouslyannounce merger merger merger scheringplough acquire share old merck whollyowne subsidiary scheringplough rename merck sharp dohme corp scheringplough continue survive public company rename merck co inc new merck company accounting purpose merger treat acquisition old merck consider accounting acquirer accordingly accompany financial statement reflect old merck standalone operation exist prior completion merger result scheringplough business include new merck financial statement period subsequent completion merger new merck financial result reflect year legacy scheringplough operation reference report accompany financial statement merck period prior merger refer old merck period completion merger new merck company global health care company deliver innovative health solution medicine vaccine biologic therapie consumer animal product market directly joint venture company operation principally manage product basis comprise reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventative pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company professional representative communicate effectiveness safety value pharmaceutical vaccine product health care professional private practice group practice manage care organization company animal health operation discover develop manufacture market animal health product include vaccine company professional representative communicate safety value company animal health product veterinarian distributor animal producer additionally company consumer health care operation develop manufacture market overthecounter otc foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet united states canada financial information information pharmaceutical segment item management discussion analysis financial condition result operation item financial statement supplementary datum product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note cozaar hyzaar register trademark ei du pont de nemours company wilmington de trademarks service mark respective owner overview discuss merger complete november merger old merck shareholder receive share common stock new merck share old merck stock own scheringplough shareholder receive share common stock new merck cash share scheringplough stock own consideration merger value billion aggregate scheringplough old merck longterm partner merckscheringplough cholesterol partnership msp partnership cash portion consideration fund table content combination exist cash include proceed sale old merck interest merial limited sale redemption investment issuance debt combine company research development pipeline great depth breadth promising drug candidate significantly broad portfolio medicine expand presence key international market particularly highgrowth emerge market company anticipate efficiency gain merger allow invest promise pipeline candidate strategic external research development opportunity combination increase company pipeline early mid late stage product candidate include significant increase number potential medicine company phase iii development candidate additionally number candidate currently review united states internationally merger expect accelerate expansion therapeutic area old merck focus recent year addition scheringplough establish presence expertise oncology neuroscience novel biologics merger expect broaden company commercial portfolio lead franchise key therapeutic area include cardiovascular respiratory oncology neuroscience infectious disease immunology women health additionally combine company expect realize potential benefit animal health business portfolio consumer health brand include claritin coppertone dr scholl legacy scheringplough product expect long period marketing exclusivity leverage combine company expand product offering company expect benefit additional revenue growth opportunity example combine company expect expand opportunity lifecycle management introduction potential new combination formulation exist product legacy company company expand global presence geographically diverse revenue base scheringplough significant international presence accelerate old merck international growth effort revenue increase drive largely incremental sale result inclusion postmerger result legacy scheringplough product remicade infliximab treatment inflammatory disease temodar temozolomide treatment certain type brain tumor nasonex mometasone furoate monohydrate nasal spray inhale nasal corticosteroid treatment nasal allergy symptom pegintron peginterferon alphab treat chronic hepatitis c recognition revenue sales zetia ezetimibe vytorin ezetimibesimvastatin cholesterol modifying medicine prior merger sale zetia vytorin recognize msp partnership result old merck interest msp partnership record equity income affiliate result merger msp partnership whollyowne company revenue product postmerger period reflect sale additionally company recognize sale postmerger period legacy scheringplough animal health consumer health care product contribute sale increase growth januvia sitagliptin phosphate janumet sitagliptin phosphate metformin hydrochloride treatment type diabete isentress raltegravir antiretroviral therapy treatment hiv infection singulair montelukast sodium medicine indicate chronic treatment asthma relief symptom allergic rhinitis varivax varicella virus vaccine live vaccine help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease increase partially offset low sale fosamax alendronate sodium treatment prevention osteoporosis fosamax fosamax plus alendronate sodiumcholecalciferol lose market exclusivity substantially formulation united states february april respectively revenue negatively affect low sale gardasil human papillomavirus quadrivalent type vaccine recombinant vaccine help prevent cervical vulvar vaginal cancer precancerous dysplastic lesion genital wart cause human papillomavirus hpv type cosopt dorzolamide hydrochloride timolol maleate ophthalmic solutiontrusopt dorzolamide hydrochloride ophthalmic solution ophthalmic product lose market exclusivity october low revenue company relationship astrazeneca lp azlp product experience decline include rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant table content child zocor simvastatin company statin modifying cholesterol primaxin imipenem cilastatin sodium treatment bacterial infection result merger company expect achieve substantial cost saving area include consolidation sale marketing research development application company lean manufacturing source strategy expand operation integration msp partnership february company announce phase new global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough business merger restructuring program intend optimize cost structure combine company phase merger restructuring program end company expect reduce total workforce approximately area company worldwide company plan eliminate vacant position phase program workforce reduction primarily come elimination duplicative position sale administrative headquarters organization consolidation certain manufacturing facility research development operation company continue hire new employee strategic growth area business period certain action ongoing reevaluation manufacturing research development facility worldwide complete include later phase merger restructuring program connection phase merger restructuring program separation costs company exist severance program worldwide record fourth quarter extent cost probable reasonably estimable company record pretax restructuring cost billion primarily employee separation cost relate merger restructuring program fourth quarter phase merger restructuring program expect complete end total pretax cost estimate billion billion company estimate approximately cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest company expect phase merger restructuring program yield annual saving approximately billion billion anticipate saving relate phase merger restructuring program portion estimate billion incremental annual saving originally disclose merger announce company expect additional saving generate subsequent phase merger restructuring program announce later year non restructure relate activity procurement saving initiative cost saving expect come area company pharmaceutical business addition previously announce ongoing cost reduction initiative legacy company result merger company obtain control interest msp partnership own company accordingly company require remeasure merck previously hold equity interest msp partnership mergerdate fair value recognize result gain earning result company record gain billion recognize income expense net old merck sell interest merial limited merial sanofiaventis billion cash sale result recognition billion gain reflect income expense net note consolidated financial statement item financial statement supplementary data information earning common share ep assume dilution reflect net impact result gain relate msp partnership sale merial partially offset increase expense amortization purchase accounting adjustment restructure mergerrelate cost eps affect dilutive impact share issue merger table content product sale sale company product follow million pharmaceutical bone respiratory immunology dermatology singulair fosamax propecia remicade arcoxia nasonex clarinex asmanex cardiovascular vytorin zetia integrilin diabete obesity januvia janumet infectious disease isentress primaxin cancidas invanz crixivanstocrin pegintron avelox rebetol mature brand cozaarhyzaar zocor vasotecvaseretic proscar claritin rx proventil neuroscience ophthalmology maxalt cosopttrusopt remeron subutexsuboxone oncology emend temodar caelyx intron vaccines proquadmmr iivarivax gardasil rotateq pneumovax zostavax womens health endocrine follistimpuregon nuvare pharmaceutical segment revenue total segment revenue sale legacy scheringplough product reflect result postmerger period december sales msp partnership product zetia vytorin represent sale postmerger period december prior merger sale zetia vytorin primarily recognize msp partnership result old merck interest msp partnership record equity income affiliate sale zetia vytorin reflect old merck sale product latin america msp partnership amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily include sale human pharmaceutical product include product franchise list separately reflect nonreportable segment include animal health consumer health care revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively revenue primarily comprise miscellaneous corporate revenue party manufacturing sale sale relate divested product business supply sale include segment result table content pharmaceutical company pharmaceutical product include therapeutic preventive agent generally sell prescription treatment human disorder bone respiratory immunology dermatology singulair remicade fosamax nasonex propecia finasteride product treatment male pattern hair loss clarinex desloratadine nonsedate antihistamine treatment allergic rhinitis arcoxia etoricoxib treatment arthritis pain asmanex twisthaler mometasone furoate inhalation powder oral drypowder corticosteroid inhaler firstline maintenance treatment asthma cardiovascular disease zetia market ezetrol outside united states vytorin market inegy outside united states integrilin eptifibatide injection platelet receptor gp iibiiia inhibitor treatment patient acute coronary syndrome undergo percutaneous coronary intervention united states prevention early myocardial infarction patient acute coronary syndrome country diabete obesity januvia janumet infectious disease isentress primaxin cancidas caspofungin acetate antifungal product pegintron invanz ertapenem sodium treatment certain infection avelox moxifloxacin company market united states broadspectrum fluoroquinolone antibiotic certain respiratory skin infection crixivan indinavir sulfate stocrin efavirenz antiretroviral therapy treatment hiv infection rebetol ribavirin usp capsule oral solution use combination pegintron intron interferon alphab recombinant treat chronic hepatitis c mature brand cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate vaseretic enalapril maleatehydrochlorothiazide company significant hypertension andor heart failure product zocor proscar finasteride urology product treatment symptomatic benign prostate enlargement claritin rx proventil hfa albuterol inhalation aerosol relief bronchospasm patient year old neuroscience ophthalmology maxalt rizatriptan benzoate acute migraine product cosopt trusopt merck largestselle ophthalmological product remeron mirtazapine antidepressant subutex sublingual tablet formulation buprenorphine suboxone sublingual tablet combination buprenorphine naloxone market company certain country outside united states treatment opiate addiction oncology temodartemodal emend aprepitant prevention chemotherapyinduce postoperative nausea vomit caelyx pegylate liposomal doxorubicin hydrochloride longcirculate formulation cancer drug doxorubicin market company outside united states treatment certain ovarian cancer kaposis sarcoma metastatic breast cancer intron injection market chronic hepatitis b c numerous anticancer indication worldwide include adjuvant therapy malignant melanoma vaccine mmr ii measles mumps rubella virus vaccine live vaccine measle mump rubella proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine measle mump rubella varicella varivax gardasil rotateq pneumovax zostavax zoster vaccine live women health follistimpuregon follitropin beta injection fertility treatment nuvare etonogestrelethinyl estradiol vaginal contraceptive ring animal health animal health segment discover develop manufacture market animal health product include vaccine principal market product segment include livestock product nuflor antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine bovine swine antiinflammatory estrumate treatment fertility table content disorder cattle regumatematrix fertility management swine horse resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zilmax revalor improve production efficiency beef cattle mpac swine pneumonia vaccine porcilis vaccine line infectious disease swine poultry product nobilisinnovax vaccine line poultry paracox coccivac coccidiosis vaccine companion animal product nobivaccontinuum vaccine line flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabete mellitus treatment dog cat panacursafeguard broadspectrum anthelmintic dewormer use animal scaliborexspot protect bite flea tick mosquitoe sandfly aquaculture product slice parasiticide sea lice salmon aquavacnorvax vaccine bacterial viral disease fish compact pd vaccine salmon aquaflor antibiotic farmraised fish consumer health care consumer health care segment develop manufacture market otc foot care sun care product principal product segment include otc product claritin nondrowsy antihistamine miralax treatment occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure afrin nasal decongestant spray correctol laxative tablet foot care dr scholl foot care product lotrimin topical antifungal product tinactin topical antifungal product foot sneaker odorwetness product sun care coppertone sun care lotion spray dry oil lipprotection product sunless tanning product solarcaine sunburn relief product discussion sale company product item management discussion analysis financial condition result operation product approval july food drug administration fda approve expand indication isentress broaden indication include use treatment adult patient start hiv therapy time treatmentnave treatmentexperience adult patient august fda approve saphris asenapine sublingual tablet acute treatment schizophrenia adult acute treatment manic mixed episode associate bipolar disorder psychotic feature adult saphris firstline treatment psychotropic drug receive initial approval indication simultaneously october fda approve gardasil use boy man year age prevention genital wart cause hpv type make gardasil hpv vaccine approve use male gardasil hpv vaccine protect hpv type cause approximately percent genital wart case addition october old merck announce center disease control prevention advisory committee immunization practice acip support permissive use gardasil boy young man age mean gardasil give male age reduce likelihood acquire genital wart discretion patient health care provider acip vote recommend funding provide use gardasil male vaccine children program october european commission ec approve simponi golimumab oncemonthly subcutaneous treatment certain inflammatory disease december fda approve zegerid otc omeprazole mgsodium bicarbonate mg capsule otc treatment frequent heartburn table content january merck receive ec approval elonva corifollitropin alpha injection new fertility treatment elonva indicate control ovarian stimulation combination gnrh antagonist development multiple follicle woman participate assist reproductive technology program joint ventures merckscheringplough partnership old merck scheringplough collectively legacy company enter agreement create equallyowne partnership develop market united states new prescription medicine cholesterol management december cholesterolmanagement partnership expand include country world exclude japan october zetia new class cholesterollowere agent launch united states july vytorin combination product contain active ingredient zetia zocor approve united states previously disclose january legacy company announce result effect combination ezetimibe highdose simvastatin vs simvastatin atherosclerotic process patient heterozygous familial hypercholesterolemia enhance clinical trial image trial patient heterozygous familial hypercholesterolemia rare genetic condition cause high level ldl bad cholesterol greatly increase risk premature coronary artery disease previously report despite fact ezetimibesimvastatin mg vytorin significantly lower ldl bad cholesterol simvastatin mg significant difference treatment ezetimibesimvastatin simvastatin prespecifie primary endpoint change thickness carotid artery wall year measure ultrasound improve reduction highrisk subject present acute coronary syndrome improveit trial underway design provide cardiovascular outcome data ezetimibesimvastatin patient acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin establish january fda announce complete review final clinical study report enhance fda state result enhance change position elevate ldl cholesterol risk factor cardiovascular disease lower ldl cholesterol reduce risk cardiovascular disease discussion concern litigation arise enhance study item risk factor item legal proceeding july efficacy safety result simvastatin ezetimibe aortic stenosis sea study announced sea design evaluate intensive lipid lower vytorin mg reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patient asymptomatic mild moderate aortic stenosis indication statin therapy vytorin fail meet primary endpoint reduction major cardiovascular event study patient group take vytorin mg high incidence cancer group take placebo nonsignificant increase death cancer patient group take vytorin versus take placebo cancer cancer death distribute major organ system company believe cancer finding sea likely anomaly take light available datum support association vytorin august fda announce investigate result sea trial december fda announce complete review datum sea trial review interim datum study heart renal protection sharp improveit trial base currently available information fda indicate believe unlikely vytorin zetia increase risk cancerrelate death sharp trial expect complete improveit trial schedule completion improveit trial blind interim efficacy analysis conduct datum safety monitoring board trial approximately endpoint accrue interim analysis expect conduct company commit work regulatory agency evaluate available data interpretation datum company believe change clinical use vytorin warrant table content astrazeneca lp old merck enter agreement astra ab astra develop market astra product united states old merck astra form equally own joint venture develop market astra new prescription medicine united states include prilosec omeprazole class medication know proton pump inhibitor slow production acid cell stomach line old merck astra restructure joint venture old merck acquire astras interest joint venture rename kbi inc kbi contribute kbis operating asset new limited partnership name astra pharmaceutical lp partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca lp azlp astras merger zeneca group plc astrazeneca merger exclusive distributor product kbi retain right company earn certain partnership return ongoing revenue base sale current future kbi product partnership return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent company share undistribute partnership azlp generally accept accounting principle gaap earning astrazeneca merger trigger partial redemption march old merck interest certain azlp product right redemption old merck receive billion azlp base primarily multiple old merck average annual variable return derive sale astra usa inc product year prior redemption limited partner share agree value old merck record billion pretax gain partial redemption partial redemption old merck interest product right result change old merck limited partnership interest describe item management discussion analysis financial condition result operation certain adjustment old merck record aggregate pretax gain billion conjunction restructure astra purchase option asset option payment million record deferred income buy old merck interest kbi product exclude gastrointestinal medicine nexium esomeprazole prilosec nonppi products astrazeneca exercise asset option half exercise price million represent net present value march project future pretax revenue receive company nonppi product appraise value february astrazeneca notify company exercise asset option old merck right require astra purchase interest appraise value february old merck advise astrazeneca exercise asset option million remain defer recognize asset option consummate addition old merck grant astra option share option buy old merck common stock interest kbi old merck interest nexium prilosec exercisable year astra exercise asset option astra exercise share option combine annual sale product fall minimum provide case long astrazenecas asset option exercise exercise price share option base net present value estimate future net sale nexium prilosec determine time exercise subject certain trueup mechanism sanofi pasteur msd old merck pasteur mrieux connaught sanofi pasteur sa form joint venture market human vaccine europe collaborate development combination vaccine distribution exist eu european free trade association old merck sanofi pasteur contribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintain presence directly affiliate branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributor rest territory table content johnson johnsonomerck consumer pharmaceutical company old merck form joint venture johnson johnson develop market broad range nonprescription medicine consumer own joint venture include canada significant joint venture product pepcid ac famotidine otc form old merck ulcer medication pepcid famotidine pepcid complete otc product combine company ulcer medication antacid calcium carbonate magnesium hydroxide merial limited old merck rhnepoulenc sa sanofiaventis combine respective animal health business form merial limited merial fully integrate animal health company standalone joint venture own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie september old merck sell interest merial sanofiaventis billion cash sale result recognition billion gain reflect income expense net connection sale merial old merck sanofiaventis scheringplough sign option agreement term option agreement follow closing merger sanofiaventis option require company combine intervetscheringplough animal health business merial form animal health joint venture own equally company sanofiaventis option agreement value merial fix billion minimum total value receive company affiliate contribute intervetscheringplough combine entity billion subject customary transaction adjustment consist floor valuation intervetscheringplough fix minimum billion subject potential upward revision base valuation exercise party additional payment sanofiaventis million base valuation exercise intervetscheringplough customary transaction adjustment merial intervetscheringplough combine payment required pay party joint venture equally own company sanofiaventis payment trueup value contribution equal formation new animal health joint venture sanofiaventis subject customary closing condition include antitrust review united states europe prior closing merger agreement provide old merck certain right terminate option fee million recognition termination fee defer fourth quarter condition trigger payment lapse license subsidiary scheringplough enter licensing agreement centocor inc johnson johnson company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company exclusive marketing right product outside united states japan certain asian market december scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition scheringplough centocor agree share certain development cost relate simponis autoinjector delivery system october ec approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille syringe result company marketing right product extend year commercial sale simponi eu follow receipt pricing reimbursement approval eu operating expense subject certain adjustment company entitle receive approximate share profit company distribution company market territory begin share profit change time share profit product share profit remain fixed remainder term company independently develop market simponi crohns disease indication territory option centocor participate centocor institute arbitration proceeding terminate agreement company right distribute product item risk factor item legal proceeding table content competition market company conduct business pharmaceutical industry highly competitive highly regulate company operation affect technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor new information clinical trial market product postmarkete surveillance generic competition company product mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect certain product competitive pressure intensify pressure industry grow effect operation competitive factor patent dispute predict pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively longstanding emphasis research development company position compete search technological innovation additional resource meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance joint venture license refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth company product therapeutic category global effort healthcare cost containment continue exert pressure product pricing access address cost containment pressure company make continue effort demonstrate medicine provide value patient pay health care addition pricing flexibility company product portfolio encourage grow use medicine mitigate effect increase cost pressure individual medicine outside united states difficult government budgetary environment company work payer encourage allocation scarce resource optimize healthcare outcome limit potentially detrimental effect government policy sale growth access innovative medicine vaccine support discovery development innovative product benefit patient company work government emerge market eastern europe latin america asia encourage increase investment health improve citizen access medicine addition certain country eu recognize economic importance researchbase pharmaceutical industry value innovative medicine society work industry representative improve competitive climate variety mean include market deregulation company anticipate worldwide trend cost containment continue result ongoing pressure healthcare budgets united states major healthcare reform introduce pass house congress final revise bill unify version consider adopt law impact action budget pressure government united states nations predict time company continues successfully launch new product contribute health care debate monitor reform new product policy strategy enable maintain strong position change economic environment predict outcome legislative regulatory advocacy initiative company believe position respond evolve health care environment market force access medicine company commit improve access medicine enhance quality life people world cite example african comprehensive hivaid partnership table content botswana partnership government botswana bill melinda gates foundation merck company foundationmerck co inc support botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support catalyze access hiv medicine develop country company make profit sale current hivaids medicine world poor country hard hit pandemic offer hivaids medicine significantly reduce price mediumincome country february old merck announce reduce price stocrin develop country world hard hit pandemic action company work independently partner public private sector address critical barrier access medicine develop world address barrier require investment education training health infrastructure improve capacity achieve increase international assistance sustainable financing addition old merck commit provide rotateq global alliance vaccine immunizationeligible country price profit old merck wellcome trust establish msd wellcome trust hilleman laboratory joint venture india develop vaccine million people poor area world government regulation pharmaceutical industry subject regulation regional country state local agency world particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time resource necessary develop new product bring market united states food drug administration modernization act fda modernization act pass culmination comprehensive legislative reform effort design streamline regulatory procedure fda improve regulation drug medical device food legislation principally design ensure timely availability safe effective drug biologic expedite premarket review process new product key provision legislation reauthorization prescription drug user fee act permit continue collection user fee prescription drug manufacturer augment fda resource earmark review human drug application help provide resource necessary ensure prompt approval safe effective new drug united states government expand access senior citizen prescription drug coverage enact medicare prescription drug improvement modernization act sign law december prescription drug coverage begin january legislation support company goal improve access medicine expand insurance coverage preserve marketbase incentive pharmaceutical innovation time legislation help control cost prescription drug cost competitive pressure encourage appropriate use medicine mention united states major healthcare reform introduce pass house congress final revise bill unify version consider adopt law congress consider consider proposal increase government role pharmaceutical pricing medicare program proposal include remove current legal prohibition secretary health human services intervene price negotiation medicare drug benefit program plan pharmaceutical company include mandate payment rebate pharmaceutical utilization medicare drug benefit plan addition congress consider proposal allow certain condition importation medicine country year pharmaceutical industry federal state oversight approval process new drug drug safety advertising promotion drug purchasing reimbursement program formulary company believe continue able conduct operation include introduction new drug market regulatory environment company continue work private public payor slow increase healthcare spending federal state government pursue method directly reduce cost drug vaccine table content pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity disproportionate share hospital hospital meet certain criterion provide minimum discount define nonfederal average manufacturer price purchase certain component federal government department veterans affairs department defense initiative state seek rebate minimum require medicaid legislation case patient eligible medicaid federal vaccine child entitlement program center disease control prevention cdc fund purchase recommend pediatric vaccine public sector price immunization medicaideligible uninsured native american certain underinsured child old merck award cdc contract supply pediatric vaccine vaccine child program outside united states company encounter similar regulatory legislative issue country business primary thrust governmental inquiry action determine drug safety effectiveness mechanism control price reimbursement prescription drug profit prescription drug company eu adopt directive concern classification label advertise wholesale distribution approval marketing medicinal product human use company policy procedure consistent substance directive consequently believe material effect company business january ec launch sector inquiry pharmaceutical industry rule eu competition law inquiry old merck office germany inspect authority begin january preliminary report ec issue november follow public consultation period final report issue july final report confirm decline number novel medicine reach market instance delay market entry generic medicine discuss industry practice contribute phenomena ec issue inquiry respect subject investigation ec allege company subsidiary engage unlawful practice company subject jurisdiction regulatory agency subject potential administrative action action include seizure product civil criminal sanction certain circumstance company deem advisable initiate product recall company believe able compete effectively environment privacy datum protection company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue potential affect directly company business include recently enact law regulation united states internationally require notification individual government authority security breach involve certain category personal information distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice manage care organization companys professional representative communicate safety value company animal health product veterinarian distributor animal producer company otc foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet table content raw material raw material supply generally available multiple source purchase worldwide normally available quantity adequate meet need company business patent trademark license patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product se pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage fda modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant exclusivity provision reauthorize prescription drug user fee act pass september current patent law provide additional patent term patent term restoration period patent product regulatory review fda table content patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection include patent term restoration pediatric exclusivity major market product product year expiration cozaar hyzaar crixivan compound formulation maxalt compound singulair cancidas compound composition propecia formulationuse asmanex use formulation avelox integrilin compound useformulation nasonex useformulationformulation temodar emend follistimpuregon pegintron conjugate mature ifnalpha zolinza invanz compound composition zostavax zetiavytorin nuvare delivery system noxafil rotateq clarinex formulation comvax method makingvector intron recombivax method makingvector saphrissycrest useformulation subject pende patent term restoration application januviajanumet compound salt isentress gardasil method makinguseproduct process compound patent note agreement dr reddys laboratory launch generic january january court hold patent temodar unenforceable decision appeal item legal proceeding patent litigation virtue litigation settlement generic give right enter market expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product ii patent relate use product iii patent relate novel composition formulation iv united states certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country table content patent provide market exclusivity cozaar hyzaar expire april addition patent cozaar expire number major european market march hyzaar lose patent protection major european market february company expect sale product decline rapidly expiration patent particularly unite states expect multiple source generic product time patent expiry addition patent provide market exclusivity singulair expire august company expect year follow patent expiration lose substantially sale singulair decline come year follow patent expiration patent singulair expire number major european market august company expect sale singulair market decline significantly addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset general increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty information respect company patent item risk factor item legal proceeding patent litigation worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty receive patent knowhow license right amount million merck pay royalty amount billion patent knowhow license hold research development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity research development expense include restructuring cost billion billion billion company maintain ongoing commitment research broad range therapeutic area clinical development support new product company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource disease area unmet medical need scientific opportunity commercial opportunity merck manage research development portfolio diverse approach discovery development balance investment appropriately novel innovative target potential major impact human health develop bestinclass approach deliver maximum value new medicine vaccine new indication new formulation important component company sciencebase diversification base expand company portfolio modality include small molecule vaccine biologic peptide rnai merck move diversify portfolio create new division merck bioventure potential harness market opportunity present biological medicine patent expiry deliver high quality followon biologic product enhance access patient worldwide company continue pursue appropriate external licensing opportunity integration plan research development focus integrate research operation legacy company include provide effective transition employee realize project merger synergy form cost saving revenue growth opportunity maintain momentum company latestage pipeline merck continue implement new model basic research global operating strategy legacy merck research laboratory site new model align franchise function align resource disease area priority balance capacity discovery phase allow company act program high probability success additionally table content disease area priority company strategy design expand access worldwide external science incorporate external research key component company early discovery pipeline order translate basic research productivity latestage clinical success company clinical pipeline include candidate multiple disease area include anemia atherosclerosis cancer diabetes heart disease hypertension infectious disease inflammatoryautoimmune disease migraine neurodegenerative disease ophthalmic osteoporosis psychiatric disease respiratory disease womens health company supplement internal research aggressive licensing external alliance strategy focus entire spectrum collaboration early research latestage compound new technology development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed united states record datum preclinical clinical experience include new drug application nda drug biologic license application bla vaccine biologic submit fda require approval company scientist discover new small molecule compound believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase ii study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness datum phase ii trial satisfactory company commence largescale phase iii trial confirm compound efficacy safety completion trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate safety tolerability immunogenicity vaccine candidate phase ii study doserange study finally phase iii trial provide necessary datum effectiveness safety successful company submit regulatory filing appropriate regulatory agency stage propose manufacturing facility undergo preapproval inspection production vaccine progress examine detail united states fda review process begin complete nda submit receive fda pursuant prescription drug user fee act fda review period target nda supplemental nda month priority review month standard review day receipt nda fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review review timeline define fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information day extension review period communicate company fda act application issue approval letter complete response letter research development update connection merger company assess pipeline identify promise highpotential compound development company complete prioritization clinical development table content program company continue work prioritization value add program relate currently market product preclinicaldiscovery program company anticipate prioritization process complete half connection process company recognize noncash impairment charge cancellation certain legacy scheringplough pipeline program measure fair value capitalize connection merger noncash impairment charge anticipate exclude company nongaap earning material company future gaap earning company currently number candidate regulatory review united states internationally additionally company drug candidate phase iii development mk vernakalant iv investigational candidate treatment atrial fibrillation currently undergo regulatory review eu april old merck cardiome pharma corp cardiome announce collaboration license agreement development commercialization vernakalant provide merck exclusive right outside united states canada mexico intravenous formulation vernakalant vernakalent oral currently phase ii development merck exclusive global right oral formulation vernakalent maintenance normal heart rhythm patient atrial fibrillation sch mff combination previously approve drug treatment asthma mometasone asmanex formoterol foradil company aim create new option patient bring key treatment july scheringplough announce file nda fda mff mff currently regulatory review eu sch nomace oral contraceptive combine selective progestin estradiol estrogen woman produce naturally drug currently regulatory review eu phase iii development market sch saphris asenapine central nervous system compound bipolar disorder schizophrenia currently undergo regulatory review eu fda approve saphris august sch bridion sugammadex medication design rapidly reverse effect certain muscle relaxant general anesthesia ensure patient remain immobile surgical procedure differ reversal agent administer muscle relaxant begins wear bridion receive regulatory approval eu australia new zealand japan regulatory review market include united states prior merger scheringplough receive complete response letter fda bridion follow communication fda company assess agencys feedback order determine new timetable response sch boceprevir hepatitis c protease inhibitor currently development boceprevir fully enrol phase iii program company expect conclude mid company expect submit nda fda boceprevir end treatmentexperience treatmentnave patient hepatitis c mk ridaforolimus novel mtor mammalian target rapamycin inhibitor evaluate treatment cancer drug candidate jointly develop commercialize ariad pharmaceuticals inc agreement enter phase iii study succeed patient metastatic softtissue bone sarcoma underway company continue anticipate file nda ridaforolimus fda subject review result plan interim analysis succeed sch allergy immunotherapy sublingual tablet ait grass pollen allergy develop company november sch meet primary endpoint phase iii study adult subject united states history grass pollen induce rhinoconjunctivitis asthma investigational grass ait treatment design work induce protective immune response grass pollen allergy provide sustained prevention allergy symptom treat symptom underlie cause disease sch ait ragweed allergy phase iii development market table content sch vorapaxar thrombin receptor antagonist antiplatelet protease activate receptor inhibitor study prevention treatment thrombosis november merck announce completion patient enrollment patient tra ptimi clinical trial phase iii randomized doubleblind placebocontrolle multinational study trial assess ability sch prevent major cardiovascular event add current antiplatelet regimen aspirin aspirin plus adp inhibitor patient previously experience heart attack stroke peripheral arterial disease sch study treatment patient acute coronary syndrome ongoing phase iii thrombin receptor antagonist clinical event reduction acute coronary syndrome trial lead duke clinical research institute company anticipate file nda vorapaxar fda mk tafluprost preservative free synthetic analogue prostaglandin f reduction elevate intraocular pressure appropriate patient primary openangle glaucoma ocular hypertension april old merck santen announce worldwide licensing agreement tafluprost previously disclose old merck submit file nda fda mkc ezetimibe combine atorvastatin investigational medication treatment dyslipidemia fda refuse file application fda identify additional manufacturing stability datum need company assess fda response anticipate file mkc candidate currently phase iii clinical development combine januvia pioglitazone type diabetes therapy company continue anticipate file nda mkc fda mk odanacatib oral onceweekly investigational treatment osteoporosis osteoporosis disease reduce bone density strength result increase risk bone fracture odanacatib cathepsin k inhibitor selectively inhibit cathepsin k enzyme cathepsin k know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin k novel approach treatment osteoporosis september datum phase iib clinical study odanacatib present st annual meeting american society bone mineral research show stop treatment year increase low lumbar spine bone mineral density bmd reverse year bmd hip femoral neck remain level observe start study additionally year treatment odanacatib mg demonstrate increase bmd key fracture site minimal impact formation new bone measure biochemical marker bone turnover odanacatib currently phase iii clinical trial evaluate largescale global outcome study determine effect vertebral hip nonvertebral fracture company continue anticipate file nda fda v ninevalent hpv vaccine development expand protection cancercause hpv type phase iii clinical program underway merck anticipate file bla fda mka drug candidate combine extendedrelease er niacin novel flush inhibitor laropiprant mka demonstrate ability low ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol low triglyceride significantly flushing traditional extend release niacin high ldl c low hdlc elevate triglyceride risk factor associate heart attack stroke april old merck receive nonapprovable action letter fda response nda mka meet discuss letter fda state additional efficacy safety datum require suggest old merck wait result treatment hdl reduce incidence vascular event hpsthrive cardiovascular outcome study expect complete company anticipates file nda fda mk mka approve country outside united states treatment dyslipidemia particularly patient combine mixed dyslipidemia characterize elevated level ldlc triglyceride low hdlc patient primary hypercholesterolemia heterozygous familial nonfamilial market tredaptive cordaptive certain country tredaptive patient combination statin cholesterol lower effect statin monotherapy inadequate tredaptive monotherapy patient statin consider inappropriate tolerate table content mkb drug candidate combine novel approach raise hdlc lower triglyceride er niacin combine laropiprant prove benefit simvastatin combination product merck seek approval mkb united states file complete response relate mka mk anacetrapib inhibitor cholesteryl ester transfer protein show promise lipid management raise hdlc reduce ldlc raise blood pressure november merck announce phase iib study patient primary hypercholesterolemia mixed hyperlipidemia treat anacetrapib monotherapy co administer atorvastatin persistent lipid effect high dose arm monotherapy coadministration treatment group week stop active therapy anacetrapib effect cetp inhibition cardiovascular risk establish phase iii trial title define ongoing evaluate safety efficacy anacetrapib patient coronary heart disease company anticipate file nda fda previously disclose old merck announce delaying file application telcagepant mk company investigational calcitonin gene relate peptide cgrpreceptor antagonist intermittent treatment acute migraine decision base finding phase iia exploratory study small number patient take telcagepant twice daily month prevention migraine find marked elevation liver transaminase daily dose regimen prevention study different dose regiman phase iii study telcagepant intermittently administer dose treat individual migraine attack occur study telcagepant acute intermittent treatment migraine continue follow meeting regulatory agency end merck planning conduct additional safety study overall phase iii program telcagepant result study inform plan filing approval sch acadesine potential firstin class adenosine regulate agent ischemia reperfusioninjury patient undergo heart bypass surgery patient enrollment red cabg phase iii clinical trial initiate sch vicriviroc treatment hiv infection treatment experience evaluate phase iii study patient population announce january primary efficacy endpoint meet merck submit nda fda vicriviroc treatmentexperience hivinfecte patient time continue evaluate vicriviroc firstline therapy treatmentnaive patient previously disclose cubist pharmaceuticals inc cubist enter license agreement old merck development commercialization cubicin daptomycin injection mk japan merck develop commercialize cubicin whollyowne subsidiary banyu pharmaceutical co ltd cubist commercialize cubicin united states mk currently phase iii development mk orexin receptor antagonist potential new approach treatment chronic insomnia currently phase iii development sch elonva corifollitropin alpha injection approve ec control ovarian stimulation combination gnrh antagonist development multiple follicle woman participate assist reproductive technology program currently phase iii development united states merck terminate internal clinical development program esmirtazapine sch hot flash insomnia strategic reason previously disclose old merck announce preliminary result pivotal phase iii study rolofylline mk investigational medicine treatment acute heart failure show rolofylline meet primary secondary efficacy endpoint old merck terminate clinical development program rolofylline chart reflect company current research pipeline february candidate show phase iii include specific product candidate show phase ii include advanced compound specific mechanism list compound mechanism currently intend table content commercialization give therapeutic area small molecule biologic give mknumber schnumber designation vaccine candidate give vnumber designation candidate phase additional indication therapeutic area additional claim line extension formulation inline product show phase ii allergy sch anemia mk asthma mkc atrial fibrillation mk vernakalant oral cancer mk dalotuzumab sch dinaciclib sch clostridium difficile infection mka copd sch diabete mk mk hepatitis c mk vaniprevir hiv sch vicriviroc hot flashes mk hypertension mk insomnia mk osteoporosis mk parkinson disease sch preladenant pediatric vaccine v progeria sch sarasar lonafarnib schizophrenia mk sch staph infection v thrombosis mk betrixaban phase iii allergy sch grass pollen sch ragweed anesthesia reversal sch sugammadex atherosclerosis mka extendedrelease niacin laropiprant mkb extendedrelease niacin laropiprantsimvastin mk anacetrapib cervical cancer v contraception sch nomace diabete mkc januviapioglitazone fertility sch corifollitropin alfa injection glaucoma mk tafluprost hepatitis c sch boceprevir insomnia mk ischemiareperfusion injury sch acadesine migraine mk telcagepant osteoporosis mk odanacatib sarcoma mk ridaforolimus staph infection mk daptomycin injection thrombosis sch vorapaxar tra review asthma sch momestasone formoterol combination useu atrial fibrillation mk vernakalant iv eu contraception sch nomace eu schizophreniabipolar disorder sch asenapine eu footnote exclusive right outside united states canada mexico vernakalant iv north american right approve certain country europe approve certain country europe japan japanese rights mkc fix dose combination ezetimibe atorvastatin anticipate submit fda commercialize regulatory legal requirement satisfy employee december company approximately employee worldwide approximately employ united state include puerto rico approximately worldwide employee company represent collective bargaining group october old merck announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness restructure program company expect eliminate approximately position active employee vacancy area company worldwide end total table content reduction occur united states restructure program old merck streamline management layer reduce total number senior midlevel executive globally prior merger scheringplough commence productivity transformation program design reduce avoid cost increase productivity february company announce phase new global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough business merger restructuring program intend optimize cost structure combine company phase merger restructuring program end company expect reduce total workforce approximately area company worldwide company plan eliminate vacant position phase program workforce reduction primarily come elimination duplicative position sale administrative headquarters organization consolidation certain manufacturing facility research development operation environmental matter company believe compliance issue associate applicable environmental law regulation material adverse effect company merck incur capital expenditure approximately million environmental protection facility company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million million million estimate million year amount consider potential recovery party company take active role identify provide cost management opinion liability environmental matter probable reasonably estimable accrue total million december possible predict certainty outcome environmental matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure material adverse effect company financial position result operation liquidity capital resource year geographic area information company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states sale sale sale increase proportion sale outside united states primarily inclusion result scheringplough follow close merger company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition result merger merck expand operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time financial information geographic area company business discuss item financial statement supplementary datum available information company internet website address wwwmerckcom company available free charge investor information portion website annual report quarterly report form q current report form k amendment report file furnish pursuant table content section securities exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec companys corporate governance guideline charter board director stand committee available company website wwwmerckcomaboutleadership information available print stockholder request company item risk factor investor carefully consider information set forth include follow risk factor decide invest company security risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result certain company major product go lose patent protection near future occur company expect significant decline sale product company depend patent provide exclusive marketing right product period time product patent company product recently expire expire united states country company face strong competition lower price generic drug loss patent protection company product typically lead rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss patent protection material adverse effect company business cash flow result operation financial position prospect patent provide market exclusivity cozaar hyzaar expire april addition patent cozaar expire number major european market march hyzaar lose patent protection major european market february company expect significant decline sale product time addition patent provide market exclusivity singulair expire august company expect year follow patent expiration lose substantially sale singulair decline come year follow patent expiration patent singulair expire number major european market august company expect sale singulair market decline significantly chart list patent protection company major market product set forth item business patent trademark license key company product generate significant company profit cash flow event adversely affect market lead product material negative impact result operation cash flow company ability generate profit operate cash flow depend largely continue profitability company key product singulair remicade vytorin zetia januvia nasonex gardasil result company dependence key product event adversely affect product market product significant impact result operation cash flow event include loss patent protection recent case temodar increase cost associate manufacture generic otc availability company product competitive product discovery previously unknown effect increase competition introduction new effective treatment discontinuation removal market product reason company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection table content like major pharmaceutical company order remain competitive company continue launch new product year decline sale product fosamax cozaar hyzaar loss market exclusivity mean company future success dependent pipeline new product include new product develop joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research develop new drug treat disease result high risk fund invest company research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest description research development process research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal accordingly company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result clinical trial new drug successful new drug effective harmful effect new drug approve fda intend use possible obtain patent new drug sale new product disappointing company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication brand extension exist product sufficient cover substantial research development cost replace sale lose profitable product fosamax cozaar hyzaar lose patent protection displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial position prospect company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication increase uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right connection merger company assess pipeline identify promise highpotential compound development company complete prioritization clinical development program company continue work prioritization value add program relate currently market product preclinicaldiscovery program company anticipate prioritization process complete half connection process company recognize non cash impairment charge cancellation certain legacy scheringplough pipeline program measure fair value capitalize connection merger noncash impairment charge anticipate exclude company nongaap earning material company future gaap earning table content company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority unite states include fda foreign regulatory authority include ec united states fda particular importance company administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states regulation outside united states primarily focus drug safety effectiveness case cost reduction fda foreign regulatory authority substantial discretion require additional testing delay withhold registration marketing approval mandate product withdrawal company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent sell new product jurisdiction approval obtain company able realize revenue new product jurisdiction approval company dependent patent right patent right invalidate circumvent business adversely affect patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent infringement similar claim company company aggressively defend important patent outside united state include file claim infringement party item legal proceeding patent litigation particular manufacturer generic pharmaceutical product time time file abbreviate new drug application anda fda seek market generic form company product prior expiration relevant patent own company company normally respond vigorously defend patent include filing lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case party patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency diminish eliminate sale profit region negatively affect company result operation recent court decision relate company patent potential legislation relate patent reform regulatory initiative result erosion intellectual property protection important product lose patent protection profitable market sale product likely decline significantly result generic version product available case certain product loss result impairment charge company result operation adversely affect lost sale company successfully launch commercially successful replacement product table content company hypertension product cozaar hyzaar lose patent protection united states april addition patent cozaar expire number major european market march hyzaar lose patent protection major european market february company expect significant decline sale product time addition patent provide market exclusivity singulair expire august company expect year follow patent expiration lose substantially sale singulair decline come year follow patent expiration patent singulair expire number major european market august company expect sale singulair market decline significantly company face intense competition lowercost generic product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak united states eu united states political pressure reduce spending prescription drug lead legislation encourages use generic product company policy actively protect patent right generic challenge company product arise time able prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially business cash flow result operation financial position prospect company face intense competition new product company product face intense competition competitor product competition increase new product enter market event competitor product safer effective effectively market sell company product alternatively case generic competition equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial position prospect company face pricing pressure respect product company face increase pricing pressure globally manage care organization institution government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers ii federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act act act include prescription drug benefit individual go effect january increase purchasing power entity negotiate behalf medicare beneficiary result pricing pressure outside united states numerous major market pervasive government involvement funding healthcare regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government decision make budgetary action respect product company expect pricing pressure increase future healthcare industry continue subject increase regulation political action company believe healthcare industry continue subject increase regulation political legal action future proposal reform healthcare system consider congress state legislature recently major health care reform introduce pass house congress final revise bill unify version consider adopt law congress table content choose action comprehensive reform instead consider incremental health care proposal involve pharmaceuticalrelate issue proposal include house senate version health reform adversely affect company sale profit margin enact proposal government intervention pharmaceutical pricing change government reimbursement increase rebate discount sale relate state federal government program change proposal enact adversely affect business include legalization commercial drug importation united states involuntary approval medicine otc use addition individual state enact propose regulation restrict certain sale marketing activity andor require track disclosure payment financial support healthcare professional similar regulation propose federal level regulation adversely affect company sale profit margin new legislative initiative enact increase government regulation government involvement healthcare low reimbursement rate change operating environment healthcare company government regulation applicable company current future product interpretation exist regulation change prevent company marketing product service period time indefinitely company predict likelihood future change healthcare industry general pharmaceutical industry particular impact company result operation financial condition business company experience difficulty delay manufacture certain product previously disclose old merck past experienced difficulty manufacture certain vaccine product issue continue particular respect manufacture bulk varicella require production company varicella zoster viruscontaining vaccine varivax proquad zostavax similarly scheringplough past experienced difficulty manufacture certain animal health product company work issue assurance issue finally resolve addition difficulty company experience currently company experience difficulty delay inherent manufacturing product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture ii construction delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply manufacturing difficulty result product shortage lead lose sale company face significant litigation relate vioxx september old merck voluntarily withdraw vioxx arthritis acute pain medication market worldwide old merck settle major portion product liability litigation company face material litigation arise voluntary withdrawal vioxx addition vioxx product liability lawsuit purport class action individual lawsuit bring old merck current officer director company allege old merck false misleading statement vioxx violation federal state security law suit refer vioxx security lawsuit april judge chesler grant defendant motion dismiss complaint prejudice plaintiff appeal judge chesler decision united states court appeal circuit september circuit issue opinion reverse judge chesler order remand case district court old merck file petition writ certiorari united states supreme court grant oral argument hold supreme court november decision expect half old merck table content petition certiorari pende plaintiff file consolidated fifth amend class action complaint district court defendant move dismiss fiffth amend class action complaint motion withdraw prejudice refile pende outcome supreme court addition putative class action bring old merck current employee officer director company allege violation erisa suit refer vioxx erisa lawsuit vioxx security lawsuit vioxx shareholder lawsuit vioxx shareholder lawsuit discuss fully item legal proceeding old merck name defendant action country outside united states suit refer vioxx foreign lawsuit old merck sue state county new york city respect marketing vioxx department justice doj issue subpoena request information relate old merck research marketing selling activity respect vioxx federal health care investigation criminal statute investigation include subpoenas witness appear grand jury ongoing investigation local authority europe company cooperate authority investigation investigation refer vioxx investigation company predict outcome investigation result potential civil andor criminal remedy vioxx product liability litigation discuss fully item legal proceeding trial representative action australia conclude june federal court australia name plaintiff allege suffer mi seek represent australia ingest vioxx suffer mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease trial judge reserve decision matter company currently anticipate vioxx product liability lawsuit try company predict timing trial relate vioxx litigation company believe meritorious defense vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit vigorously defend company insurance coverage respect vioxx lawsuit adequate cover defense cost loss merck spend approximately million aggregate legal defense cost worldwide relate vioxx lawsuit ii vioxx investigation collectively vioxx litigation merck record charge million include million fourth quarter add reserve solely future legal defense cost relate vioxx litigation million december million vioxx reserve december vioxx reserve base certain assumption describe item legal proceeding well estimate minimum company believe incur connection remain aspect vioxx litigation event additional trial vioxx litigation event arise course vioxx litigation affect ultimate defense cost incur company company currently able estimate additional amount require pay connection vioxx lawsuit vioxx investigation proceeding expect continue year company predict course proceeding view inherent difficulty predict outcome litigation particularly claimant claimant seek unspecified damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit include settlement program reserve establish connection settlement shareholder derivative action discuss item legal proceeding company establish reserve potential liability relate vioxx lawsuit include settlement program vioxx investigation series unfavorable outcome vioxx lawsuit vioxx investigation result payment substantial damage fine result criminal penalty material adverse effect company business cash flow result operation financial position prospect table content issue concern vytorin enhance seas clinical trial adverse effect sale vytorin zetia united states result ongoing trial adverse effect sale company sell vytorin zetia previously disclose january legacy company announce result enhance clinical trial image trial patient heterozygous familial hypercholesterolemia rare genetic condition cause high level ldl bad cholesterol greatly increase risk premature coronary artery disease previously report despite fact ezetimibesimvastatin mg vytorin significantly lower ldl bad cholesterol simvastatin mg significant difference treatment ezetimibesimvastatin simvastatin prespecifie primary endpoint change thickness carotid artery wall year measure ultrasound improveit trial underway design provide cardiovascular outcome data ezetimibesimvastatin patient acute coronary syndrome incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrate simvastatin establish january fda announce complete review final clinical study report enhance fda state result enhance change position elevate ldl cholesterol risk factor cardiovascular disease lower ldl cholesterol reduce risk cardiovascular disease discussion concern litigation arise enhance study item legal proceeding previously disclose legacy company receive letter address companies house committee energy commerce subcommittee oversight investigation oi rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer addition legacy company receive additional letter oi seek certain information document relate seas clinical trial describe detail legacy company receive subpoenas new york new jersey state attorney general office letter connecticut attorney general seek similar information document finally september legacy company receive letter civil division doj inform doj investigate company conduct relate promotion vytorin cause false claim submit federal health care program company cooperate investigation previously disclose number shareholder lawsuit arise enhance study bring old merck scheringplough july efficacy safety result sea study announced sea design evaluate intensive lipid lower vytorin mg reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patient asymptomatic mild moderate aortic stenosis indication statin therapy vytorin fail meet primary endpoint reduction major cardiovascular event study patient group take vytorin mg high incidence cancer group take placebo nonsignificant increase death cancer patient group take vytorin versus take placebo cancer cancer death distribute major organ system company believe cancer finding sea likely anomaly take light available datum support association vytorin august fda announce investigate result sea trial december fda announce complete review datum sea trial review interim datum sharp improveit trial base currently available information fda indicate believe unlikely vytorin zetia increase risk cancerrelate death sharp trial expect complete improveit trial schedule completion improveit trial blind interim efficacy analysis conduct datum safety monitoring board trial approximately endpoint accrue interim analysis expect conduct base result interim analysis trial halt concern relate vytorin material adverse effect sale vytorin zetia similarly note sharp trial expect complete negative result sharp trial adverse affect sale vytorin zetia table content follow announcement enhance seas clinical trial result sale vytorin zetia decline united states issue concern enhance sea clinical trial adverse effect sale vytorin zetia continue adverse effect sale sale product materially adversely affect company business cash flow result operation financial position prospect materially adversely affect addition unfavorable outcome result litigation concern sale promotion product material adverse effect company business cash flow result operation financial position prospect arbitration proceeding commence centocor scheringplough result company loss right market remicade simponi subsidiary company party distribution agreement centocor wholly own subsidiary johnson johnson scheringplough subsidiary right distribute commercialize rheumatoid arthritis treatment remicade simponi nextgeneration treatment certain territory section c distribution agreement party acquire party come control define section distribution agreement party promptly notify party subject change control party subject change control right later thirty day notification notify write party subject change control termination agreement take effect immediately change control shall mean merger reorganization consolidation combination party agreement survive corporation ii person meaning section section security exchange act exclude partys affiliate beneficial owner directly indirectly security party represent percent thenoutstanding share common stock party b combine voting power party thenoutstande voting security iii individual effective date april constitute board directors party incumbent board cease reason constitute majority board director party provide individual director subsequent effective date election nomination election partys shareholder approve vote majority director comprise incumbent board shall consider individual member incumbent board exclude purpose individual initial assumption office occur result actual threaten election contest respect election removal director actual threaten solicitation proxy consent behalf person board iv approval shareholder party complete liquidation complete dissolution party section distribution agreement define control mean ability entity control entity directly indirectly ownership security agreement method direct manner percent outstanding voting right entity control entity represent security shall cast right receive percent profit earning control management decision entity control entity centocor deliver scheringplough notice initiate arbitration proceeding resolve result propose merger centocor permit terminate distribution agreement relate agreement arbitration process centocor position right terminate distribution agreement ground merger scheringplough scheringplough subsidiary party distribution agreement acquire party come control define section party andor ii undergo change control define section c hearing arbitration schedule commence late september sale remicade simponi include company result postmerger period million million respectively sale remicade recognize scheringplough prior merger billion company vigorously contest centocor attempt terminate distribution agreement result merger arbitrator conclude centocor permit terminate distribution agreement result merger centocor fact terminate distribution agreement table content company subsidiary able distribute remicade simponi addition arbitration centocor claim damage determine result merck allege nontermination distribution agreement centocor prevail arbitration merck liable net damage include offset mitigation arbitration panel find centocor incur result nontermination company suffer impairment charge unfavorable outcome arbitration material adverse effect company financial position liquidity result operation finally uncertainty surround outcome arbitration party choose settle dispute mutually agreeable term agreement reach centocor resolve dispute distribution agreement result term distribution agreement modify manner reduce benefit distribution agreement company pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim change law regulation adversely affect company business aspect company business include research development manufacturing marketing pricing sale litigation intellectual property right subject extensive legislation regulation change applicable federal state law agency regulation material adverse effect company business reliance party relationship outsource arrangement adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company party service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure significant breakdown intrusion interruption corruption system datum breach material adverse effect business addition company currently proceed multiyear implementation enterprise wide resource planning system include modification design operation documentation internal control financial reporting intends implement resource planning system united states material problem implementation material adverse effect company business development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval include result postmarkete phase iv trial decrease demand company product include follow rereview product market new scientific information evolution scientific theory recall loss marketing approval product market change government standard public expectation safety efficacy labeling change great scrutiny advertising promotion table content past year clinical trial postmarkete surveillance certain market drug company competitor industry raise safety concern lead recall withdrawal adverse labeling market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda european medicines agency emea pharmaceutical medical device agency increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty regulatory process great regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability claim product negative event animal health industry negative impact future result operation future sale key animal health product adversely impact number risk factor include certain risk specific animal health business example outbreak disease carry animal bovine spongiform encephalopathy bse mad cow disease lead widespread death precautionary destruction reduce consumption demand animal adversely impact company result operation outbreak highly contagious disease near company main production site require company immediately halt production vaccine site force company incur substantial expense procure raw material vaccine risk specific animal health include epidemic pandemic government procurement pricing practice weather global agribusiness economic event animal health segment company business significant impact event future result operation significant biologic carry unique risk uncertainty negative impact future result operation successful development testing manufacturing commercialization biologic particularly human animal health vaccine long expensive uncertain process unique risk uncertaintie biologic include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction united states european states eu result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost development manufacturing marketing biologic subject regulation fda emea regulatory body regulation complex extensive regulation applicable pharmaceutical product example united states bla include preclinical clinical trial datum extensive datum manufacturing table content procedure require human vaccine candidate fda approval require release manufacture lot manufacture biologic especially large quantity complex require use innovative technology handle living microorganism lot approve biologic undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process company require provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic frequently costly manufacture production ingredient derive live animal plant material biologic synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead allegation harm include infection allergic reaction closure product facility possible contamination event result substantial cost currently process united states submission approval generic biologic base abbreviate datum package show sameness approve biologic public dialogue fda congress scientific statutory basis product know biosimilar follow biologic approve market united states company certain congress create statutory pathway approval biosimilar company predict impact approval biosimilar sale company product united states europe emea issue guideline approve biological product abbreviate pathway biosimilar approve europe biosimilar version company product approve europe negative effect sale product company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter acquisition licensing borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate negatively affect company result operation financial position cash flow order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful company subject evolve complex tax law result additional liability affect result operation company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return periodically examine tax authority company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue february president obamas administration propose significant change international tax law include change limit tax deduction expense relate unrepatriated table content foreignsource income modify foreign tax credit rule determine proposal enact law change proposal prior enact law change international tax law enact significant impact financial result company addition company impact change tax law include tax rate change change law relate remittance foreign earning deferral limitation impact tax treatment foreign earning new tax law revise tax law interpretation domestic foreign jurisdiction company fail realize anticipated cost saving revenue enhancement benefit expect merger adversely affect value company common stock success merger depend company ability successfully combine business old merck scheringplough realize anticipated benefit cost saving combination company combine company able achieve objective anticipated time frame value company common stock adversely affect possible integration process result loss key employee result disruption legacy company ongoing business identify inconsistency standard control procedure policy adversely affect ability maintain relationship customer supplier distributor creditor lessor clinical trial investigator manager achieve anticipate benefit merger specifically issue address integrate operation legacy company order realize anticipate benefit merger include thing integrate research development manufacturing distribution marketing promotion activity information technology system old merck schere plough conforming standard control procedure accounting policy business culture compensation structure company identify eliminate redundant underperform operation asset manage tax cost inefficiency associate integrate operation combine company integration effort company divert management attention resource inability realize extent anticipate benefit merger delay encounter integration process adverse effect company business result operation affect value share company common stock addition actual integration result additional unforeseen expense anticipate benefit integration plan realize actual cost sale synergy achieve low company expect long achieve anticipate company able adequately address challenge unable successfully integrate operation legacy company realize anticipated benefit integration legacy company delay encounter integration process material adverse effect revenue expense operating result financial condition company company expect significant benefit increase cost saving result merger assurance company realize anticipated benefit company incur significant transaction mergerrelate transition cost connection merger company incur significant cost connection consummate merger integrating operation company significant portion cost incur year completion merger company continue assess magnitude cost additional unanticipated cost incur integration business legacy company company believe elimination duplicative cost realization efficiency relate integration business offset incremental transaction mergerrelate cost time assurance give net benefit achieve near term table content company debt obligation incur finance merger adversely affect business company finance strategy merger focus preserve financial strength flexibility continue invest company business key growth driver postmerger debt obligation incur finance merger affect company flexibility planning react change business industry operates place competitive disadvantage compare competitor indebtedness company decide retire pay indebtedness early require dedicate substantial portion cash flow operation reduce availability cash flow purpose include business development effort merger acquisition product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost increase significantly respect product liability company self insure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august include liability legacy merck product sell date company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise company significant global operation expose additional risk adverse event material negative impact company result operation extent company operation outside united states significant fact majority scheringplough legacy operation outside united states risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement foreign exchange fluctuation diminish protection intellectual property country possible nationalization expropriation discuss venezuelan economy recently determine hyperinflationary require company remeasure local currency operation dollar remeasurement record quarter addition venezuelan government recently devalue currency action adverse effect company result operation financial position cash flow addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease cautionary factor affect future result cautionary statement private security litigation reform act report include annual report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product table content potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant litigation relate vioxx vytorin zetia arbitration proceeding involve company right distribute remicade simponi legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states eu legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state united states require security breach notification change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item b unresolved staff comment table content item property companys corporate headquarters locate whitehouse station new jersey company commercial operation headquarter upper gwynedd pennsylvania company pharmaceutical business conduct divisional headquarters locate upper gwynedd whitehouse station new jersey company vaccine business conduct divisional headquarters locate west point pennsylvania mercks animal health global headquarters locate boxmeer netherland principal research facility locate rahway kenilworth summit union new jersey west point palo alto california nebraska animal health principal research facility outside locate netherlands scotland company production facility human health product location united states puerto rico outside united states subsidiary company own interest manufacturing plant property australia canada japan singapore south africa countries western europe central south america asia capital expenditure billion compare billion united states amount million million abroad expenditure amount million million company subsidiarie principal facility manufacturing plant title consider satisfactory company consider property good operating condition machinery equipment maintain plant manufacture product suitable intend purpose capacity project capacity adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action vioxx litigation product liability lawsuit previously disclose individual putative class action file old merck state federal court allege personal injury andor economic loss respect purchase use vioxx action file federal court coordinate multidistrict litigation district court eastern district louisiana mdl district judge eldon e fallon number action file state court coordinate separate coordinate proceeding state court new jersey california texas counties philadelphia pennsylvania washoe clark county nevada december company serve aware name defendant approximately pende lawsuit include approximately plaintiff group allege personal injury result use vioxx approximately putative class action allege personal injury andor economic loss action discuss paragraph lawsuit collectively refer vioxx product liability lawsuit lawsuit approximately lawsuit represent approximately plaintiff group slate federal mdl approximately lawsuit represent approximately plaintiff group include coordinate proceed new jersey superior court judge carol e higbee plaintiff group describe currently vioxx settlement program describe december plaintiff group eligible settlement program participate claim remain pende old merck addition claim approximately plaintiff group eligible settlement program remain pende old merck number plaintiff group subject motion dismiss failure comply courtordere deadline december certain plaintiff group dismiss addition table content claim plaintiff dismiss december vast majority dismiss result settlement process discuss november old merck announce enter agreement settlement agreement law firm comprise executive committee plaintiff steering committee psc federal vioxx mdl representatives plaintiff counsel texas new jersey california state coordinate proceeding resolve state federal myocardial infarction mi ischemic stroke claim file date united states settlement agreement apply legal resident allege mi occur united states settlement agreement provide old merck pay fix aggregate billion fund billion mi claim million claim interim final payment certain qualifying claimant expect remainder billion distribute half company complete make payment settlement fund vioxx product liability lawsuit currently schedule trial old merck previously disclose outcome vioxx product liability lawsuit try prior case go trial mcdarby matter resolve fourth quarter leave unresolved posttrial appeal ernst v merck garza v merck previously report september old merck file notice appeal august jury verdict favor plaintiff texas state court case ernst v merck texas court appeal reverse trial court judgment issue judgment favor old merck court appeal find evidence legally insufficient issue causation plaintiff file motion rehear en banc court appeal june response plaintiff motion rehear court appeal issue new opinion reverse jurys verdict render judgment old merck september plaintiff file second motion rehear en banc court appeal deny november december plaintiff file motion rehear court appeal deny plaintiff file petition review supreme court texas february previously report april garza v merck jury state court rio grande city texas return verdict favor family decedent leonel garza jury award total million compensatory damage mr garzas widow son jury purport award million punitive damage texas law case potential punitive damage cap san antonio court appeal reverse judgment render judgment favor old merck december court appeal rehear vacate prior ruling issue replacement new rule court order takenothe judgment old merck design defect claim reverse remand new trial strict liability claim juror misconduct january old merck file petition review texas supreme court texas supreme court grant old merck petition review oral argument hold january lawsuit approximately claim individual private thirdparty payor file new jersey court federal court mdl september old merck announce finalize settlement agreement previously disclose resolve pende lawsuit usbased private thirdparty payor tpps seek reimbursement covering vioxx purchase plan member certain claimant participate resolution agreement provide old merck admit wrongdoing fault settlement agreement old merck pay fix total million include settlement fund divide tpps insurer employee benefit plan union welfare fund participate resolution accordance formula base product volume provision potential payment attorney fee return settling tpp dismiss lawsuit release claim old merck stipulate dismissal settle ttp action file new jersey mdl december old merck record charge million second quarter relate settlement pay table content million fourth quarter settlement additional tpp case file pende mdl proceeding separately pende court putative class action purportedly bring behalf individual purchaser user vioxx seek reimbursement allege economic loss mdl proceeding class action remain old merck move dismiss master complaint include case mdl court rule motion march new jersey superior court deny plaintiff motion class certification martinkleinman v merck putative consumer class action plaintiff move leave appeal decision new jersey supreme court november january new jersey supreme court deny plaintiff request appellate review denial class certification june missouri state court certify class missouri plaintiff seek reimbursement outofpocket cost relate vioxx plaintiff allege personal injury take vioxx missouri court appeal affirm trial court certification class missouri supreme court deny old merck application review decision september trial set april addition indiana plaintiff file motion certify class indiana vioxx purchaser case pende circuit court marion county indiana discovery case ongoing briefing complete plaintiff motion certify class kentucky vioxx purchaser circuit court pike county kentucky hearing matter hold february judge cook county illinois consolidate putative class action bring vioxx purchaser plaintiff action recently voluntarily dismiss lawsuit plaintiff file class action california state court seek certification class california thirdparty payor enduser trial court deny motion class certification april court appeal affirm rule december january plaintiff file petition review california supreme court old merck name defendant twentyone separate lawsuit bring government entity include attorney general thirteen state county city new york private citizen bring qui tam taxpayer derivative suit action allege old merck misrepresented safety vioxx seek recovery cost vioxx purchase reimburse government entity agencies ii reimbursement sum pay government entity agency medical service treatment person injure vioxx iii damage common law theory andor iv remedy state statutory theory include state consumer fraud andor fair business practice medicaid fraud statute include civil penalty thirteen case pende mdl proceed subject conditional order transfer mdl proceed remand state court lawsuit bring county class action file santa clara county california behalf similarly situate california county old merck motion summary judgment grant november case bring attorney general texas schedule trial early texas attorney general appeal michigan attorney general case old merck currently seek appellate review trial court order deny old merck motion dismiss trial court enter stay proceeding include discovery pende result appeal finally attorney general action mdl describe previous paragraph discovery phase louisiana attorney general case currently schedule trial mdl court april shareholder lawsuit previously disclose addition vioxx product liability lawsuit old merck current officer director defendant putative class action individual lawsuit federal security law state security law vioxx security lawsuit vioxx security lawsuit pende federal court transfer judicial panel multidistrict litigation jpml district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx security table content lawsuit purpose putative class action request damage behalf purchaser old merck stock october allege defendant false misleading statement vioxx violation section b securities exchange act seek unspecified compensatory damage cost suit include attorney fee complaint assert claim section security exchange act certain defendant relate sale old merck stock section security act certain defendant base statement registration statement certain prospectus file connection old merck stock investment plan dividend reinvestment plan april judge chesler grant defendant motion dismiss complaint prejudice plaintiff appeal judge chesler decision court appeal circuit september circuit issue opinion reverse judge chesler order remand case district court old merck file petition writ certiorari united states supreme court january supreme court grant oral argument hold november decision expect half petition certiorari pende plaintiff file consolidated fifth amend class action complaint district court old merck file motion dismiss complaint follow district court proceeding stay pende outcome supreme court appeal motion dismiss district court withdraw prejudice old merck right refile motion pende outcome supreme court appeal october dutch pension fund file complaint district new jersey allege violation federal security law violation state law old merck certain officer pursuant case management order govern shareholder mdl case base allegation vioxx security lawsuit consolidate vioxx security lawsuit defendant motion dismiss pension fund complaint file august september dutch pension fund file amend complaint respond defendant motion dismiss addition new complaint file district new jersey behalf foreign institutional investor allege violation federal security law violation state law old merck certain officer stipulation defendant require respond complaint resolution motion dismiss consolidated security action addition previously disclose putative class action file federal court employee retirement income security act erisa old merck certain current officer director vioxx erisa lawsuit vioxx security lawsuit vioxx derivative lawsuit describe vioxx shareholder lawsuit transfer shareholder mdl consolidated purpose consolidate complaint assert claim breach fiduciary duty behalf certain old merck current employee participant certain old merck retirement plan complaint make similar allegation respect vioxx allegation contain vioxx security lawsuit july judge chesler grant deny defendant motion dismiss erisa complaint october plaintiffs move certification class individual participant beneficiary old merck retirement saving plan time october september plan account include investment old merck common stock fund andor old merck common stock february court deny motion certification class count grant motion remain count court exclude class definition individual injure connection investment old merck stock ii execute post separation settlement agreement release claim erisa march judge chesler deny defendant motion judgment pleading judge chesler enter order deny plaintiff motion partial summary judgment certain individual defendant file december previously disclose october individual shareholder demand old merck board legal action mr raymond gilmartin chairman president chief executive officer individual allegedly cause damage old merck respect allegedly improper marketing vioxx december special committee board director retain honorable john martin jr debevoise plimpton llp conduct independent investigation thing allegation set forth demand judge martin report public september table content base special committee recommendation careful consideration martin report impact derivative litigation old merck board reject demand october shareholder file shareholder derivative lawsuit purportedly old merck behalf state court atlantic county new jersey current officer director old merck plaintiff allege board rejection demand unreasonable improper defendant breach duty old merck allow vioxx market party reach propose settlement february court issue order preliminarily approve settlement require notice propose settlement merck shareholder set hearing consider final approval settlement march february merck notify shareholder propose settlement term propose settlement merck agree certain corporate governance change supplement policy procedure previously establish company agree pay award fee expense plaintiff attorney determined court exceed million addition merck plaintiff individual defendant exchange mutual release claim assert derivative action propose settlement constitute admission liability wrongful conduct merck defendant name action approve court propose settlement resolve federal consolidated shareholder derivative action describe previously disclose shareholder derivative action file federal court transfer shareholder mdl consolidated purpose judge chesler vioxx derivative lawsuit judge chesler grant defendant motion dismiss ground plaintiff fail demonstrate demand excuse deny plaintiff request leave amend complaint plaintiff appeal argue judge chesler err deny plaintiff leave amend complaint document acquire stipulation party july united states court appeal circuit reverse district court decision ground judge chesler allow plaintiff seek leave amend complaint document acquire stipulation remand case district court consideration additional material plaintiff propose amendment futile plaintiff file brief support request leave amend complaint propose amend complaint november court deny motion june dismiss case plaintiff appeal judge chesler decision united states court appeal circuit oral argument appeal hold july november decision issue appeal stay pende approval settlement reach derivative action pende new jersey superior court resolve state federal shareholder derivative claim relate vioxx international lawsuit previously disclose addition lawsuit discuss old merck name defendant litigation relate vioxx country collectively vioxx foreign lawsuit europe canada brazil argentina australia turkey israel philippines singapore november superior court quebec authorize institution class action behalf individual quebec consume vioxx suffer damage arise ingestion plaintiff serve introductory motion class action base authorization case remain preliminary stage litigation provincial court queen bench saskatchewan canada enter order certify class vioxx user canada quebec old merck appeal certification order march court appeal grant old merck appeal quash certification order october supreme court canada dismiss plaintiff appeal application decide review judgment saskatchewan court appeal july superior court ontario deny old merck motion stay class proceeding ontario decide certify overlap class vioxx user canada quebec saskatchewan allege negligence entitlement elect waive tort february ontario divisional court dismiss appeal order deny stay ontario court appeal deny leave appeal october supreme court canada dismiss old merck application decide review judgment ontario court appeal court appeal saskatchewan quash multijurisdictional certification order enter province old merck applied ontario court appeal leave appeal table content ontario certification order leave appeal grant appeal file accordance court decision old merck seek leave appeal divisional court deny december procedural decision canadian litigation address merit plaintiff claim litigation canada remain early stage trial representative action australia commence march federal court australia name plaintiff allege suffer mi seek represent australia ingest vioxx suffer mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease march trial judge enter order direct advance issue proceed issue determine trial issue fact law name plaintiff individual case issue fact law trial judge find hear evidence common claim group member name plaintiff allege represent trial representative action conclude june trial judge reserve decision insurance previously disclose company director officer insurance coverage applicable vioxx security lawsuit vioxx derivative lawsuit state upper limit approximately million company fiduciary insurance vioxx erisa lawsuit state upper limit approximately million result previously disclose arbitration additional insurance coverage claim available need upperlevel excess policy provide coverage variety risk dispute insurer availability company insurance coverage claim likely additional dispute amount actually recover policy discuss paragraph state upper limit investigation previously disclose old merck receive subpoenas doj request information relate old merck research marketing selling activity respect vioxx federal health care investigation criminal statute investigation include subpoenas witness appear grand jury previously disclose march old merck receive letter attorney office district massachusetts identify target grand jury investigation vioxx previously disclose investigation conduct local authority certain city europe order determine criminal charge bring concern vioxx company cooperate governmental entity respective investigation vioxx investigation company predict outcome inquiry result potential civil andor criminal remedy addition old merck receive subpoena september state california attorney general seek document information relate placement vioxx california medical formulary company cooperate attorney general respond subpoena reserve discuss november old merck enter settlement agreement law firm comprise executive committee psc federal vioxx mdl representatives plaintiff counsel texas new jersey california state coordinate proceeding resolve state federal mi claim file date united states result enter settlement agreement old merck record pretax charge billion represent fix aggregate pay plaintiff qualify payment settlement program vioxx product liability lawsuit trial schedule trial company predict timing trial relate vioxx litigation company believe meritorious defense vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit include table content settlement program company establish reserve potential liability relate vioxx lawsuit include settlement program reserve establish connection resolution shareholder derivative lawsuit discuss vioxx investigation unfavorable outcome vioxx litigation material adverse effect company financial position liquidity result operation legal defense cost expect incur connection loss contingency accrue probable reasonably estimable december old merck aggregate reserve approximately billion vioxx reserve settlement program future legal defense cost relate vioxx litigation merck spend approximately million aggregate legal defense cost worldwide include approximately million fourth quarter relate vioxx product liability lawsuit ii vioxx shareholder lawsuit iii vioxx foreign lawsuit iv vioxx investigation collectively vioxx litigation addition old merck pay additional billion settlement fund connection settlement program merck record million charge include million fourth quarter solely future legal defense cost vioxx litigation consequently december aggregate vioxx reserve approximately million solely future legal defense cost vioxx litigation significant factor consider review vioxx reserve follow actual cost incur company development company legal defense strategy structure light scope vioxx litigation include settlement agreement expectation certain lawsuit continue pende number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial vioxx litigation vioxx reserve december represent company good estimate minimum defense cost incur connection remain aspect vioxx litigation event additional trial vioxx litigation event arise course vioxx litigation affect ultimate defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase vioxx reserve time future base factor set forth believe appropriate product liability litigation fosamax previously disclose old merck defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case include approximately plaintiff group file pende old merck federal state court include case seek class action certification damage andor medical monitoring action plaintiff allege thing suffer osteonecrosis jaw generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax addition plaintiff approximately percent action allege sustain stress andor low energy femoral fracture association use fosamax august jpml order fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax mdl coordinated pretrial proceeding fosamax mdl transfer judge john keenan district court southern district new york result jpml order approximately case judge keenan judge keenan issue case management order amendment thereto set forth schedule governing proceeding focus primarily resolve class action certification motion complete fact discovery initial group case october briefing argument plaintiff motion certification medical monitoring class complete judge keenan issue order deny motion january january judge keenan issue order dismiss prejudice class claim assert class action lawsuit file old merck seek personal injury damage andor medical monitoring relief class wide basis daubert motion file table content judge keenan conduct daubert hearing july july judge keenan issue rule party respective daubert motion ruling deny plaintiff steering committee motion grant deny old merck motion mdl trial boles v merck begin august end september september mdl court declare mistrial bole person jury reach unanimous verdict consequently bole case set retry june second mdl case set trial fleming v merck schedule start january judge keenan grant old merck motion summary judgment dismiss case november mdl case set trial maley v merck currently schedule start april old merck file motion summary judgment maley mdl court grant deny january result company expect trial commence currently schedule april february judge keenan select new bellwether case judith grave v merck replace fleming bellwether case mdl court dismiss grant summary judgment favor old merck mdl court set grave trial begin september trial alabama currently schedule begin trial florida currently schedule begin june addition july application atlantic county superior court new jersey request fosamax case pende new jersey consider mass tort designation centralize management judge new jersey october new jersey supreme court order pende future action file new jersey arise use fosamax seeking damage exist dental jawrelate injury include osteonecrosis jaw solely seek medical monitoring designate mass tort centralize management purpose judge higbee atlantic county superior court december approximately case pende old merck new jersey coordinated proceeding july judge higbee enter case management order amendment thereto set forth schedule contemplate complete fact discovery initial group case february follow expert discovery case project trial date july case try new jersey coordinated proceeding discovery ongoing fosamax mdl litigation new jersey coordinated proceed remain jurisdiction fosamax case pende company intend defend lawsuit december company remain reserve approximately million solely future legal defense cost fosamax litigation company spend approximately million add million reserve consequently december company reserve approximately million solely future legal defense cost fosamax litigation significant factor consider establishment reserve fosamax litigation legal defense cost follow actual defense cost incur far development company legal defense strategy structure light creation fosamax mdl number case bring company anticipate timing progression relate cost pretrial activity fosamax litigation company continue monitor legal defense cost review adequacy associate reserve uncertain nature litigation company unable reasonably estimate cost quarter company establish reserve potential liability relate fosamax litigation unfavorable outcome fosamax litigation material adverse effect company financial position liquidity result operation nuvare begin number complaint file jurisdiction assert claim company subsidiarie organon usa inc organon pharmaceuticals usa inc organon international collectively organon scheringplough arise organon marketing sale nuvare combine hormonal contraceptive vaginal ring plaintiff contend organon scheringplough fail adequately warn allege increase risk venous thromboembolism vte pose nuvare andor downplay risk vte plaintiff seek damage injury allegedly sustain product use include alleged death heart attack stroke majority case currently pende federal multidistrict litigation venue missouri new jersey state court case pende state table content vetsulin december scheringplough animal health name defendant putative class action lawsuit file district court northern district ohio lawsuit entitle friedman v scheringplough animal health individual plaintiff seek represent class people purchase vetsulin household pet suit allege vetsulin contaminate improperly manufacture vetsulin insulin product administer diabetic dog cat plaintiff seek compensatory punitive damage base theory negligence violation consumer sale practice act breach warranty product liability allegedly defective manufacturing merck intend defend lawsuit vigorously commercial litigation awp litigation investigation previously disclose old merck join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level complaints allege violation federal state law include fraud medicaid fraud consumer protection violation claim outcome litigation investigation include substantial damage imposition substantial fine penalty injunctive administrative remedy jpml order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action expand number manufacturer include like old merck defendant prior pende case court grant old merck motion dismiss consolidated class action dismiss old merck class action case old merck pharmaceutical manufacturer defendant similar complaint pende federal state court include case bring individually number county state new york county case consolidate new york state court old merck dismiss suffolk county case new york county case file addition new york county case december old merck defendant state case bring attorney general state defend february kansas attorney general file suit old merck manufacturer awp claim bring attorney general arizona old merck drop court awp case pende hawaii list old merck set trial mid scheringplough reach settlement claim relate awp august scheringplough pharmaceutical company settle claim bring behalf alabama medicaid program combine total million addition july scheringplough reach settlement relator acting behalf united states non intervene awp qui tam action pende federal district court massachusetts states california florida combine total million settlement resolve claim bring behalf medicaid programs states california florida approve district court district massachusetts hold preclusive claim federal share allege medicaid overpayment remain state consistent applicable precedent january district court district massachusetts hold unit scheringplough drugmaker overcharge new york city new york county certain generic drug court reserve issue damage penalty future proceeding company continue respond litigation bring certain state private payor investigation initiate department health human services department justice state awp company cooperate investigation centocor distribution agreement centocor wholly own subsidiary johnson johnson deliver scheringplough notice initiate arbitration proceeding resolve result merger centocor permit terminate company right distribute commercialize remicade simponi sale remicade simponi include company result postmerger period million million respectively sale remicade recognize scheringplough prior merger table content billion arbitration process involve number step include selection independent arbitrator information exchange hearing final decision reach hearing arbitration schedule commence late september unfavorable outcome arbitration material adverse effect company financial position liquidity result operation information matter item risk factor governmental proceeding previously disclose february old merck enter corporate integrity agreement cia department health human service office inspector general hhsoig fiveyear term cia require thing old merck maintain ethic training program policy procedure govern promotional practice medicaid price reporting require cia old merck retain independent review organization iro conduct system review promotional policy procedure conduct sample basis transactional review old merck promotional program certain medicaid pricing calculation old merck require provide regular report certification hhsoig compliance cia similarly previously disclose scheringplough scheringplough enter cia hhsoig fiveyear term august enter addendum cia effective year requirement old merck scheringplough cia similar identical failure comply cia requirement result financial penalty exclusion participation federal health care program company believe promotional practice medicaid price report meet requirement cias vytorinzetia litigation previously disclose legacy company receive letter house committee energy commerce subcommittee oversight investigation oi rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer addition previously disclose august old merck scheringplough receive additional letter oi include identical letter date february seek certain information document relate seas clinical trial previously disclose legacy company receive subpoenas new york state attorney general office letter connecticut attorney general seek similar information document july legacy company announce reach civil settlement attorney general represent state district columbia resolve previously disclose investigation group legacy company violate state consumer protection law market vytorin zetia settlement legacy company agree reimburse investigative cost state district columbia total million voluntary assurance compliance relate promotion vytorin zetia include agree continue comply food drug cosmetic act food drug administration amendment act law require truthful nonmisleading marketing pharmaceutical product settlement include admission misconduct liability legacy company furthermore previously disclose september legacy company receive letter civil division doj inform doj investigate conduct relate promotion vytorin cause false claim submit federal health care program company cooperate investigation respond inquiry previously disclose legacy company aware serve approximately civil class action lawsuit allege common law state consumer fraud claim connection msp partnership sale promotion vytorin zetia certain lawsuit allege personal injury andor seek medical monitoring lawsuit old merck scheringplough consolidated single multidistrict litigation docket judge cavanaugh district new jersey vytorinzetia marketing sale practice product liability litigation august old merck scheringplough jointly announce cholesterol joint venture enter agreement resolve total fix million civil class table content action lawsuit msp partnership record charge second quarter february judge cavanaugh grant final approval settlement previously disclose april old merck shareholder file putative class action lawsuit federal court eastern district pennsylvania allege old merck chairman president chief executive officer richard clark violate federal security law suit withdraw refiled district new jersey consolidate federal security lawsuit caption merck co inc vytorin security litigation amend consolidated complaint file october name defendant old merck merckscheringplough pharmaceutical llc certain company current officer director specifically complaint allege old merck delay release unfavorable result enhance clinical trial efficacy vytorin old merck false misleading statement expect earning know result vytorin study release sale vytorin decline old merck earning suffer december old merck defendant move dismiss lawsuit ground plaintiff fail state claim relief grant september court issue opinion order deny defendant motion dismiss lawsuit october old merck defendant file answer amend consolidated complaint similar consolidated putative class action security lawsuit pende district new jersey file scheringplough shareholder scheringplough chairman president chief executive officer fre hassan caption scheringplough corporationenhance security litigation amend consolidated complaint file september name defendant schere plough merckscheringplough pharmaceutical llc certain company current officer director underwriter participate august public offering scheringplough common prefer stock december scheringplough defendant file motion dismiss lawsuit ground plaintiff fail state claim relief grant september court issue opinion order deny defendant motion dismiss lawsuit september defendant file motion reconsideration court september opinion order deny motion dismiss motion reconsideration fully brief october decision remain pende defendant file answer consolidate amend complaint november previously disclose april member old merck erisa plan file putative class action lawsuit old merck certain company current officer director alleging breach fiduciary duty erisa time similar erisa lawsuit file old merck district new jersey lawsuit consolidate caption merck co inc vytorin erisa litigation consolidate amend complaint file february name defendant old merck current member company board director plaintiff allege erisa plan investment old merck stock imprudent old merck earning dependent commercial success cholesterol drug vytorin defendant know know result scientific study cause medical community turn expensive drug cholesterol management april old merck defendant move dismiss lawsuit ground plaintiff fail state claim relief grant september court issue opinion order deny defendant motion dismiss lawsuit november plaintiff move strike certain defendant affirmative defense motion fully brief december pende court similar consolidated putative class action erisa lawsuit currently pende district new jersey file member scheringplough erisa plan schere plough certain current officer director alleging breach fiduciary duty erisa caption scheringplough corp enhance erisa litigation consolidate amend complaint file october name defendant scheringplough current member scheringploughs board director current member committee scheringploughs board director november company defendant file motion dismiss lawsuit ground plaintiff fail state claim relief grant plaintiff opposition table content motion dismiss file december motion fully brief january decision remain pende november stockholder company file shareholder derivative lawsuit local international brotherhood electrical worker pension fund v clark local district new jersey behalf nominal defendant company shareholder company company certain company officer director allege insider certain predecessor company officer director allege insider allege breach fiduciary duty waste unjust enrichment gross mismanagement similar shareholder derivative lawsuit cain v hassan file scheringplough stockholder currently pende district new jersey amend complaint file scheringplough stockholder behalf nominal defendant scheringplough scheringplough shareholder lawsuit scheringplough scheringplough thencurrent board director certain scheringplough current officer director allege insider plaintiff local cain v hassan allege defendant withhold enhance study result false misleading statement deceive cause harm company scheringplough respectively invest public unjustly enrich insider waste corporate asset defendant local intend dismiss plaintiff complaint defendant cain v hassan move dismiss amend complaint july motion fully brief october decision remain pende company intend defend lawsuit refer section unfavorable outcome result government investigation civil litigation material adverse effect company financial position liquidity result operation november individual shareholder previously deliver letter old merck board director demand board legal action responsible individual recover amount pay old merck resolve certain governmental investigation deliver letter board demand board subcommittee thereof commence investigation matter raise civil suit governmental investigation relate vytorin security class action litigation federal security litigation follow scheringploughs announcement february fda conduct inspection manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice delay approval clarinex lawsuit file scheringplough certain name officer lawsuit allege defendant violate federal security law allegedly fail disclose material information make material misstatement specifically allege scheringplough fail disclose allege risk new drug application clarinex delay result manufacturing issue allege company fail disclose allege depth severity manufacturing issue complaint consolidate action district court district new jersey consolidated amend complaint file october purport represent class shareholder purchase share scheringplough stock february complaint seek compensatory damage behalf class february court sign order preliminarily approve settlement agreement scheringplough provide settlement fund million resolve claim class fund place escrow time vast majority settlement cover insurance december district court grant final approval settlement settlement consummated expiration appeal period final approval decision erisa litigation march scheringplough serve putative class action complaint file district court new jersey allege scheringplough employee saving plan plan administrator current director certain corporate officer breach fiduciary obligation certain participant plan complaint seek damage loss allegedly table content suffer plan complaint dismiss june plaintiff appeal august court appeal circuit reverse dismissal district court matter remand district court proceeding september district court enter order grant deny name putative class representative motion class certification scheringplough petition district court appeal circuit leave appeal class certification decision scheringplough petition grant december december circuit vacate district court order remand case proceeding consistent court rule kdur antitrust litigation june january scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upshersmith file abbreviate new drug application follow commencement administrative proceeding united states federal trade commission ftc allege anticompetitive effect settlement resolve scheringploughs favor allege class action suit file federal state court behalf direct indirect purchaser kdur scheringplough upshersmith lederle suit claim violation federal state antitrust law state statutory common law cause action suit seek unspecified damage february special master recommend district court district new jersey dismiss class action lawsuit summary judgment district court judge rule recommendation thirdparty payor action discuss july connection settlement investigation doj attorney office eastern district pennsylvania schering plough enter fiveyear cia cia amend august connection million settlement investigation state massachusetts involve certain scheringplough sale marketing clinical trial practice program massachusetts investigation purport class action litigation file follow announcement settlement massachusetts investigation plaintiff action seek damage behalf thirdparty payor result allegation offlabel promotion improper payment physician issue massachusetts investigation action consolidate multidistrict litigation federal district court district new jersey july district court dismiss consolidated class action complaint grant plaintiff leave refile september plaintiff file amend complaint company motion dismiss complaint pende vaccine litigation previously disclose old merck party individual class action product liability lawsuit claim united states involve pediatric vaccine eg hepatitis b vaccine contain thimerosal preservative vaccine december approximately thimerosal relate lawsuit pende old merck defendant vast majority lawsuit currently active defendant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result exposure thimerosal pediatric vaccine case currently schedule trial company defend lawsuit possible unfavorable outcome material adverse effect company financial position liquidity result operation old merck successful case type dismiss stay ground action prohibit national childhood vaccine injury act vaccine act vaccine act prohibit person file maintain civil action state federal court seek damage vaccine manufacturer vaccinerelate injury petition file united states court federal claim hereinafter vaccine court vaccine act file civil action vaccine manufacturer petitioner pursue petition conclusion vaccine court timely table content file election proceed civil action lieu accept vaccine court adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribe time period old merck party vaccine court proceeding petition bring united states department health human service company aware approximately case pende vaccine court involve allegation thimerosalcontaine vaccine andor mmr ii vaccine cause autism spectrum disorder thimerosalcontaine vaccine involve vaccine court proceeding company vaccine company sole source mmr ii vaccine domestically special master preside vaccine court proceeding hold hearing test case involve theory combination mmr ii vaccine thimerosal vaccine cause autism spectrum disorder february special master issue decision case find theory unsupported valid scientific evidence petitioner case entitle compensation case currently appeal special master hold similar hearing different test case involve theory thimerosal vaccine cause autism spectrum disorder decision issue second set test case special master previously indicate hold similar hearing involve theory mmr ii cause autism spectrum disorder state long intend vaccine court indicate intend use evidence present test case hearing guide adjudication remain autism spectrum disorder case patent litigation time time generic manufacturer pharmaceutical product file andas fda seek market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market united states generic forms fosamax nexium singulair emend cancidas respectively prior expiration old mercks astrazenecas case nexium patent concern product addition anda submit fda seek market united states generic form zetia anda submit fda seek market united states generic form vytorin prior expiration scheringplough patent concern product generic company anda generally include allegation noninfringement invalidity unenforceability patent company file patent infringement suit federal court company file andas generic alendronate fosamax montelukast singulair astrazeneca company file patent infringement suit federal court company file andas generic esomeprazole nexium company scheringplough file patent infringement suit federal court company file andas generic version ezetimibe zetia ezetimibesimvastatin vytorin schere corp schering subsidiary company file patent infringement suit federal court generic company file andas generic version temodar integrilin levitra nasonex similar patent challenge exist certain foreign jurisdiction company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product february scheringplough receive notice generic company indicate file anda zetia challenge patent list zetia prior merger company market zetia joint venture msp singapore company llc march scheringplough msp singapore company llc file patent infringement suit glenmark pharmaceuticals inc usa parent corporation glenmark lawsuit automatically stay fda approval glenmark anda october adverse court decision whichever occur early trial matter schedule commence previously disclose february old merck receive notice teva pharmaceuticals inc teva generic company indicate file anda montelukast challenge patent list singulair april old merck file patent infringement action teva trial matter hold february august court issue decision uphold table content validity old merck singulair patent order tevas anda approve prior expiry old merck exclusivity right august teva appeal decision january teva withdraw appeal trial court decision uphold validity old merck singulair patent addition united states patent trademark office grant petition article partner llc reexamine old merck singulair patent december united states patent trademark office issue notice indicating allow claim company singulair patent product exclusivity accordingly expect maintain august federal court canada trial division issue decision refuse bar approval generic alendronate ground old merck patent weekly alendronate likely invalid decision appeal generic alendronate launch canada june july old merck sue federal court canada apotex corp apotex seek damage lose sale generic weekly alendronate patent proceeding october federal court canada issue decision awarding apotex lose profit generic alendronate product period time hold market old merck lawsuit june trial court decision uphold company seek leave appeal supreme court canada january supreme court canada decline hear appeal leave intact decision apotex entitle damage discrete period time market entry postpone litigation launch old merck previously disclose september old merck appeal decision opposition division european patent office epo revoke company patent europe cover onceweekly administration alendronate march board appeal epo uphold decision opposition division revoke patent march epo issue patent europe old merck cover onceweekly administration alendronate term new patent effective july old merck sue multiple party european country assert european patent cover onceweekly dose fosamax decision render netherlands belgium invalidate patent country old merck appeal decision opposition file epo patent hearing hold march opposition division epo issue appealable decision revoke patent old merck appeal decision addition previously disclose japan proceeding file challenging validity old merck japanese patent onceweekly administration alendronate patent office invalidate patent decision appeal october patent dorzolamide cover trusopt cosopt expire old merck experience significant decline sale product company involve litigation proceeding correspond patent canada great britain germany november trial court great britain issue decision find old merck cosopt patent invalid canada trial hold december company canadian trusopt cosopt patent company await decision old merck astrazeneca receive notice october ranbaxy file anda esomeprazole magnesium anda contain paragraph iv challenge patents nexium november old merck astrazeneca sue ranbaxy district court new jersey previously disclose astrazeneca old merck ranbaxy enter settlement agreement provide ranbaxy bring generic esomeprazole product market united states company astrazeneca receive cid ftc july settlement agreement ranbaxy company cooperate ftc respond cid old merck astrazeneca receive notice january ivax pharmaceuticals inc ivax subsequently acquire teva file anda esomeprazole magnesium anda contain paragraph iv challenge patent nexium march old merck astrazeneca sue teva district court new jersey january astrazeneca old merck tevaivax enter settlement agreement provide tevaivax bring generic esomeprazole product market united states addition january old merck astrazeneca sue dr reddys laboratories dr reddys district court new jersey base dr reddys filing anda table content esomeprazole magnesium trial schedule january respect ivaxs dr reddys andas postpone new trial date set old merck astrazeneca receive notice december sandoz inc sandoz file anda esomeprazole magnesium anda contain paragraph iv challenge patent nexium january old merck astrazeneca sue sandoz district court new jersey base sandozs file anda esomeprazole magnesium addition old merck astrazeneca receive notice september lupin ltd lupin file anda esomeprazole magnesium anda contain paragraph iv challenge patents nexium october old merck astrazeneca sue lupin district court new jersey base lupins file anda esomeprazole magnesium january old merck receive notice sandoz file anda challenge old merck patent list fda orange book emend february old merck file patent infringement suit sandoz lawsuit automatically stay fda approval sandozs anda july adverse court decision whichever occur early case schedule trial december europe old merck aware company seek registration generic losartan active ingredient cozaar hyzaar old merck patent right losartan license ei du pont de nemour company du pont old merck du pont file patent infringement proceeding company portugal spain norway finland belgium netherlands austria october old merck receive notice teva parenteral medicine tpm file anda caspofungin acetate challenge patent list fda orange book cancidas november company file patent infringement suit tpm lawsuit automatically stay fda approval tpms anda april adverse court decision whichever occur early november schering receive notice apotex file anda mometasone furoate nasal spray challenge patent list fda orange book nasonex december schering file patent infringement suit apotex lawsuit automatically stay fda approval apotexs anda adverse court decision whichever occur early november scheringplough receive notice mylan file anda ezetimibesimvastatin challenge patent list fda orange book vytorin december scheringplough file patent infringement suit mylan lawsuit automatically stay fda approval mylans anda adverse court decision whichever occur early july schering licensor cancer research technology limited crt receive notice barr laboratories barr subsidiary teva barr file anda temodar challenge crt patent temozolomide july schering crt file patent infringement action barr january court issue decision find crt patent unenforceable ground prosecution lache inequitable conduct schere crt process appeal decision january schering licensor millennium receive notice teva file anda eptifibatide challenge millennium patent list fda orange book integrilin february schering millennium file patent infringement action teva lawsuit automatically stay fda approval tevas anda august adverse court decision whichever occur early schere bayer schering pharma ag bayer healthcare pharmaceutical receive notice teva file anda vardenofil challenging bayer patent list fda orange book levitra vardenifil june schering bayer file patent infringement action teva lawsuit automatically stay fda approval tevas anda november adverse court decision whichever occur early table content legal proceeding relate merger connection merger separate class action lawsuit bring old merck scheringplough challenge merger seek form relief previously disclose lawsuit settle pende court approval settlement approve court resolve release claim brought shareholder old merck scheringplough challenging aspect propose merger include merger disclosure claim litigation french matter base complaint french competition authority competitor france pursuant court order french competition authority obtain document french subsidiary company relate subutex product subsidiary market sell resolution matter adverse french subsidiary result imposition civil fine injunctive administrative remedy july juge des libert et de la dtention order annulment search seizure procedural ground july french authority appeal order french supreme court french supreme court overturn annulment remand case paris court appeal basis juge des libert et de la dtention examine document assess seize lawfully seize case pende paris court appeal april competitor request interim relief portion grant french competition authority december interim relief require company french subsidiary publish specialized newspaper information include generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirm decision french competition authority january french supreme court confirm decision french competition authority legal proceeding principally product liability intellectual property suit involve company pende feasible predict outcome proceeding proceeding discuss item opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company proceeding separate assessment provide item environmental matter company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability de minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include table content reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party previously disclose approximately plaintiff file amend complaint old merck defendant district court eastern district california assert claim clean water act resource conservation recovery act negligence nuisance suit seek damage personal injury diminution property value medical monitoring allege real personal property damage associate groundwater soil contamination find site old merck subsidiary merce california old merck intend defend claim management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year executive officer registrant age february richard clark age november chairman president chief executive officer merck co inc scheringplough corporation april chairman president chief executive officer old merck chief executive officer president old merck june president merck manufacturing division old merck responsible company manufacture information service operational excellence organization worldwide adele ambrose age november senior vice president chief communication officer merck co inc scheringplough corporation responsible global communication organization december vice president chief communication officer old merck responsible global communication organization april sabbatical prior april ms ambrose executive vice president public relation investor communication att wireless wireless service provider september april stanley f barshay age november executive vice president president consumer health care merck co inc scheringplough corporation responsible consumer health care organization mr barshay retire effective april prior november mr barshay chairman consumer health care scheringplough corporation june table content richard bowles iii age november executive vice president chief compliance officer merck co inc scheringplough corporation responsible company compliance function include global safety environment system assurance ethic privacy prior november dr bowles senior vice president global quality operation scheringplough corporation march john canan age november senior vice president global controller merck co inc scheringplough corporation responsible company global control organization include accounting control external reporting financial standard policy january senior vice president controller old merck responsible corporate controller group september vice president controller old merck responsible corporate controller group willie deese age november executive vice president president merck manufacturing division mmd merck co inc scheringplough corporation responsible company global manufacturing procurement distribution logistic function january executive vice president president mmd old merck responsible company global manufacturing procurement distribution logistic function president mmd old merck responsible company global manufacturing procurement operational excellence function january senior vice president global procurement kenneth c frazi age november executive vice president president global human health merck co inc scheringplough corporation responsible company market sale organization worldwide include global pharmaceutical vaccine franchise august executive vice president president global human health old merck responsible company market sale organization worldwide include global pharmaceutical vaccine franchise november executive vice president general counsel old merck responsible legal public affair function merck company foundation notforprofit charitable organization affiliate company december senior vice president general counsel old merck responsible legal public affair function merck company foundation notforprofit charitable organization affiliate company mirian graddickweir age november executive vice president human resources merck co inc scheringplough corporation responsible global human resource organization january executive vice president human resource old merck responsible global human resource organization september senior vice president human resource old merck table content prior september dr graddickweir executive vice president human resource employee communication att communications service provider hold senior human resource leadership position att year bridgette heller age effective march executive vice president president consumer health care merck co inc scheringplough corporation responsible consumer health care organization prior march ms heller president johnson johnsons baby global business unit global president baby kid wind care prior join johnson johnson ms heller founder managing partner heller associates peter n kellogg age november executive vice president chief financial officer merck co inc scheringplough corporation responsible company worldwide financial organization investor relation corporate development licensing company joint venture relationship august executive vice president chief financial officer old merck responsible company worldwide financial organization investor relation corporate development licensing company joint venture relationship prior august mr kellogg executive vice president finance chief financial officer biogen idec biotechnology company november merger biogen inc idec pharmaceuticals corporation peter kim age november executive vice president president merck research laboratories merck co inc scheringplough corporation january responsible company research development effort worldwide january executive vice president president merck research laboratory old merck responsible company research development effort worldwide january president merck research laboratory old merck responsible company research development effort worldwide raul e kohan age november executive vice president president animal health merck co inc scheringplough corporation responsible company animal health organization october senior vice president president intervetscheringplough animal health scheringplough corporation october deputy head animal health senior vice president corporate excellence administrative service scheringplough corporation february senior vice president president animal health scheringplough corporation prior february mr kohan group head global specialty operation president animal health scheringplough corporation table content bruce n kuhlik age november executive vice president general counsel merck co inc scheringplough corporation responsible legal communication public policy function merck company foundation notforprofit charitable organization affiliate company january executive vice president general counsel old merck responsible legal communication public policy function merck company foundation notforprofit charitable organization affiliate company august senior vice president general counsel old merck responsible legal communication public policy function merck company foundation notforprofit charitable organization affiliate company vice president associate general counsel old merck primary responsibility company vioxx litigation defense prior mr kuhlik senior vice president general counsel pharmaceutical research manufacturers america october michael rosenblatt age december executive vice president chief medical officer merck co inc scheringplough corporation company primary voice global medical community critical issue patient safety oversee company global center scientific affair prior december dr rosenblatt dean tufts university school medicine j chris scalet age november executive vice president global services chief information officer cio merck co inc scheringplough corporation responsible global share service human resource finance site service information service function enterprise business process redesign initiative january executive vice president global services cio old merck responsible global share service human resource finance site service information service function enterprise business process redesign initiative january senior vice president global services cio old merck responsible global share service human resource finance site service information service function enterprise business process redesign initiative march senior vice president information services cio old merck responsible area information technology service include application development technical support voice datum communication computer operation worldwide mervyn turner age november chief strategy officer senior vice president emerge market research development merck research laboratories merck co inc schere plough corporation responsible lead formulation execution company long term strategic plan additional responsibility license external research merck research laboratory november chief strategy officer senior vice president worldwide license external research merck research laboratory old merck october senior vice president worldwide license external research old merck officer list serve pleasure board director officer elect pursuant arrangement understand officer board table content ii item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol sgp prior merger mrk merger common stock market price information set forth table base historical nyse market price follow table set forth calendar period indicate dividend share information cash dividend pay common share year th q rd q nd q st q common stock market price th q rd q nd q st q high low high low old merck pay quarterly cash dividend common share annual january approximately shareholders record equity compensation plan information follow table summarize information option warrant right equity compensation company legacy merck legacy scheringplough equity plan close business december table include information tax qualified plan msd employee saving security plan schere plough employee saving plan number security number remain available security future issuance issue weightedaverage equity exercise exercise price compensation plan outstanding outstanding exclude option warrant option warrant security right right reflect column plan category b c equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck sharp dohme incentive stock plan merck co inc nonemployee directors stock option plan scheringplough corporation stock incentive plan table content exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan share restrict stock unit performance share unit exclude accrue dividend scheringplough corporation stock incentive plan exclude share phantom stock defer merck co inc deferral program table include information equity compensation plan option warrant right assume company connection merger acquisition pursuant remain outstanding option warrant right collectively assume plan include rosetta inpharmatics inc employee stock option plan total share merck common stock purchase assume plan weight average exercise price grant assume plan table content performance graph follow graph assume investment december reinvestment dividend companys common share sp index composite peer group major usbased pharmaceutical company abbott laboratories bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp performance graph reflect scheringploughs tock perf ormanc e ecembe r thr ou gh c lose rg er n ew mer cks sto c k perform ance n vember december assume cash component merger consideration reinveste new merck stock closing price november compound annual growth rate october wyeth pfizer inc complete previously announce merger pfizerwyeth merger wyeth whollyowne subsidiary pfizer inc discuss november old merck scheringplough complete merger pfizerwyeth merger transaction old merck subsequently rename merck sharp dohme corp whollyowne subsidiary scheringplough subsequently rename merck co inc result transaction wyeth old merck long exist publicly trade entity cease trade common stock close business respective merger date wyeth old merck permanently remove peer group index table content recent sale unregistered security november january company inadvertently issue total approximately unregistered share common stock certain director employee old merck exercise stock option hold aggregate exercise price pay connection stock option exercise approximately million addition january company inadvertently issue total approximately unregistered share common stock certain senior employee old merck vest performance share unit hold table content item select financial datum follow select financial datum read conjunction item management discussion analysis financial condition result operation consolidate financial statement note thereto contain item financial statement supplementary datum report merck co inc subsidiarie million share amount result year sale material production cost market administrative expense research development expense restructure cost equity income affiliate vioxx settlement agreement charge income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck co inc preferred stock dividend net income available common shareholder basic earning common share available common shareholder earning common share assume dilution available common shareholder cash dividend declare cash dividend pay common share capital expenditure depreciation average common share outstanding million average common share outstanding assume dilution million yearend position work capital property plant equipment net total asset longterm debt total equity yearend statistic number stockholder record number employee amount include impact merger scheringplough corporation november include recognition gain represent fair value stepup merck previously hold interest merckscheringplough partnership result obtain control interest increase material production cost result amortization intangible asset inventory stepup include gain sale merck interest merial limited favorable impact certain tax item impact restructure action additional legal defense cost amount include gain distribution astrazeneca lp gain relate sale remain worldwide right aggrastat favorable impact certain tax item impact restructure action additional legal defense cost expense contribution merck company foundation amount include impact vioxx settlement agreement charge restructuring action civil governmental investigation charge insurance arbitration settlement gain inprocess research development expense result acquisition additional vioxx legal defense cost gain sale asset product divestiture net gain settlement certain patent dispute amount include impact restructuring action inprocess research development expense result acquisition additional vioxx legal defense cost adoption new accounting standard require expense stock option amount include impact net tax charge primarily associate american job creation act repatriation restructuring action additional vioxx legal defense cost reflect dividend pay common shareholder old merck addition approximately million dividend pay subsequent merger scheringplough million pay prior merger relate common stock prefer stock dividend declare scheringplough table content item management discussion analysis financial condition result operation description merck business november merck co inc old merck scheringplough corporation scheringplough complete previouslyannounce merger merger merger scheringplough acquire share old merck whollyowne subsidiary scheringplough rename merck sharp dohme corp scheringplough continue survive public company rename merck co inc new merck company accounting purpose merger treat acquisition old merck consider accounting acquirer accordingly accompany financial statement reflect old merck standalone operation exist prior completion merger result scheringplough business include new merck financial statement period subsequent completion merger new merck financial result reflect year legacy scheringplough operation reference report accompany financial statement merck period prior merger refer old merck period completion merger new merck company global health care company deliver innovative health solution medicine vaccine biologic therapie consumer animal product market directly joint venture company operation principally manage product basis comprise reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventative pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesalers physician distributor government entity company professional representative communicate effectiveness safety value pharmaceutical vaccine product health care professional private practice group practice manage care organization company animal health operation discover develop manufacture market animal health product include vaccine company professional representative communicate safety value company animal health product veterinarian distributor animal producer additionally company consumer health care operation develop manufacture market overthecounter otc foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet united states canada overview discuss merger complete november merger old merck shareholder receive share common stock new merck share old merck stock own scheringplough shareholder receive share common stock new merck cash share scheringplough stock own consideration merger value billion aggregate scheringplough old merck longterm partner merckscheringplough cholesterol partnership msp partnership cash portion consideration fund combination exist cash include proceed sale old merck interest merial limited sale redemption investment issuance debt combine company research development pipeline great depth breadth promising drug candidate significantly broad portfolio medicine expand presence key international market particularly highgrowth emerge market company anticipate efficiency gain merger allow invest promise pipeline candidate strategic external research development opportunity combination increase company pipeline early mid late stage product candidate include significant increase number potential medicine company phase iii development table content candidate additionally number candidate currently review united states internationally merger expect accelerate expansion therapeutic area old merck focus recent year addition scheringplough establish presence expertise oncology neuroscience novel biologics merger expect broaden company commercial portfolio lead franchise key therapeutic area include cardiovascular respiratory oncology neuroscience infectious disease immunology women health additionally combine company expect realize potential benefit animal health business portfolio consumer health brand include claritin coppertone dr scholl legacy scheringplough product expect long period marketing exclusivity leverage combine company expand product offering company expect benefit additional revenue growth opportunity example combine company expect expand opportunity lifecycle management introduction potential new combination formulation exist product legacy company company expand global presence geographically diverse revenue base scheringplough significant international presence accelerate old merck international growth effort revenue increase drive largely incremental sale result inclusion postmerger result legacy scheringplough product remicade treatment inflammatory disease temodar treatment certain type brain tumor nasonex nasal spray inhale nasal corticosteroid treatment nasal allergy symptom pegintron treat chronic hepatitis c recognition revenue sales zetia vytorin cholesterol modifying medicine prior merger sale zetia vytorin recognize msp partnership result old merck interest msp partnership record equity income affiliate result merger msp partnership whollyowne company revenue product postmerger period reflect sale additionally company recognize sale post merger period legacy scheringplough animal health consumer health care product contribute sale increase growth januvia janumet treatment type diabete isentress antiretroviral therapy treatment hiv infection singulair medicine indicate chronic treatment asthma relief symptom allergic rhinitis varivax vaccine help prevent chickenpox varicella pneumovax vaccine help prevent pneumococcal disease increase partially offset low sale fosamax treatment prevention osteoporosis fosamax fosamax plus lose market exclusivity substantially formulation united states february april respectively revenue negatively affect low sale gardasil vaccine help prevent cervical vulvar vaginal cancer precancerous dysplastic lesion genital wart cause human papillomavirus hpv type cosopttrusopt ophthalmic product lose market exclusivity october low revenue company relationship astrazeneca lp azlp product experience decline include rotateq vaccine help protect rotavirus gastroenteritis infant child zocor company statin modify cholesterol primaxin treatment bacterial infection result merger company expect achieve substantial cost saving area include consolidation sale marketing research development application company lean manufacturing source strategy expand operation integration msp partnership february company announce phase new global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough business merger restructuring program intend optimize cost structure combine company phase merger restructuring program end company expect reduce total workforce approximately area company worldwide company plan eliminate vacant position phase program workforce reduction primarily come elimination duplicative position sale administrative headquarters organization consolidation certain manufacturing facility research development operation company continue hire new employee strategic growth area business period certain action ongoing reevaluation manufacture research development facility table content worldwide complete include later phase merger restructuring program connection phase merger restructuring program separation cost company exist severance program worldwide record fourth quarter extent cost probable reasonably estimable company record pretax restructuring cost billion primarily employee separation cost relate merger restructuring program fourth quarter phase merger restructuring program expect complete end total pretax cost estimate billion billion company estimate approximately cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest company expect phase merger restructuring program yield annual saving approximately billion billion anticipate saving relate phase merger restructuring program portion estimate billion incremental annual saving originally disclose merger announce company expect additional saving generate subsequent phase merger restructuring program announce later year non restructure relate activity procurement saving initiative cost saving expect come area company pharmaceutical business addition previously announce ongoing cost reduction initiative legacy company result merger company obtain control interest msp partnership own company accordingly company require remeasure merck previously hold equity interest msp partnership mergerdate fair value recognize result gain earning result company record gain billion recognize income expense net old merck sell interest merial limited merial sanofiaventis billion cash sale result recognition billion gain reflect income expense net note consolidated financial statement earning common share ep assume dilution reflect net impact result gain relate msp partnership sale merial partially offset increase expense amortization purchase accounting adjustment restructure mergerrelate cost eps affect dilutive impact share issue merger competition health care environment competition market company conduct business pharmaceutical industry highly competitive highly regulate company operation affect technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor new information clinical trial market product postmarkete surveillance generic competition company product mature addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect certain product competitive pressure intensify pressure industry grow effect operation competitive factor patent dispute predict pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively longstanding emphasis research development company position compete search technological innovation additional resource meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance joint venture license refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number table content compound available treat particular disease typically increase time result slow sale growth company product therapeutic category global effort healthcare cost containment continue exert pressure product pricing access address cost containment pressure company make continue effort demonstrate medicine provide value patient pay healthcare addition pricing flexibility company product portfolio encourage grow use medicine mitigate effect increase cost pressure individual medicine outside united states difficult government budgetary environment company work payer encourage allocation scarce resource optimize healthcare outcome limit potentially detrimental effect government policy sale growth access innovative medicine vaccine support discovery development innovative product benefit patient company work government emerge market eastern europe latin america asia encourage increase investment health improve citizen access medicine addition certain country european union eu recognize economic importance research base pharmaceutical industry value innovative medicine society work industry representative improve competitive climate variety mean include market deregulation company anticipate worldwide trend cost containment continue result ongoing pressure healthcare budgets united states major healthcare reform introduce pass house congress final revise bill unify version consider adopt law impact action budget pressure government united states nations predict time company continues successfully launch new product contribute healthcare debate monitor reform new product policy strategy enable maintain strong position change economic environment predict outcome legislative regulatory advocacy initiative company believe position respond evolve healthcare environment market force access medicine company commit improve access medicine enhance quality life people world cite example african comprehensive hivaids partnership botswana partnership government botswana bill melinda gates foundation merck company foundationmerck co inc support botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support catalyze access hiv medicine develop country company make profit sale current hivaids medicine world poor country hard hit pandemic offer hivaids medicine significantly reduce price mediumincome country february old merck announce reduce price stocrin develop country world hard hit pandemic action company work independently partner public private sector address critical barrier access medicine develop world address barrier require investment education training health infrastructure improve capacity develop country achieve increase international assistance sustainable financing addition old merck commit provide rotateq vaccine help protect rotavirus gastroenteritis infant child global alliance vaccine immunizationeligible country price profit old merck wellcome trust establish msd wellcome trust hilleman laboratory joint venture india develop vaccine million people poor area world government regulation pharmaceutical industry subject regulation regional country state local agency world particular importance food drug administration fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase table content time resource necessary develop new product bring market united states food drug administration modernization act fda modernization act pass culmination comprehensive legislative reform effort design streamline regulatory procedure fda improve regulation drug medical device food legislation principally design ensure timely availability safe effective drug biologic expedite premarket review process new product key provision legislation reauthorization prescription drug user fee act permit continue collection user fee prescription drug manufacturer augment fda resource earmark review human drug application help provide resource necessary ensure prompt approval safe effective new drug united states government expand access senior citizen prescription drug coverage enact medicare prescription drug improvement modernization act sign law december prescription drug coverage begin january legislation support company goal improve access medicine expand insurance coverage preserve marketbase incentive pharmaceutical innovation time legislation help control cost prescription drug cost competitive pressure encourage appropriate use medicine mention united states major healthcare reform introduce pass house congress final revise bill unify version consider adopt law congress consider consider proposal increase government role pharmaceutical pricing medicare program proposal include remove current legal prohibition secretary health human services intervene price negotiation medicare drug benefit program plan pharmaceutical company include mandate payment rebate pharmaceutical utilization medicare drug benefit plan addition congress consider proposal allow certain condition importation medicine country year pharmaceutical industry federal state oversight approval process new drug drug safety advertising promotion drug purchasing reimbursement program formulary company believe continue able conduct operation include introduction new drug market regulatory environment company continue work private public payor slow increase healthcare spending federal state government pursue method directly reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity disproportionate share hospital hospital meet certain criterion provide minimum discount define nonfederal average manufacturer price purchase certain component federal government department veterans affairs department defense initiative state seek rebate minimum require medicaid legislation case patient eligible medicaid federal vaccine child entitlement program center disease control prevention cdc fund purchase recommend pediatric vaccine public sector price immunization medicaideligible uninsured native american certain underinsured child old merck award cdc contract supply pediatric vaccine vaccine child program outside united states company encounter similar regulatory legislative issue country business primary thrust governmental inquiry action determine drug safety effectiveness mechanism control price reimbursement prescription drug profit prescription drug company eu adopt directive concern classification label advertise wholesale distribution approval marketing medicinal product human use company policy procedure consistent substance directive consequently believe material effect company business january european commission ec launch sector inquiry pharmaceutical industry rule eu competition law inquiry old merck office germany inspect authority begin january preliminary report ec issue november follow public consultation period final report issue july final report confirm decline number novel medicine reach market instance delay market entry generic medicine discuss industry practice contributed table content phenomena ec issue inquiry respect subject investigation ec allege company subsidiary engage unlawful practice company subject jurisdiction regulatory agency subject potential administrative action action include seizure product civil criminal sanction certain circumstance company deem advisable initiate product recall company believe able compete effectively environment privacy datum protection company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue potential affect directly company business include recently enact law regulation united states internationally require notification individual government authority security breach involve certain category personal information operating result sale worldwide sale total billion increase compare foreign exchange unfavorably affect global sale performance revenue increase largely reflect incremental sale result inclusion postmerger result legacy scheringplough product remicade temodar nasonex nasal spray pegintron recognition revenue sale zetia vytorin prior merger sale zetia vytorin recognize msp partnership result old merck interest msp partnership record equity income affiliate result merger msp partnership whollyowne company revenue product postmerger period reflect sale additionally company recognize sale postmerger period legacy scheringplough animal health consumer healthcare product contribute sale increase growth januvia janumet isentress singulair varivax pneumovax increase partially offset low sale fosamax fosamax plus lose market exclusivity substantially formulation united states february april respectively revenue negatively affect low sale gardasil cosopttrusopt lose market exclusivity october low revenue company relationship azlp product experience decline include rotateq zocor primaxin domestic sale increase compare foreign sale rose drive primarily incremental sale result inclusion postmerger result legacy scheringplough product domestic sale increase drive high sale januvia janumet isentress singulair increase partially offset low sale fosamax fosamax plus cosopttrusopt gardasil rotateq foreign sale growth reflect strong performance januvia janumet isentress partially offset low sale fosamax fosamax plus vaccine foreign sale represent total sale worldwide sale total billion decline compare foreign exchange favorably affect global sale performance revenue decline largely reflect low sale fosamax fosamax plus contribute decline low sale zocor vasotecvaseretic sale certain vaccine include hepatitis haemophilus influenzae type b hib vaccine partially offset decline high sale januvia janumet isentress cozaarhyzaar rotateq singulair foreign sale represent total sale table content sale company product follow million pharmaceutical bone respiratory immunology dermatology singulair fosamax propecia remicade arcoxia nasonex clarinex asmanex cardiovascular vytorin zetia integrilin diabete obesity januvia janumet infectious disease isentress primaxin cancidas invanz crixivanstocrin pegintron avelox rebetol mature brand cozaarhyzaar zocor vasotecvaseretic proscar claritin rx proventil neuroscience ophthalmology maxalt cosopttrusopt remeron subutexsuboxone oncology emend temodar caelyx intron vaccines proquadmmr iivarivax gardasil rotateq pneumovax zostavax womens health endocrine follistimpuregon nuvare pharmaceutical segment revenue total segment revenue sale legacy scheringplough product reflect result postmerger period december sales msp partnership product zetia vytorin represent sale postmerger period december prior merger sale zetia vytorin primarily recognize msp partnership result old merck interest msp partnership record equity income affiliate sale zetia vytorin reflect old merck sale product latin america msp partnership amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily include sale human pharmaceutical product include product franchise list separately reflect nonreportable segment include animal health consumer health care revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively revenue primarily comprise miscellaneous corporate revenue thirdparty manufacture sale sale relate divested product business supply sale include segment result table content pharmaceutical segment revenue bone respiratory immunology dermatology worldwide sale singulair leukotriene receptor antagonist chronic treatment asthma relief symptom allergic rhinitis grow reach billion primarily drive favorable pricing strong performance japan asia pacific global sale singulair rise billion reflect high sale outside united states include volume growth europe japan positive effect foreign exchange partially offset low sale domestically singulair continue number prescribe product respiratory market sale singulair billion patent provide marketing exclusivity singulair expire august company expect year follow patent expiration lose substantially sale singulair decline come year follow patent expiration addition patent singulair expire number major european market august company expect sale singulair market decline significantly worldwide sale fosamax fosamax plus market fosavance eu fosamac japan treatment case fosamax prevention osteoporosis decrease billion decline billion substantially formulation medicine lose market exclusivity company experience significant decline sales united states fosamax product franchise company expect decline continue international sale remicade treatment inflammatory disease million postmerger period december remicade market company outside united states japan certain asian market product compete remicade launch past year october ec approve simponi golimumab oncemonthly subcutaneous treatment certain inflammatory disease company launch simponi canada germany denmark launch international market ongoing plan note consolidated financial statement discussion arbitration proceeding involve remicadesimponi global sale nasonex nasal spray inhale nasal corticosteroid treatment nasal allergy symptom million postmerger period december global sale clarinex market aerius country outside united states nondrowsy antihistamine million postmerger period december product include bone respiratory immunology dermatology franchise include propecia product treatment male pattern hair loss arcoxia treatment arthritis pain asmanex orally inhale steroid asthma cardiovascular sale zetia cholesterol absorption inhibitor vytorin combination product contain active ingredient zetia zocor million million respectively postmerger period december prior merger sale product recognize msp partnership result old merck interest msp partnership record equity income affiliate result merger msp partnership whollyowne company revenue product reflect sale discussion performance zetia vytorin prior closing merger select joint venture affiliate information global sale integrilin injection legacy scheringplough product treatment patient acute coronary syndrome sell company united states canada million postmerger period december june launches tredaptive begin international market december merck launch tredaptive country include major european market tredaptive lipidmodifying therapy patient mix dyslipidemia primary hypercholesterolemia tredaptive know trademark cordaptive certain country approve country outside united states united states remain investigational table content diabetes obesity global sale januvia mercks dipeptidyl peptidase dpp inhibitor treatment type diabete billion billion million januvia approve fda october ec march dpp inhibitor represent class prescription medication improve blood sugar control patient type diabete enhance natural body system call incretin system help regulate glucose affect beta cell alpha cell pancreas januvia receive regulatory approval japan china ec approved restrict line use januvia treatment type diabete approval sitagliptin indicate improve glycemic control diet exercise provide adequate glycemic control metformin inappropriate contraindication intolerance sitagliptin diabete treatment dpp inhibitor class restrict line indication eu worldwide sale janumet merck oral antihyperglycemic agent combine sitagliptin mercks dpp inhibitor januvia metformin single tablet target key defect type diabete million compare million million janumet initially approve adjunct diet exercise improve blood sugar control adult patient type diabete adequately control metformin sitagliptin patient treat combination sitagliptin metformin february fda approval market janumet initial treatment type diabete receive july janumet approve marketing eu iceland norway ec approve use januvia tablet janumet tablet addon insulin treatment type diabetes sitagliptin diabete treatment dpp inhibitor class indication use addon insulin eu united states supplemental new drug application concern use januvia janumet combination insulin accept fda currently review infectious disease worldwide sale isentress antiretroviral therapy treatment hiv infection million million million sale growth reflect positive performance united states internationally strong launch certain country include france spain italy isentress available major international market october fda grant isentress accelerate approval use combination antiretroviral agent treatment hiv infection treatment experience adult patient evidence viral replication hiv strain resistant multiple antiretroviral agent isentress medicine approve class antiretroviral drug call integrase inhibitors isentress work inhibit insertion hiv dna human dna integrase enzyme inhibit integrase perform essential function limit ability virus replicate infect new cell january fda grant traditional approval isentress follow review week datum benchmrk clinical trial july fda approve expand indication isentress include use treatment adult patient start hiv therapy time treatment nave treatment experience adult patient september isentress grant expand license ec use combination antiretroviral medicinal product treatment hiv infection adult patient include treatmentnave adult patient treatmentexperience adult patient commission decision applicable country member eu iceland norway additionally october merck announce isentress indicate use treatmentnave adult canada sale primaxin antibacterial product decline million compare result reflect competitive pressure reflect supply constraint patent primaxin expire worldwide multiple generic approve europe accordingly company experience decline sale product company expect decline continue sale primaxin essentially flat compare table content worldwide sale pegintron treat chronic hepatitis c million postmerger period december product contain infectious disease franchise include cancida antifungal product crixivan stocrin antiretroviral therapy treatment hiv infection avelox fluoroquinolone antibiotic treatment certain respiratory skin infection invanz treatment certain infection mature brand mercks mature brand human health pharmaceutical product approach expiration marketing exclusivity long protect patent develop market continue core company offer market world global sale cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension billion comparable sale reflect unfavorable effect foreign exchange offset strong performance product united states hyzaar japan market preminent global sale cozaar hyzaar grow billion drive strong performance hyzaar japan positive effect foreign exchange cozaar hyzaar lead medicine angiotensin receptor blocker class patent provide market exclusivity cozaar hyzaar expire april addition patent cozaar expire number major european market march hyzaar lose patent protection number major european market february company anticipate significant decline future cozaarhyzaar sale multiple source generic expect medicine time patent expiry worldwide sale zocor statin modifying cholesterol decline zocor lose market exclusivity june lose market exclusivity major international market product contain mature brand franchise include prescription claritin treatment seasonal outdoor allergy yearround indoor allergy vasotecvaseretic hypertension andor heart failure proscar urology product treatment symptomatic benign prostate enlargement neuroscience ophthalmology sale cosopt trusopt merck largestselle ophthalmic product decline million compare patent provide market exclusivity cosopt trusopt expire october cosopt lose market exclusivity number major european market trusopt lose market exclusivity number major european market april company expect sale market decline significantly sale cosopt trusopt decline compare saphris asenapine mercks sublingual tablet acute treatment schizophrenia adult acute treatment manic mixed episode associate bipolar disorder approve fda august launch underway company file supplemental new drug application fda saphris adjunct therapy patient mania maintenance therapy patient schizophrenia application asenapine review eu companys muscle relaxant reversal drug bridion currently approve country include japan launch country world saflutan tafluprost launch number country include united kingdom spain additional launch country expect year pende regulatory approval saflutan preservative free synthetic analogue prostaglandin f reduction elevate intraocular pressure appropriate patient primary openangle glaucoma ocular hypertension tafluprost phase iii development united states april old merck santen pharmaceutical co ltd santen announce worldwide licensing agreement tafluprost research development update table content old merck divest marketing right timoptic product franchise aton pharma inc timoptic product franchise include ophthalmic product treat elevated intraocular pressure patient ocular hypertension openangle glaucoma oncology sale temodar treatment certain type brain tumor million postmerger period december temodar lose patent exclusivity eu january company announce district court district delaware rule company patent infringement suit teva pharmaceuticals usa inc note consolidated financial statement decision appeal effect rule uncertain matter appeal product oncology franchise include emend treatment chemotherapy induce nausea vomit caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma marketing right caelyx return johnson johnson december vaccine follow discussion vaccine include sale vaccine sell major european market sanofi pasteur msd spmsd company joint venture sanofi pasteur result include equity income affiliate select joint venture affiliate information supply sale spmsd include worldwide sale gardasil record merck decline billion decline billion gardasil world topselle hpv vaccine indicate girl woman year age prevention cervical vulvar vaginal cancer precancerous dysplastic lesion genital wart cause hpv type gardasil approve united states use boy man age year age prevention genital wart cause hpv type sale performance drive largely decline united states continue affect saturation yearold female cohort rapid early uptake ongoing challenge vaccinate yearold female age group sale include million revenue result government purchase center disease control prevention cdc strategic national stockpile sale performance reflect low sale domestically partially offset growth outside united states sale include initial purchase state cdc vaccine children program company party certain party license agreement respect gardasil include crosslicense settlement agreement glaxosmithkline result agreement company pay royalty worldwide gardasil sale vary country include material production cost october fda approve gardasil use boy man make gardasil hpv vaccine approve use male later october merck announce cdcs advisory committee immunization practice acip support permissive use gardasil boy man age mean gardasil give male age reduce likelihood acquire genital wart acip vote recommend funding provide use gardasil male vaccine children program january fda issue second complete response letter supplemental biologic license application sbla use gardasil woman age fda complete review response old merck provide july fdas complete response letter issue june recommend old merck submit additional datum month study complete initial sbla include datum collect average month enrollment study number prespecifie endpoint meet merck provide response fda fourth quarter class response generally carry month review time point fda accept file complete response letter affect current indication gardasil females age global sale rotateq vaccine help protect rotavirus gastroenteritis infant child record merck decline million reflect moderate impact competition table content united states great impact public sector worldwide sale rotateq grow million primarily drive continued uptake united states successful launch world sale include purchase million support cdc strategic national stockpile old merck receive regulatory approval united states certain market increase manufacturing capacity company varicella zoster virus vzv contain vaccine company manufacture bulk varicella produce dose varivax zostavax proquad pediatric combination vaccine help protect measle mump rubella varicella vzvcontaine vaccine currently available order order transition appropriate mmr ii varivax total sale record merck proquad million million merck anticipate proquad available market merck sale varivax vaccine help prevent chickenpox varicella billion million million varivax vaccine available united states help protect chickenpox unavailability proquad sale reflect million revenue result government purchase cdcs strategic national stockpile varivax benefit acip june second dose recommendation merck sale mmr ii vaccine help protect measle mump rubella million million million sale varivax mmr ii affect unavailability proquad combine sale proquad mmr ii varivax increase decline sale zostavax vaccine help prevent shingles herpe zoster record merck million million million sale year affect supply issue normal shipping schedule zostavax united states resume june company anticipate zostavax available united states customer likely experience order zostavax year international launch zostavax delay vaccine medical option prevention shingle sale pneumovax vaccine help prevent pneumococcal disease million compare million million increase favorable pricing united states high demand associated flu pandemic september old merck announce enter exclusive agreement csl biotherapie csl subsidiary csl limited market distribute afluria csls seasonal influenza flu vaccine united states flu season term agreement company assume responsibility aspect commercialization afluria united states csl supply afluria merck retain responsibility marketing vaccine outside united states afluria indicate active immunization person age month old influenza disease cause influenza virus subtype type b present vaccine effort resolve manufacturing issue relate hibcontaine vaccine pedvaxhib comvax ongoing december january pedvaxhib fully available united states routine vaccination booster dose catchup vaccination time availability outside united states dependent local regulatory requirement market return comvax dependent supply situation company hibcontaine vaccine hepatitis b vaccine pediatricadolescent formulation vaqta vaccine hepatitis currently available company continue prioritize pediatricadolescent formulation merck anticipate adult formulation available outside united states supply vaqta limited availability vary region pediatricadolescent formulation recombivax hb vaccine hepatitis b available december company anticipate availability adult formulation half company anticipate dialysis formulation available end table content women health endocrine global sale follistimpuregon fertility treatment million postmerger period december follistimpuregon lose market exclusivity eu august worldwide sale nuvare contraceptive product million postmerger period december january merck receive ec approval elonva elonva indicate control ovarian stimulation combination gnrh antagonist development multiple follicle woman participate assist reproductive technology program ec approval merck receive marketing authorization elonva unify labeling valid european union member states elonva class sustain follicle stimulant ability initiate sustain multiple follicular growth entire week single subcutaneous injection recommend dose elonva replace seven injection daily recombinant follicle stimulate hormone rfsh preparation control ovarian stimulation treatment cycle january company azlp teva pharmaceuticals inc acquire ivax pharmaceuticals inc enter settlement agreement resolve patent litigation respect esomeprazole nexium provide tevaivax bring generic esomeprazole product market united states old merck azlp enter similar agreement ranbaxy laboratories ltd ranbaxy provide ranbaxy bring generic esomeprazole product market united states company face challenge respect outstanding patent infringement matter esomeprazole note consolidated financial statement animal health global sale animal health product include livestock poultry companion animal aquaculture product prevent treat animal disease total million postmerger period december animal health sale affect intense competition frequent introduction generic product consumer health care global sale consumer health care product include otc foot care sun care product million postmerger period december consumer health care product sale affect competition frequent competitive product introduction consumer spending pattern consumer health care product include dr scholl foot care product claritin nondrowsy antihistamine miralax treatment occasional constipation coppertone sun care product december merck announce fda approve zegerid otc overthecounter treatment frequent heartburn agreement santarus inc specialty pharmaceutical company develop currently market prescription zegerid scheringplough healthcare product consumer healthcare division merck responsible development manufacturing commercialization zegerid otc product heartburnrelate indications united states canada table content cost expense million change c hange material production marketing administrative research development restructuring cost equity income affiliate vioxx settlement agreement charge income expense net great material production material production cost billion compare billion material production cost include expense relate sale legacy schere plough product postmerger period additionally cost unfavorably affect billion amortization purchase accounting adjustment scheringplough inventory billion expense amortization intangible asset recognize merger include material production cost million cost associate restructuring activity substantially represents accelerate depreciation associate plan sale closure manufacturing facility note consolidated financial statement material production cost decline compare decline sale primarily reflect low restructuring cost include material production cost million restructuring cost comprise million accelerate depreciation million cost primarily asset writeoff compare restructure cost million represent million accelerate depreciation million asset impairment gross margin compare additional amortization expense result merger restructuring charge reflect period note unfavorable impact percentage point percentage point percentage point gross margin reflect change product mix include decline fosamax fosamax plus sale result loss market exclusivity manufacturing efficiency gross margin reflect slight unfavorable impact change product mix positive impact manufacturing efficiency market administrative marketing administrative expense increase drive largely inclusion expense relate scheringplough activity postmerger period additionally million mergerrelate cost recognize consist transaction cost directly related merger include advisory legal fee integration cost increase partially offset initiative reduce cost base place prior consummation merger separation cost associate sale force reduction incur reflect restructure cost discuss addition marketing administrative expense benefit foreign exchange marketing administrative expense include million million respectively additional reserve solely future vioxx legal defense cost expense reflect million additional reserve solely future legal defense cost fosamax litigation note consolidated financial statement information vioxx fosamax litigation relate matter market administrative expense decline compare include marketing administrative expense million million respectively additional reserve solely future vioxx legal defense cost include cost million additional reserve solely future legal defense cost fosamax litigation addition marketing table content administrative expense include million gain insurance arbitration award relate vioxx product liability litigation coverage addition low expense future legal defense cost decline marketing administrative expense compare reflect effort reduce cost base research development research development expense increase compare incremental expenditure associate inclusion scheringploughs result postmerger period additionally expense reflect million cost associate restructuring activity include closure sale research facility connection restructuring program substantially represent accelerate depreciation note consolidated financial statement addition research development expense compare reflect increase development spending support continue advancement research pipeline include investment latestage clinical trial research development expense decline compare expense reflect million cost relate restructuring activity expense reflect million inprocess research development expense relate novacardia acquisition research development expense compare reflect increase development spending support continue advancement research pipeline sharebase compensation total pretax sharebase compensation expense million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize weighted average period year segment report sharebased compensation cost unallocated expense restructure cost restructure cost billion billion million respectively restructure cost record billion relate merger restructure program million related restructuring program million relate legacy scheringplough productivity transformation program restructuring cost record million related restructuring program remainder associate restructure program separation cost billion million million respectively incur associate actual headcount reduction estimate expense exist severance program headcount reduction probable reasonably estimate merck eliminate position relate restructuring program position approximately related restructuring program relate restructuring program position position elimination comprise actual headcount reduction elimination contractor vacant position include restructuring cost curtailment settlement termination charge pension postretirement benefit plan shutdown cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include material production cost research development expense equity income affiliate equity income affiliate reflect performance company joint venture partnership decline primarily drive low equity income msp partnership whollyowne company result merger result reflect consolidated result company begin date merger decrease equity income merial sale old merck interest september partially offset high partnership return azlp decline equity income affiliate reflect decrease equity income msp partnership low partnership return azlp partially offset high equity income merial spmsd decrease equity income msp partnership primarily result low revenue vytorin zetia follow announcement enhance seas clinical trial result low partnership return azlp table content primarily attributable quarter partial redemption old merck interest certain azlp product right result reduction priority return variable return base sale certain astra usa inc product high equity income merial primarily reflect high sale biological product increase equity income spmsd largely attributable high sale gardasil joint venture territory outside united states select joint venture affiliate information vioxx settlement agreement charge november old merck enter agreement settlement agreement law firm comprise executive committee plaintiff steering committee federal multidistrict vioxx litigation representative plaintiff counsel state coordinate proceeding resolve state federal myocardial infarction mi ischemic stroke claim file date old merck united states settlement agreement old merck pay aggregate fix billion fund qualify claim consist billion qualifying mi claim million qualifying claim enter resolution process settlement program million pay fund remainder consequence settlement agreement pretax charge billion record note consolidated financial statement income expense net include income expense net billion gain relate merck previously hold interest msp partnership result merger company obtain control interest msp partnership own company previously company noncontrolle interest business combination acquirer hold noncontrolle equity investment acquiree immediately obtain control acquiree refer step acquisition acquirer require remeasure previously hold equity interest acquiree acquisitiondate fair value recognize result gain loss earning additionally billion gain recognize sale old merck interest merial note consolidated financial statement include income expense net million investment portfolio recognize net gain million charge relate settlement vioxx thirdparty payor litigation united states note consolidated financial statement include income expense net aggregate gain distribution azlp billion note consolidated financial statement gain million relate sale remain worldwide right aggrastat million expense contribution merck company foundation million investment portfolio recognize net loss million charge relate resolution investigation old merck violate state consumer protection law respect sale marketing vioxx merck experience decline interest income compare primarily result low interest rate change investment portfolio mix cash shorterdate security anticipation merger merck recognize high interest expense largely million commitment fee incremental interest expense relate financing merger change income expense net compare primarily aggregate gain azlp billion impact million charge relate resolution certain civil governmental investigation gain million relate sale remain worldwide right aggrastat partially offset million expense contribution merck company foundation increase exchange loss million high recognize loss million net investment portfolio million charge relate resolution investigation old merck violate consumer protection law respect sale marketing vioxx fluctuation exchange loss gain primarily high cost foreign currency contract low interest rate unfavorable impact periodtoperiod change foreign currency exchange rate net long net short foreign currency position consider net monetary asset relate foreign currency contract table content segment profit million pharmaceutical segment profit nonreportable segment profit income income taxis segment profit comprise segment revenue certain element material production cost operating expense include component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker merck allocate production cost standard cost research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit gain related msp partnership amortization purchase accounting adjustment gain disposition merial gain distribution azlp restructuring cost vioxx settlement agreement charge taxis pay joint venture level portion equity income additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item reflect table include miscellaneous corporate profit operate profit relate divested product business supply sale adjustment eliminate effect double counting certain item income expense pharmaceutical segment profit rise largely drive inclusion legacy scheringplough result postmerger period pharmaceutical segment profit decrease largely drive low sale fosamax fosamax plus zocor decrease equity income msp partnership taxis income effective income tax rate effective tax rate reflect favorable impact increase income low tax jurisdiction include favorable impact msp partnership gain high expense certain jurisdiction include amortization purchase accounting adjustment restructure cost effective income tax rate benefit tax settlement include previously announce settlement canada revenue agency cra favorable impact partially offset unfavorable effect gain sale old merck interest merial taxable united states combine federal state tax rate approximately net favorable impact item effective tax rate approximately percentage point effective tax rate reflect net favorable impact compare statutory rate approximately percentage point include favorable impact relate tax settlement result reduction liability unrecognized tax benefit approximately million realization foreign tax credit favorable tax impact foreign exchange rate change fourth quarter particularly strengthen japanese yen dollar partially offset unfavorable impact result azlp gain fully taxable united states combine federal state tax rate approximately quarter old merck decide distribute certain prior year foreign earning united states result utilization foreign tax credit foreign tax credit arise result tax payment outside united states prior year realizable quarter base change old merck decision distribute foreign earning effective tax rate reflect reduction domestic pretax income primarily result vioxx settlement agreement charge relate change mix domestic foreign pretax income net income earning common share net income available common shareholder billion compare billion billion earning common share assume dilution available common shareholder ep compare increase net income earning share largely drive gain associate msp partnership recognize conjunction merger gain record sale old merck interest merial partially offset incremental charge associate merger include amortization intangible asset table content inventory stepup recognition mergerrelate cost eps affect dilutive impact share issue merger increase net income earning share compare primarily attributable gain distribution azlp impact vioxx settlement agreement civil governmental investigation charge addition increase reflect positive impact certain tax item low inprocess research development cost low expense legal defense cost partially offset high restructuring cost low equity earning recognition insurance arbitration gain nongaap income nongaap ep nongaap income nongaap eps alternative view company performance management merck provide management believe information enhance investor understand company result nongaap income nongaap earning share exclude certain item nature item impact analysis underlie business performance trend exclude item certain purchase accounting item relate merger restructuring activity merger relate cost certain item exclude item significant component understand assess financial performance information nongaap income non gaap eps consider addition lieu net income earning share prepare accordance generally accept accounting principle united states gaap additionally nongaap income nongaap ep measure determine accordance gaap standardize mean prescribed gaap comparable calculation similar measure company nongaap income nongaap ep important internal measure company senior management receive monthly analysis operating result include nongaap income nongaap ep performance company measure basis performance metric senior management annual compensation derive nongaap income nongaap ep table content reconciliation gaap financial measure nongaap financial measure follow million pretax income report gaap increase decrease exclude item purchase accounting restructuring activity mergerrelate cost item gain related msp partnership gain merial gain distribution azlp vioxx settlement agreement charge civil governmental investigation charge insurance arbitration gain taxis income report gaap tax benefit expense exclude item nongaap taxis income nongaap net income ep assume dilution report gaap eps impact exclude item nongaap ep assume dilution purchase accounting adjustment nongaap income nongaap eps exclude certain amount record connection merger note consolidated financial statement amount include amortization intangible asset inventory stepup restructuring activity nongaap income nongaap eps exclude restructuring activity include restructuring activity relate merger note consolidated financial statement amount include employee separation cost accelerate depreciation associate facility sell closed company undertake restructuring different type cover period charge consider nonrecurre management exclude amount nongaap income nongaap eps believe helpful understanding performance continue business mergerrelate cost nongaap income nongaap eps exclude transaction cost associate directly merger integration cost cost exclude management believe cost unique merger transaction representative ongoing normal business activity integration cost associate merger occur year impact year vary integration progress certain item nongaap income nongaap eps exclude certain item item represent substantive unusual item evaluate individual basis evaluation consider quantitative table content qualitative aspect unusual nature generally represent item result nature magnitude management anticipate occur company normal business regular basis certain item include item gain fair value adjustment merck exist interest msp partnership result merger gain divestiture interest merial gain distribution azlp certain legal settlement research development chart reflect company current research pipeline february set forth item business research development research development update connection merger company assess pipeline identify promise highpotential compound development company complete prioritization clinical development program company continue work prioritization value add program relate currently market product preclinicaldiscovery program company anticipate prioritization process complete half connection process company recognize non cash impairment charge cancellation certain legacy scheringplough pipeline program measure fair value capitalize connection merger noncash impairment charge anticipate exclude company nongaap earning material company future gaap earning company currently number candidate regulatory review united states internationally additionally company drug candidate phase iii development mk vernakalant iv investigational candidate treatment atrial fibrillation currently undergo regulatory review eu april old merck cardiome pharma corp cardiome announce collaboration license agreement development commercialization vernakalant provide merck exclusive right outside united states canada mexico intravenous formulation vernakalant vernakalent oral currently phase ii development merck exclusive global right oral formulation vernakalent maintenance normal heart rhythm patient atrial fibrillation sch mff combination previously approve drug treatment asthma mometasone asmanex formoterol foradil company aim create new option patient bring key treatment july scheringplough announce file new drug application nda fda mff mff currently regulatory review eu sch nomace oral contraceptive combine selective progestin estradiol estrogen woman produce naturally drug currently regulatory review eu phase iii development market sch saphris asenapine central nervous system compound bipolar disorder schizophrenia currently undergo regulatory review eu fda approve saphris august sch bridion sugammadex medication design rapidly reverse effect certain muscle relaxant general anesthesia ensure patient remain immobile surgical procedure differ reversal agent administer muscle relaxant begins wear bridion receive regulatory approval eu australia new zealand japan regulatory review market include united states prior merger scheringplough receive complete response letter fda bridion follow communication fda company assess agencys feedback order determine new timetable response sch boceprevir hepatitis c protease inhibitor currently development boceprevir fully enrol phase iii program company expect conclude mid company expect submit nda fda boceprevir end treatmentexperience treatmentnave patient hepatitis c table content mk ridaforolimus novel mtor mammalian target rapamycin inhibitor evaluate treatment cancer drug candidate jointly develop commercialize ariad pharmaceuticals inc agreement enter phase iii study succeed patient metastatic softtissue bone sarcoma underway company continue anticipate file nda ridaforolimus fda subject review result plan interim analysis succeed sch allergy immunotherapy sublingual tablet ait grass pollen allergy develop company november sch meet primary endpoint phase iii study adult subject united states history grass pollen induce rhinoconjunctivitis asthma investigational grass ait treatment design work induce protective immune response grass pollen allergy provide sustained prevention allergy symptom treat symptom underlie cause disease sch ait ragweed allergy phase iii development market sch vorapaxar thrombin receptor antagonist antiplatelet protease activate receptor inhibitor study prevention treatment thrombosis november merck announce completion patient enrollment patient tra ptimi clinical trial phase iii randomized doubleblind placebocontrolle multinational study trial assess ability sch prevent major cardiovascular event add current antiplatelet regimen aspirin aspirin plus adp inhibitor patient previously experience heart attack stroke peripheral arterial disease sch study treatment patient acute coronary syndrome ongoing phase iii thrombin receptor antagonist clinical event reduction acute coronary syndrome trial lead duke clinical research institute company anticipate file nda vorapaxar fda mk tafluprost preservative free synthetic analogue prostaglandin f reduction elevate intraocular pressure appropriate patient primary openangle glaucoma ocular hypertension april old merck santen announce worldwide licensing agreement tafluprost previously disclose old merck submit file nda fda mkc ezetimibe combine atorvastatin investigational medication treatment dyslipidemia fda refuse file application fda identify additional manufacturing stability datum need company assess fda response anticipate file mkc candidate currently phase iii clinical development combine januvia pioglitazone type diabetes therapy company continue anticipate file nda mkc fda mk odanacatib oral onceweekly investigational treatment osteoporosis osteoporosis disease reduce bone density strength result increase risk bone fracture odanacatib cathepsin k inhibitor selectively inhibit cathepsin k enzyme cathepsin k know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin k novel approach treatment osteoporosis september datum phase iib clinical study odanacatib present st annual meeting american society bone mineral research show stop treatment year increase low lumbar spine bone mineral density bmd reverse year bmd hip femoral neck remain level observe start study additionally year treatment odanacatib mg demonstrate increase bmd key fracture site minimal impact formation new bone measure biochemical marker bone turnover odanacatib currently phase iii clinical trial evaluate largescale global outcome study determine effect vertebral hip nonvertebral fracture company continue anticipate file nda fda v ninevalent hpv vaccine development expand protection cancercause hpv type phase iii clinical program underway merck anticipates file biologic license application bla fda table content mka drug candidate combine extendedrelease er niacin novel flush inhibitor laropiprant mka demonstrate ability low ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol low triglyceride significantly flushing traditional extend release niacin high ldl c low hdlc elevate triglyceride risk factor associate heart attack stroke april old merck receive nonapprovable action letter fda response nda mka meet discuss letter fda state additional efficacy safety datum require suggest old merck wait result treatment hdl reduce incidence vascular event hpsthrive cardiovascular outcome study expect complete company anticipate file nda fda mk mka approve country outside united states treatment dyslipidemia particularly patient combine mixed dyslipidemia characterize elevated level ldlc triglyceride low hdlc patient primary hypercholesterolemia heterozygous familial nonfamilial market tredaptive cordaptive certain country tredaptive patient combination statin cholesterol lower effect statin monotherapy inadequate tredaptive monotherapy patient statin consider inappropriate tolerate mkb drug candidate combine novel approach raise hdlc lower triglyceride er niacin combine laropiprant prove benefit simvastatin combination product merck seek approval mkb united states file complete response relate mka mk anacetrapib inhibitor cholesteryl ester transfer protein show promise lipid management raise hdlc reduce ldlc raise blood pressure november merck announce phase iib study patient primary hypercholesterolemia mixed hyperlipidemia treat anacetrapib monotherapy co administer atorvastatin persistent lipid effect high dose arm monotherapy coadministration treatment group week stop active therapy anacetrapib effect cetp inhibition cardiovascular risk establish phase iii trial title define ongoing evaluate safety efficacy anacetrapib patient coronary heart disease company anticipate file nda fda previously disclose old merck announce delaying file application telcagepant mk company investigational calcitonin gene relate peptide cgrpreceptor antagonist intermittent treatment acute migraine decision base finding phase iia exploratory study small number patient take telcagepant twice daily month prevention migraine find marked elevation liver transaminase daily dose regimen prevention study different dose regiman phase iii study telcagepant intermittently administer dose treat individual migraine attack occur study telcagepant acute intermittent treatment migraine continue follow meeting regulatory agency end merck planning conduct additional safety study overall phase iii program telcagepant result study inform plan filing approval sch acadesine potential firstin class adenosine regulate agent ischemia reperfusioninjury patient undergo heart bypass surgery patient enrollment red cabg phase iii clinical trial initiate sch vicriviroc treatment hiv infection treatment experience evaluate phase iii study patient population announce january primary efficacy endpoint meet merck submit nda fda vicriviroc treatmentexperience hivinfecte patient time continue evaluate vicriviroc firstline therapy treatmentnaive patient previously disclose cubist pharmaceuticals inc cubist enter license agreement old merck development commercialization cubicin daptomycin injection mk japan merck develop commercialize cubicin whollyowne subsidiary banyu pharmaceutical co ltd cubist commercialize cubicin united states mk currently phase iii development table content mk orexin receptor antagonist potential new approach treatment chronic insomnia currently phase iii development sch elonva corifollitropin alpha injection approve ec control ovarian stimulation combination gnrh antagonist development multiple follicle woman participate assist reproductive technology program currently phase iii development united states merck terminate internal clinical development program esmirtazapine sch hot flash insomnia strategic reason previously disclose old merck announce preliminary result pivotal phase iii study rolofylline mk investigational medicine treatment acute heart failure show rolofylline meet primary secondary efficacy endpoint old merck terminate clinical development program rolofylline inprocess research development connection merger company record fair value human animal health research project underway scheringplough approximately billion consideration transfer merger allocate pharmaceutical segment iprd project billion allocate animal health operating segment iprd project significant project include bridion vorapaxar boceprevir phase iii clinical development ezetimibeatorvastatin combination product project discuss detail note company expect file nda fda boceprevir vorapaxar ezetimibeatorvastatin combination product fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probability adjust future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value discount rate range actual cash flow likely different assume additional research development require program reach technological feasibility cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval december estimate cost complete project phase iii development human health analogous stage development animal health approximately billion iprd project subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally certain iprd program fail abandon development result company portfolio prioritization process company realize future cash flow estimate record iprd merger date company recover research development expenditure merger develop program circumstance occur company future operating result adversely affect acquisition research collaboration license agreement merck continue remain focused augment internal effort capitalize growth opportunity drive near longterm growth transaction broad range therapeutic category early stage technology transaction complete merck actively table content monitor landscape growth opportunity meet company strategic criterion highlight activity include december merck avecia investment limited announce definitive agreement merck acquire biologics business avecia group total purchase price million avecia biologic contract manufacturing organization specific expertise microbialderive biologic term agreement merck acquire avecia biologic limit avecia asset include avecias process development scaleup manufacture quality business support operation locate billingham united kingdom transaction close february accordingly result operation acquire business include merck result operation begin acquisition date july old merck portola pharmaceuticals inc portola sign exclusive global collaboration license agreement development commercialization betrixaban mk investigational oral factor xa inhibitor anticoagulant currently phase ii clinical development prevention stroke patient atrial fibrillation return exclusive worldwide license betrixaban old merck pay portola initial fee million closing record research development expense portola eligible receive additional cash payment total million achievement certain development regulatory commercialization milestone doubledigit royalty worldwide sale betrixaban approve company assume development commercialization cost include cost phase iii clinical trial portola retain option cofund phase iii clinical trial return additional royalty b copromote betrixaban merck united states term agreement commence august terminate early continue remain royalty payment obligation country time agreement expire entirety country agreement terminate party event material uncured breach bankruptcy party agreement terminate merck event party merck decide cease development betrixaban safety efficacy addition merck terminate agreement time day prior write notice portola terminate agreement event merck challenge portola patent cover betrixaban termination agreement depend circumstance party vary right obligation respect continued development commercialization betrixaban case termination cause merck certain royalty obligation april old merck medarex inc medarex massachusetts biologic laboratory mbl university massachusetts medical school announce exclusive worldwide license agreement cda cdb mka know mdxmdx mblcdamblcdb investigational fully human monoclonal antibody combination develop target neutralize clostridium difficile toxin b treatment c difficile infection cda cdb codevelope medarex mbl term agreement merck gain worldwide right develop commercialize cda cdb medarex mbl receive aggregate upfront payment million closing record research development expense potentially eligible receive additional cash payment million aggregate achievement certain milestone associate development approval drug candidate cover agreement commercialization medarex mbl eligible receive doubledigit royalty product sale milestone certain sale target meet term agreement commence closing date terminate early continue remain royalty payment obligation country time agreement expire entirety country party terminate agreement uncured material breach party bankruptcy insolvency party merck terminate agreement time provide day prior write notice medarex mbl april old merck santen pharmaceutical co ltd santen announce worldwide licensing agreement tafluprost mk prostaglandin analogue investigation united states tafluprost preserve preservativefree formulation receive marketing approval reduction elevate intraocular pressure openangle glaucoma ocular hypertension european nordic country japan file approval additional european asia pacific market term agreement old merck pay fee capitalize amortize material table content production cost life underlie patent pay milestone royalty payment base future sale tafluprost preserve preservativefree formulation exchange exclusive commercial right tafluprost western europe exclude germany north america south america africa santen retain commercial right tafluprost country eastern europe northern europe asia pacific include japan merck provide promotion support santen germany poland tafluprost approve united states santen option copromote agreement old merck santen expire countrybycountry basis occur expiry expire valid patent claim b expiration expire royalty merck terminate agreement time day prior write notice time day prior write notice merck determine product present issue safety tolerability addition merck terminate agreement event enumerate agreement santen co ownerlicensor certain intellectual property terminate expire materially adversely affect merck merck santen materially breach agreement fail cure receive notice nonbreache party terminate agreement agreement provide termination noninsolvent party bankruptcy party finally agreement terminate term merck develop commercialize competitive product term define agreement addition april old merck cardiome pharma corp cardiome announce collaboration license agreement development commercialization vernakalant mk investigational candidate treatment atrial fibrillation agreement provide merck exclusive global right oral formulation vernakalant vernakalant oral maintenance normal heart rhythm patient atrial fibrillation provide merck affiliate merck sharp dohme switzerland gmbh exclusive right outside united states canada mexico intravenous iv formulation vernakalant vernakalant iv rapid conversion acute atrial fibrillation normal heart rhythm term agreement old merck pay cardiome initial fee million closing record research development expense addition cardiome eligible receive million payment base achievement certain milestone associate development approval vernakalant product include million submission regulatory approval europe vernakalant iv old merck pay result submission million initiation plan phase iii program vernakalant oral million milestone associate approval subsequent indication intravenous oral formulation cardiome receive tiere royalty payment sale approve product potential receive million milestone payment base achievement significant sale threshold cardiome retain option copromote vernakalant oral merck hospitalbase sale force united states merck responsible future cost associate development manufacturing commercialization candidate merck grant cardiome secure interestbeare credit facility million cardiome access tranches year commence cardiome codevelopment partner north america astellas pharma inc submit nda fda kynapid vernakalant hydrochloride injection december include result pivotal phase iii clinical trial december cardiovascular renal drug advisory committee recommend fda approve vernakalant iv rapid conversion atrial fibrillation august fda issue approvable action letter request additional information phase iib doubleblind placebocontrolle randomized doserange clinical trial patient risk recurrent atrial fibrillation show mg dose vernakalant oral significantly reduce rate atrial fibrillation relapse compare placebo agreement continue effect expiration cardiome copromotion right royalty milestone payment obligation agreement terminate event insolvency material uncured breach party additionally collaboration terminate merck event merck determine good faith advisable continue development commercialization vernakalant product result safety issue addition merck terminate agreement time month prior write notice cardiome terminate agreement event merck challenge cardiome patent cover vernakalant termination agreement depend circumstance party vary right obligation respect continued development commercialization vernakalant case continue royalty obligation table content march old merck acquire insme incs insme portfolio followon biologic therapeutic candidate commercial manufacturing facility locate boulder colorado term agreement old merck pay insme aggregate million cash acquire right boulder facility insmed pipeline followon biologic candidate insmed followon biologic portfolio include clinical candidate mk investigational recombinant granulocytecolony stimulate factor gcsf evaluate ability prevent infection patient cancer receive chemotherapy mk pegylate recombinant gcsf design allow frequent dose transaction account business combination accordingly asset acquire liability assume recorded respective fair value acquisition date determination fair value require management significant estimate assumption connection acquisition substantially purchase price allocate insmed followon biologics portfolio mk mk indefinitelive intangible asset record fair value determine base present value expect future cash flow new product candidate result insmed followon biologics portfolio adjust probability estimate technical marketing success utilize income approach reflect appropriate riskadjuste discount rate ongoing activity relate mk mk expect material company research development expense remain net asset acquire material milestone royalty obligation associate acquisition transaction close march accordingly result operation acquire business include merck result operation begin april company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource disease area unmet medical need scientific opportunity commercial opportunity merck manage research development portfolio diverse approach discovery development balance investment appropriately novel innovative target potential major impact human health develop bestinclass approach deliver maximum value new medicine vaccine new indication new formulation important component company sciencebase diversification base expand company portfolio modality include small molecule vaccine biologic peptide rnai merck move diversify portfolio create new division merck bioventure potential harness market opportunity present biological medicine patent expiry deliver high quality followon biologic product enhance access patient worldwide company continue pursue appropriate external licensing opportunity integration plan research development focus integrate research operation legacy company include provide effective transition employee realize project merger synergy form cost saving revenue growth opportunity maintain momentum company latestate pipeline merck continue implement new model basic research global operating strategy legacy merck research laboratory site new model align franchise function align resource disease area priority balance capacity discovery phase allow company act program high probability success additionally disease area priority company strategy design expand access worldwide external science incorporate external research key component company early discovery pipeline order translate basic research productivity latestage clinical success company clinical pipeline include candidate multiple disease area include anemia atherosclerosis cancer diabetes heart disease hypertension infectious disease inflammatoryautoimmune disease migraine neurodegenerative disease ophthalmic osteoporosis psychiatric disease respiratory disease womens health company supplement internal research aggressive licensing external alliance strategy focus entire spectrum collaboration early research latestage compound new technology table content select joint venture affiliate information expand research base realize synergy combine capability opportunity asset previous year old merck form number joint venture note consolidated financial statement merckscheringplough partnership old merck scheringplough collectively partner enter agreement create equallyowne partnership develop market united states new prescription medicine cholesterol management agreement generally provide equal sharing development cost copromotion approve product company cholesterolmanagement partnership expand include country world exclude japan ezetimibe new class cholesterollowere agent launch united states zetia market ezetrol outside united states combination product contain active ingredient zetia zocor approve united states vytorin market inegy outside united states vytorin combination tablet cholesterol treatment provide ldl cholesterol lower dual inhibition cholesterol production absorption cholesterol agreement provide share operating income generate msp partnership base percentage vary product sale level country market partner share profit zetia vytorin sale equally exception million annual zetia sale scheringplough receive great share profit operating income include expense partner contractually agree share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service ongoing clinical research market support market research market expansion specialty sale force physician education program expense incur support msp partnership share partner market administrative expense include certain sale force cost certain manufacturing cost include equity income affiliate cost reflect overall result legacy company certain research development expense generally share equally partner adjust earn milestone result merger msp partnership own company result msp partnership date merger reflect equity income affiliate result sale msp partnership product merger consolidate merck result sale joint venture product follow million premerger postmerger total vytorin zetia amount exclude sale product partner outside msp partnership follow previously announce enhance sea clinical trial result discuss sale vytorin zetia decline previously disclose january legacy company announce result effect combination ezetimibe highdose simvastatin vs simvastatin atherosclerotic process patient heterozygous familial hypercholesterolemia enhance clinical trial image trial patient heterozygous familial hypercholesterolemia rare genetic condition cause high level ldl bad cholesterol greatly increase risk premature coronary artery disease previously report despite fact ezetimibesimvastatin mg vytorin significantly lower ldl bad cholesterol simvastatin mg significant difference treatment ezetimibesimvastatin simvastatin prespecifie primary endpoint change thickness carotid artery wall year measure ultrasound improve reduction highrisk subject present acute coronary syndrome improveit trial underway design provide cardiovascular outcome data ezetimibesimvastatin patient acute coronary syndrome incremental benefit ezetimibe table content simvastatin cardiovascular morbidity mortality demonstrate simvastatin establish january fda announce complete review final clinical study report enhance fda state result enhance change position elevate ldl cholesterol risk factor cardiovascular disease lower ldl cholesterol reduce risk cardiovascular disease july efficacy safety result simvastatin ezetimibe aortic stenosis sea study announced sea design evaluate intensive lipid lower vytorin mg reduce need aortic valve replacement risk cardiovascular morbidity mortality versus placebo patient asymptomatic mild moderate aortic stenosis indication statin therapy vytorin fail meet primary end point reduction major cardiovascular event study patient group take vytorin mg high incidence cancer group take placebo nonsignificant increase death cancer patient group take vytorin versus take placebo cancer cancer death distribute major organ system company believe cancer finding sea likely anomaly take light available datum support association vytorin august fda announce investigate result sea trial december fda announce complete review datum sea trial review interim datum study heart renal protection sharp improveit trial base currently available information fda indicate believe unlikely vytorin zetia increase risk cancerrelate death sharp trial expect complete improveit trial schedule completion improveit trial blind interim efficacy analysis conduct datum safety monitoring board trial approximately endpoint accrue interim analysis expect conduct company commit work regulatory agency evaluate available data interpretation datum company believe change clinical use vytorin warrant note consolidated financial statement information respect litigation involve partner msp partnership relate sale promotion zetia vytorin result old merck interest msp partnership completion merger record equity income affiliate equity income billion billion billion financial statement msp partnership include item financial statement schedule astrazeneca lp old merck enter agreement astra ab astra develop market astra product royaltybeare license old merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami old merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach line old merck astra complete restructure ownership operation joint venture old merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical lp partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca lp azlp astras merger zeneca group plc astrazeneca merger exclusive distributor product kbi retain right table content maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale current future kbi product revenue billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent merck share undistribute azlp gaap earning return aggregate million million million respectively astrazeneca merger trigger partial redemption march old merck interest certain azlp product right redemption old merck receive billion azlp base primarily multiple old merck average annual variable return derive sale astra usa inc product year prior redemption limited partner share agree value pretax gain billion partial redemption record partial redemption old merck interest product right result change old merck limited partnership interest conjunction restructure astra purchase option asset option payment million record deferred income buy old merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi products astrazeneca exercise asset option half exercise price million represent net present value march project future pretax revenue receive old merck nonppi product appraise value february astrazeneca notify company exercise asset option old merck right require astra purchase interest appraise value february old merck advise astrazeneca exercise asset option million remain defer recognize asset option consummate addition old merck grant astra option share option buy old merck common stock interest kbi old merck interest nexium prilosec exercisable year astra exercise asset option astra exercise share option combine annual sale product fall minimum provide case long astrazenecas asset option exercise exercise price share option base net present value estimate future net sale nexium prilosec determine time exercise subject certain trueup mechanism astrazeneca merger constitute trigger event kbi restructuring agreement result merger exchange old mercks relinquishment right future astra product exist pende patent time merger astra pay million advance payment advance payment defer remain subject trueup calculation trueup directly dependent fair market value march astra product right retain old merck calculate trueup million return azlp march pretax gain million recognize related residual advance payment balance provision kbi restructuring agreement trigger event occur sum limit partner share agree value appraise value trueup guarantee minimum billion distribution limited partner share agree value payment trueup result cash receipt old merck billion aggregate pretax gain billion include income expense net astrazeneca purchase old merck interest nonppi product contingent exercise asset option astrazeneca payment appraise value occur march billion outstanding loan astra plus interest redemption date settle result transaction old merck receive net proceed azlp billion table content merial limited old merck rhnepoulenc sa sanofiaventis combine animal health business form merial limited merial fully integrate animal health company standalone joint venture own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie september old merck sell interest merial sanofiaventis billion cash sale result recognition billion gain reflect income expense net connection sale merial old merck sanofiaventis scheringplough sign option agreement term option agreement follow closing merger sanofiaventis option require company combine intervetscheringplough animal health business merial form animal health joint venture own equally company sanofiaventis option agreement value merial fix billion minimum total value receive company affiliate contribute intervetscheringplough combine entity billion subject customary transaction adjustment consist floor valuation intervetschere plough fix minimum billion subject potential upward revision base valuation exercise party additional payment sanofiaventis million base valuation exercise intervetscheringplough customary transaction adjustment merial intervetscheringplough combine payment required pay party joint venture equally own company sanofiaventis payment trueup value contribution equal formation new animal health joint venture sanofiaventis subject customary closing condition include antitrust review united states europe prior closing merger agreement provide old merck certain right terminate option fee million recognition termination fee defer fourth quarter condition trigger payment lapse sale joint venture product follow million fipronil product biological product avermectin product product amount include sale september divestiture date sanofi pasteur msd old merck pasteur merieux connaught sanofi pasteur sa establish own joint venture market vaccine europe collaborate development combination vaccine distribution europe sale joint venture product follow million gardasil influenza vaccine viral vaccine hepatitis vaccine rotateq vaccine table content johnson johnsonmerck consumer pharmaceutical company old merck form joint venture johnson johnson develop market broad range nonprescription medicine consumer own joint venture subsequently expand canada significant joint venture product pepcid ac overthecounter form company ulcer medication pepcid pepcid complete overthecounter product combine company ulcer medication antacids sale joint venture product follow million gastrointestinal product product capital expenditure capital expenditure billion billion billion expenditure united states million million million expenditure include million production facility million research development facility million environmental project million administrative safety general site project approximately represent capital investment relate multiyear initiative standardize company information system depreciation expense billion billion billion billion billion billion respectively apply location united states total depreciation expense include accelerate depreciation million million million respectively associate restructuring activity note consolidated financial statement analysis liquidity capital resource merck strong financial profile enable fully fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operation total debt billion cash portion consideration merger fund combination exist cash include proceed sale old merck interest merial discuss sale redemption shortterm investment issuance debt preparation merger old merck close underwritten public offer billion senior unsecured note discuss additionally significant portion longterm investment december liquidate anticipation merger cash provide operating activity billion billion billion continue company primary source fund finance operating need capital expenditure treasury stock purchase dividend pay shareholder cash provide operating activity reflect billion payment vioxx settlement fund million payment connection previously disclose settlement cra cash provide operating activity reflect billion receive connection partial redemption old merck partnership interest azlp represent table content distribution old merck accumulate earning investment azlp inception cash provide operating activity affect million payment connection previously disclose resolution investigation civil claim federal state authority relate certain past marketing selling activity million payment vioxx settlement fund cash provide operating activity reflect payment previously disclose settlement internal revenue service irs cash provide investing activity billion compare cash investing activity billion change primarily drive release restrict cash primarily release pledge collateral certain vioxxrelate matter low purchase security investment proceed disposition old merck interest merial increase cash investing activity partially offset use cash fund merger distribution azlp represent return old merck investment azlp cash investing activity billion compare billion low use cash investing activity primarily reflect distribution azlp billion payment connection december acquisition sirna therapeutics inc partially offset high net purchase security investment high capital expenditure increase restrict asset cash financing activity billion compare billion reflect issuance billion senior unsecured note purchase treasury stock low payment debt partially offset net decrease shortterm borrowing cash financing activity billion compare billion reflect high purchase treasury stock low proceed exercise stock option high payment debt connection settlement note astra partially offset net increase shortterm borrowing dividend pay stockholder billion billion december total worldwide cash investment billion include billion cash cash equivalent shortterm investment million longterm investment addition company million cash investment restrict certain collateral arrangement discuss work capital level adequate meet operating requirement company august old merck execute billion letter credit agreement financial institution satisfy certain condition set forth vioxx settlement agreement note consolidated financial statement old merck pledge collateral financial institution approximately billion pursuant term letter credit agreement asset pledge collateral set letter credit agreement asset hold custody party asset manage old merck old merck consider asset pledge letter credit agreement restrict letter credit require collateral balance decline payment million settlement agreement december billion record deferred income taxis current asset billion classified asset remain payment vioxx settlement fund pursuant vioxx settlement agreement accordingly letter credit agreement terminate collateral release previously disclose irs complete examination old merck tax return year result examination old merck aggregate payment billion february payment offset tax refund million receive amount previously pay matter ii federal tax benefit approximately million related interest include payment result net cash cost old merck approximately billion impact year subsequent item review examination include payment year remain open respect close irs examination material impact result operation amount previously accrue previously disclose october cra issue old merck notice reassessment contain adjustment relate certain intercompany pricing matter february old merck cra negotiate settlement agreement regard matter accordance settlement old merck pay additional tax approximately million dollar interest approximately million dollar table content additional amount penalty assessment settlement account quarter old merck previously establish reserve matter significant portion taxis pay expect creditable tax purpose resolution matter material effect financial position liquidity respect associate collateral discuss addition july november cra propose additional adjustment respectively relate intercompany pricing matter adjustment increase canadian tax approximately million dollar plus million dollar interest december possible cra propose similar adjustment later year company disagree position take cra believe merit company intend contest assessment cra appeal process court necessary management believe resolution matter material effect company financial position liquidity connection appeal process matter discuss old merck pledge collateral financial institution provide guarantee cra quebec ministry revenue represent portion tax interest assess result settlement note guarantee require appeal dispute reduce eliminate approximately million associate collateral release certain cash investment continue collateralized guarantee require appeal canadian tax dispute collateral include defer income taxis current asset asset consolidate balance sheet total approximately million billion december respectively irs examine old merck federal income tax return addition state foreign tax examination progress significant tax jurisdiction state foreign company income tax return open examination period second quarter irs complete examination scheringplough federal income tax return company seek resolution issue raise examination irs administrative appeal process july scheringplough payment million irs pertain examination company income tax return remain open irs tax year irs commence examination federal income tax return examination expect complete significant tax jurisdiction state foreign company income tax return open examination period company contractual obligation december follow payment period million total purchase obligation loan payable current portion longterm debt longterm debt interest relate debt obligation unrecognize tax benefit operating lease december company consolidated balance sheet reflect liability unrecognize tax benefit interest penalty billion include million reflect current liability high degree uncertainty time future cash outflow liability unrecognize tax benefit year reasonable estimate period cash settlement year table content purchase obligation consist primarily good service enforceable legally binding include obligation minimum inventory contract research development advertising amount reflect research development obligation include contingent milestone payment loan payable current portion longterm debt reflect million longdate note subject repayment option holder annual basis require funding obligation relate company pension postretirement benefit plan expect material company currently anticipate contribute approximately million million respectively pension plan postretirement benefit plan june old merck close underwritten public offer billion senior unsecured note consist billion aggregate principal note billion aggregate principal note billion aggregate principal note million aggregate principal note interest note payable semiannually note series redeemable time company option redemption price specify note associate prospectus proceed note fund portion cash consideration merger december company file security registration statement security exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year connection merger march old merck enter finance commitment letter jpmorgan chase bank na jp morgan securities inc collectively jpmorgan jpmorgan commit provide billion financing old merck enter billion day senior unsecured interim term loan facility bridge loan facility billion day asset sale revolve credit facility asset sale facility billion day corporate revolve credit facility incremental facility connection billion offering bridge loan facility terminate commitment lender day asset sale facility reduce completion sale merial sanofiaventis note consolidated financial statement asset sale facility terminate incremental facility available backstop commercial paper general corporate purpose facility draw expire november merck incur commitment fee approximately million associate facility amortize commitment period april old merck amend billion year revolve credit facility mature april allow facility remain place merger company exist billion credit facility mature august remain outstanding facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility connection merger effective november new merck execute unconditional guarantee exist debt old merck old merck execute unconditional guarantee exist debt new merck exclude commercial paper include payment principal interest company longterm credit rating assign moodys investor service standard poor aa stable outlook aa positive outlook respectively rating continue allow access capital market flexibility obtain fund competitive term company continue maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer despite strong financial profile certain contingent event realize discuss note consolidated financial statement material adverse impact company liquidity capital resource company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation november february board director declare quarterly dividend share company common stock second quarter respectively declare table content quarterly dividend share mandatory convertible preferred stock second quarter respectively november board director approve purchase time billion merck common stock treasury purchase treasury stock old merck purchase billion billion treasury stock respectively previous program approve old merck board director july financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment dollarbase research development extent dollar value cash flow diminish result strengthen dollar company ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate functional currency entity objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company partially hedge forecast foreign currency denominate party intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion party intercompany distributor sale hedge get close expect date forecast foreign currency denominate sale probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase value anticipate foreign currency cash flow company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow weak dollar result net benefit market value merck hedge decline million million respectively uniform weaken dollar december market value determine foreign exchange option pricing model hold factor exchange rate constant merck principally use purchase local currency option uniform weaken dollar yield large overall potential loss market value option sensitivity measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe table content threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow dollar functional currency company foreign subsidiary primary objective balance sheet risk management program protect dollar value foreign currency denominate net monetary asset effect volatility foreign exchange occur prior conversion dollar instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange dollar cash flow derive net asset dollar functional currency company foreign subsidiary merck execute spot trade convert foreign currency dollar base shortterm forecast need dollar proceed invest require company foreign subsidiary merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level applicable company use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly strengthen currency exposure company december income taxis decline million company net long position relative major foreign currency consideration forward contract uniform strengthen dollar yield large overall potential net loss earning exchange december old merck net short position relative major foreign currency consideration forward contract uniform weaken dollar reduce income taxis million measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow venezuelan economy recently determine hyperinflationary require company remeasure local currency operation dollar accordingly accordance gaap company remeasure monetary asset liability operation earning quarter effective january venezuelan government devalue currency bsf dollar twotiere official exchange rate essential rate bsf dollar nonessential rate bsf dollar company product expect classified essential anticipate majority transaction settle essential rate bsf dollar action adverse effect company result operation financial position cash flow interest rate risk management addition revenue hedge balance sheet risk management program company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party seven payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap mature notional amount million effectively convert company million fixedrate note float rate instrument swap mature notional amount million effectively convert million company billion fixedrate note float rate instrument fair value change note attributable change benchmark interest rate record interest expense offset fair value change swap table content contract old merck terminate interest rate swap contract notional amount million terminate interest rate swap contract notional million swap effectively convert billion fixedrate note million fixedrate note variable rate debt result swap termination old merck receive million cash exclude accrue interest material correspond gain relate basis adjustment debt associate terminate swap contract defer amortize reduction interest expense remain term note cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value merck investment debt relate swap contract change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument million million respectively percentage point decrease december negatively affect net aggregate market value million million respectively increase sensitivity interest rate movement prior year attributable sale redemption longterm fix rate investment fund merger increase debt include exist scheringplough debt debt issue fund merger fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model critical accounting policy matter companys consolidated financial statement include certain amount base management good estimate judgment estimate accounting amount record connection merger acquisition include fair value determination asset liability additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement merger acquisition january new guidance issue fasb adopt change way acquisition method apply business combination change way asset liability recognize purchase accounting prospective basis acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur company determine asset acquire meet definition business acquisition method accounting transaction table content account acquisition asset business combination goodwill record fair value intangible asset include acquire inprocess research development base significant judgment management accordingly significant item company typically obtain assistance party valuation specialist amount allocate acquire inprocess research development capitalize account similar indefinitelived intangible asset subject impairment testing completion abandonment project successful completion project merck separate determination useful life asset begin amortization valuation useful life assumption base information available near merger acquisition date base expectation assumption deem reasonable management judgment determine estimate fair value assign asset acquire liability assume asset life materially affect company result operation fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain market regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent net cash flow probability adjust appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probability adjust future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate revenue recognition revenue sale product recognize time delivery title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale provision aggregate indirect customer discount cover chargeback rebate chargeback discount occur contract customer purchase directly intermediary wholesaler contract customer generally purchase product contract price plus markup wholesaler wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision base expect payment drive patient usage contract performance benefit provider customer company use historical customer segment mix adjust know event order estimate expect provision amount accrue aggregate indirect customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager customer amount accrue adjustment record trend significant event indicate change estimate provision appropriate table content company continually monitor provision aggregate indirect customer discount material adjustment estimate associate aggregate indirect customer discount provision summarize information change aggregate indirect customer discount accrual follow millions balance january current provision scheringplough accrual assume merger adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million million respectively december million million respectively december company maintain return policy allow customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market additional generic competition change formulary launch overthecounter product product return provision actual return net sale distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return wholesaler generally provide mention datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin relate product candidate phase iii clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december significant table content contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable december old merck aggregate reserve approximately billion vioxx reserve settlement program future legal defense cost worldwide relate vioxx product liability lawsuit ii vioxx shareholder lawsuit iii vioxx foreign lawsuit iv vioxx investigation collectively vioxx litigation note consolidated financial statement merck spend approximately million aggregate legal defense cost worldwide include approximately million fourth quarter relate vioxx litigation addition old merck pay additional billion settlement fund connection settlement program merck record charge million include million fourth quarter solely future legal defense cost vioxx litigation consequently december aggregate vioxx reserve approximately million solely future legal defense cost vioxx litigation significant factor consider review vioxx reserve follow actual cost incur company development company legal defense strategy structure light scope vioxx litigation include settlement agreement expectation certain lawsuit continue pende number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial vioxx litigation vioxx reserve december represent company good estimate minimum defense cost incur connection remain aspect vioxx litigation event additional trial vioxx litigation event arise course vioxx litigation affect ultimate defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase vioxx reserve time future base factor set forth believe appropriate vioxx product liability lawsuit trial schedule company predict timing trial relate vioxx litigation company believe meritorious defense vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit include settlement program company establish reserve potential liability relate vioxx lawsuit include settlement program reserve establish connection resolution shareholder derivative lawsuit note consolidated financial statement vioxx investigation unfavorable outcome vioxx litigation material adverse effect company financial position liquidity result operation december old merck remaining reserve approximately million solely future legal defense cost fosamax litigation merck spend approximately million add million reserve consequently december company reserve approximately million solely future legal defense cost fosamax litigation significant factor consider establishment reserve fosamax litigation legal defense cost follow actual cost incur company far development company legal defense strategy structure light creation fosamax multidistrict litigation number case bring company anticipate timing progression relate cost pretrial activity table content fosamax litigation company continue monitor legal defense cost review adequacy associate reserve uncertain nature litigation company unable estimate cost quarter company establish reserve potential liability relate fosamax litigation unfavorable outcome fosamax litigation material adverse effect company financial position liquidity result operation company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify provide cost past old merck perform worldwide survey assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually similar process follow legacy scheringplough site company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation environmental liability million estimate million year management opinion liability environmental matter probable reasonably estimable accrue total million million december december respectively liabilitie undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option pension postretirement benefit plan net pension postretirement benefit cost total million million million increase compare primarily million cost associate scheringplough benefit plan date merger december decrease compare primarily low amortization actuarial net loss higher expect return plan asset partially offset increase termination benefit attributable restructuring action pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect table content prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come december discount rate company pension postretirement benefit plan range compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum actual return company plan asset reference information company develop forwardlooke return expectation asset category weight average expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate result analysis company expect rate return range compare range pension postretirement benefit plan company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact net pension postretirement benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact net pension postretirement benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption record component accumulate comprehensive income expect return pension plan base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize marketrelated value asset ratably fiveyear period net loss amount accumulate comprehensive income excess certain threshold amortize net pension postretirement benefit cost average remain service life employee amortization net loss companys plan december expect increase net pension postretirement benefit cost approximately million annually restructure cost restructuring cost record connection restructuring program design reduce cost structure increase efficiency enhance competitiveness result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance relate cost reflect restructuring cost assetrelate charge reflect material production cost research development expense depend nature asset table content impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach company test goodwill impairment annually fair value base test goodwill represent excess consideration transfer fair value net asset business purchase assign reporting unit acquire intangible exclude inprocess research development record fair value amortize straightline basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate cash flow company test indefinitelive intangible include inprocess research development impairment annually onestep test compare fair value indefinite live intangible asset asset carry value impairment testing purpose company combine separately record indefinitelive intangible asset unit account base relevant fact circumstance generally company combine indefinitelive intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize company operate result impairment investment company review investment impairment base determination decline market value investment carrying value otherthan temporary company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment april new authoritative guidance fasb adopt amend otherthantemporary recognition guidance debt security pursuant new guidance otherthantemporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize comprehensive income taxis income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operates estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax table content position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning recently issue accounting standard june fasb issue amendment accounting disclosure requirement transfer financial asset effective january amendment eliminate concept qualify specialpurpose entity change requirement derecognize financial asset require enhance disclosure provide financial statement user great transparency transfer financial asset include securitization transaction entitys continue involvement exposure risk relate transfer financial asset effect adoption company financial position result operation expect material june fasb amend exist accounting disclosure guidance consolidation variable interest entity effective january amend guidance require enhance disclosure intend provide user financial statement transparent information enterprise involvement variable interest entity effect adoption company financial position result operation expect material october fasb issue new guidance revenue recognition multiple deliverable effective revenue arrangement enter materially modify fiscal year begin june early adoption permit guidance eliminate residual method current guidance replace relative sell price method allocate revenue multiple deliverable arrangement sell price deliverable shall determine vendor specific objective evidence sell price exist thirdparty evidence sell price shall exist deliverable vendor shall use good estimate sell price deliverable adoption guidance require expand qualitative quantitative disclosure company currently assess impact adoption financial position result operation january fasb amend exist disclosure guidance fair value measurement effective january disclosure purchases sale issuance settlement roll forward activity level fair value measurement effective january thing update guidance require additional disclosure amount significant transfer level level measurement require certain level disclosure gross basis additionally update amend exist guidance require great level disaggregate information robust disclosure valuation technique input fair value measurement amend guidance require additional disclosure adoption affect company financial position result operation table content cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form k q k item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck co inc subsidiary december relate consolidated statement income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck co inc subsidiary year end december millions share amount sale cost expense material production marketing administrative research development restructuring cost equity income affiliate vioxx settlement agreement charge income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck co inc preferred stock dividend net income available common shareholder basic earning common share available common shareholder earning common share assume dilution available common shareholder accompany note integral consolidated financial statement table content consolidate balance sheet merck co inc subsidiary december millions share amount asset current asset cash cash equivalent shortterm investment account receivable net allowance doubtful account inventory exclude inventory classify asset note defer income taxis current asset total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress allowance depreciation goodwill intangible net asset liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable mandatory convertible prefer stock par value authorize share issue outstanding share total current liability longterm debt defer income taxis noncurrent liability merck co inc stockholders equity common stock par value par value authorize share share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck co inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck co inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck co inc total comprehensive income net tax comprehensive income net tax cumulative effect adoption guidance accounting unrecognized tax benefit cash dividend declare common stock share treasury stock share purchase acquisition novacardia inc net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck co inc total comprehensive loss net tax comprehensive income net tax cash dividend declare common stock share treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck co inc total comprehensive loss net tax comprehensive income net tax scheringplough merger cancellation treasury stock prefer stock conversion cash dividend declare common stock share net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck co inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity gain related merckscheringplough partnership gain disposition interest merial limited gain distribution astrazeneca lp equity income affiliate dividend distribution equity affiliate vioxx settlement agreement charge depreciation amortization defer income taxis sharebase compensation inprocess research development taxis pay internal revenue service settlement net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity cash flow invest activity capital expenditure purchase security investment proceed sale security investment proceed sale interest merial limited scheringplough merger net cash acquire acquisition business net cash acquire distribution astrazeneca lp increase restricted asset net cash provide investing activity cash flow financing activity net change shortterm borrowing proceed issuance debt payment debt purchase treasury stock dividend pay stockholder dividend pay proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent net increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year supplemental cash flow information note accompany note integral consolidated financial statement table content note consolidated financial statement merck co inc subsidiarie million share amount nature operation november merck co inc old merck scheringplough corporation scheringplough complete previouslyannounce merger merger merger scheringplough acquire share old merck whollyowne subsidiary scheringplough rename merck sharp dohme corp scheringplough continue survive public company rename merck co inc new merck company accounting purpose merger treat acquisition old merck consider accounting acquirer accordingly accompany financial statement reflect old merck standalone operation exist prior completion merger reference financial statement merck period prior merger refer old merck period completion merger new merck results scheringploughs business include new merck financial statement period subsequent completion merger new merck financial result reflect year legacy scheringplough operation merger result inclusion scheringplough asset liabilitie merger date respective fair value limited exception accordingly merger materially affect merck result operation financial position note company global health care company deliver innovative health solution medicine vaccine biologic therapie consumer animal product market directly joint venture company operation principally manage product basis comprise reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesalers physician distributor government entity company professional representative communicate effectiveness safety value pharmaceutical vaccine product health care professional private practice group practice manage care organization company animal health operation discover develop manufacture market animal health product include vaccine company professional representative communicate safety value company animal health product veterinarian distributor animal producer additionally company consumer health care operation develop manufacture market overthecounter foot care sun care product sell wholesale retail drug food chain mass merchandiser outlet united states canada summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis merger acquisition january new guidance issue financial accounting standard board fasb adopt change way acquisition method apply table content business combination acquisition method accounting require asset acquire liability assume record date merger acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement result operation date merger acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record foreign currency translation international subsidiary local currency determine functional currency net asset subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include accumulate comprehensive income loss aoci reflect separate component equity subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost market cost substantial majority domestic pharmaceutical vaccine inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstin firstout fifo method inventory consist currently market product certain product await regulatory approval evaluate recoverability inventory produce preparation product launch company consider probability revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt equity security classify availableforsale report fair value fair value company investment determine quote market price active market identical asset liability quote price similar asset liability input observable corroborate observable market datum substantially term asset liability change fair value consider temporary report net tax aoci decline fair value equity security consider otherthantemporary impairment loss charge income expense net company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment april new guidance issue fasb adopt amend otherthantemporary recognition guidance debt security pursuant new guidance otherthantemporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning record income expense net limited portion attribute table content credit loss remain portion otherthantemporary impairment relate factor recognize aoci realize gain loss debt equity security include income expense net revenue recognition revenue sale product recognize time delivery title risk loss pass customer recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale accrual chargeback reflect direct reduction account receivable accrual rebate record current liability accrue balance relative provision include account receivable accrue current liability million million respectively december million million respectively december company recognize revenue sale vaccine federal government placement stockpile relate pediatric vaccine stockpile accordance securities exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate method estimate useful life primarily range year building year machinery equipment office furnishing software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development capitalize software cost include property plant equipment amortize begin asset substantially ready use capitalize software cost associate company multiyear implementation enterprisewide resource planning system amortize year december approximately million million respectively remain unamortized capitalize software cost associate initiative capitalize software cost amortize period range year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business purchase goodwill assign reporting unit evaluate impairment annual basis fair value base test goodwill increase substantially result merger note acquire intangible acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year note event circumstance warrant review company assess recoverability future operation acquire intangible pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow acquire intangible balance increase substantially result merger note inprocess research development inprocess research development iprd represent fair value assign incomplete research project company acquire business combination time acquisition reach technological feasibility transaction close prior fair value project expense acquisition transaction close fair value research project record intangible asset consolidate balance sheet expense amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project table content merck determination useful life intangible asset begin amortization company test indefinitelive intangible include inprocess research development impairment annually onestep test compare fair value indefinitelive intangible asset asset carry value iprd increase result merger note research development research development expense incur upfront milestone payment party connection research development collaboration prior regulatory approval expense incur payment party subsequent regulatory approval capitalize amortize shorter remaining license product patent life nonrefundable advance payment good service future research development activity expense activity perform good receive payment sharebased compensation company expense sharebased payment employee include grant stock option requisite service period base grant date fair value award restructuring cost company record liability cost associate exit disposal activity period liability incur cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period employee termination cost primarily record action probable estimable contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty exchange gain loss associate uncertain tax position component taxis income consolidate statement income use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection merger acquisition include fair value determination asset liability additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation recently adopt accounting standard new accounting standard issue fasb adopt january new guidance business combination adopt change way acquisition method apply business combination guidance require acquirer recognize asset acquire liability assume acquisition date fair value limited exception additionally guidance require contingent consideration record fair value acquisition date acquire inprocess research development capitalize record intangible asset acquisition table content date require transaction cost cost restructure acquire company expense april additional guidance issue amend accounting contingency business combination company business combination transaction account new guidance include merger note january new guidance accounting reporting disclosure noncontrolle interest adopt require thing noncontrolle interest record equity consolidated financial statement adoption new guidance result reclassification billion noncontrolling interest refer minority interest separate component equity consolidate balance sheet note additionally net income attributable noncontrolle interest show separately parent net income consolidate statement income prior period restate reflect presentation disclosure requirement new guidance january new guidance adopt require enhance disclosure derivative instrument hedging activity allow well understanding effect entity financial position financial performance cash flow thing new guidance require disclosure fair value derivative instrument associate gain loss tabular format note new guidance require additional disclosure derivative hedging activity adoption affect merck financial position result operation january new guidance adopt clarifie unvested sharebased payment award contain nonforfeitable right dividend dividend equivalent pay unpaid consider participate security shall include computation earning share pursuant class method effect adoption material merck result operation provision guidance retrospective prior period restate note january new guidance adopt define collaborative arrangement establish reporting requirement transaction participant collaborative arrangement participant arrangement party effect adoption material merck financial position result operation note associated disclosure company collaborative arrangement january new guidance adopt clarifie account certain transaction impairment consideration involve equity method investment effective prospective basis january new guidance adopt clarifie defensive intangible asset intangible asset entity intend actively use intend hold prevent obtain access asset account separate unit accounting assign useful life reflect entitys consumption expect benefit relate asset guidance effective prospective basis april new guidance adopt establish general standard accounting disclosure event occur balance sheet date financial statement issue available issue guidance subsequently amend february long require disclosure date entity evaluate subsequent event effect adoption material april new guidance adopt provide additional guideline estimate fair value significant decrease volume level activity asset liability relation normal market activity asset liability similar asset liability addition new guidance include guideline identify circumstance indicate transaction asset liability orderly case entity shall place little weight transaction price indicator fair value effect adoption merck financial position result operation material april new guidance adopt amend otherthantemporary recognition guidance debt security impairment model equity securities affect impairment exist current fair value individual security amortize cost basis pursuant new guidance otherthantemporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security table content likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize comprehensive income loss determine credit loss occur company evaluate expect cash flow receive sufficient recover amortize cost basis security new guidance material effect adoption period adoption december december company adopt new guidance amend exist authoritative literature provide guidance employer disclosure plan asset define pension postretirement benefit plan amend guidance require disclosure plan asset include investment allocation decision major category plan asset input valuation technique measure fair value plan asset effect fair value measurement significant unobservable input level change plan asset period significant concentration risk plan asset amend guidance require additional disclosure company pension postretirement plan asset note adoption affect company financial position result operation recently issue accounting standard fasb issue new accounting pronouncement effective company june fasb issue amendment accounting disclosure requirement transfer financial asset effective january amendment eliminate concept qualify specialpurpose entity change requirement derecognize financial asset require enhance disclosure provide financial statement user great transparency transfer financial asset include securitization transaction entitys continue involvement exposure risk relate transfer financial asset effect adoption company financial position result operation expect material june fasb amend exist accounting disclosure guidance consolidation variable interest entity effective january amend guidance require enhance disclosure intend provide user financial statement transparent information enterprise involvement variable interest entity effect adoption company financial position result operation expect material october fasb issue new guidance revenue recognition multiple deliverable effective revenue arrangement enter materially modify fiscal year begin june early adoption permit guidance eliminate residual method current guidance replace relative sell price method allocate revenue multiple deliverable arrangement sell price deliverable shall determine vendor specific objective evidence sell price exist thirdparty evidence sell price shall exist deliverable vendor shall use good estimate sell price deliverable adoption guidance require expand qualitative quantitative disclosure company currently assess impact adoption financial position result operation january fasb amend exist disclosure guidance fair value measurement effective january disclosure purchases sale issuance settlement roll forward activity level fair value measurement effective january thing update guidance require additional disclosure amount significant transfer level level measurement require certain level disclosure gross basis additionally update amend exist guidance require great level disaggregate information robust disclosure valuation technique input fair value measurement amend guidance require additional disclosure adoption impact companys financial position result operation table content merger scheringplough corporation november old merck scheringplough complete merger merger scheringplough acquire share old merck whollyowne subsidiary scheringplough rename merck sharp dohme corp scheringplough continue survive public company rename merck co inc accounting purpose merger treat acquisition old merck consider accounting acquirer term merger agreement issue outstanding share schering plough common stock convert right receive combination cash share common stock new merck issue outstanding share old merck common stock automatically convert share common stock new merck base closing price old merck stock november consideration receive scheringplough shareholder value share billion aggregate cash portion consideration fund combination exist cash include sale old merck interest merial limited sale redemption investment issuance debt note completion merger issue outstanding share scheringplough mandatory convertible preferred stock scheringplough preferred stock convert accordance term prefer stock remain outstanding share merck mandatory convertible preferred stock prefer stock right set forth new merck certificate incorporation note right substantially similar right scheringplough preferred stock merger expand company pipeline product candidate broaden company commercial portfolio expand global presence increase manufacturing capability additionally company expect realize substantial cost saving synergy include opportunity consolidation sale marketing research development calculation consideration transfer scheringplough common stock share outstanding november net treasury share unit merger consideration arise conversion prefer stock share unit eligible cash shareunit cash consideration outstanding sharesunit prefer stock makewhole dividend payment value scheringplough defer stock unit settle cash total cash consideration share unit eligible common stock exchange ratio shareunit equivalent new merck share share issue settle certain performancebase award new merck share issue old merck common stock share price november common stock equity consideration fair value prefer stock convert fair value sharebase compensation award employee benefit relate amount payable result merger total consideration transfer completion merger period day holder prefer stock entitle convert share prefer stock number unit merger consideration equal conversion rate determine table content accordance term prefer stock represent unit merger consideration relate preferred stock convert holder day period follow merger represent present value remain future dividend payment conversion date mandatory conversion date august pay holder prefer stock elect convert connection merger discount rate stipulate term prefer stock represent cash consideration pay holder scheringplough defer stock unit issue prior convert right receive cash specify merger agreement attributable precombination service represent fair value scheringplough stock option performance share unit defer stock unit replacement awards attributable precombination service issue holder award merger fair value outstanding scheringplough stock option performance share unit award prior immediately vest effective time merger attribute precombination service include consideration transfer stock option performance share unit defer stock unit award immediately vest completion merger award fair value award attribute precombination service include consideration transfer fair value attribute postcombination service recognize compensation cost requisite service period postcombination financial statement new merck preliminary allocation consideration transfer net asset acquire follow amount represent preliminary determination fair value identifiable asset acquire liability assume merger final determination fair value certain asset liability complete result adjustment preliminary value present cash cash equivalent inventory current asset property plant equipment identifiable intangible asset product product right year weight average useful life inprocess research development iprd tradename year weight average useful life noncurrent asset current liability defer income tax liability longterm debt noncurrent liability total identifiable net asset goodwill estimate consideration transfer connection merger company obtain control interest merckscheringplough partnership table reflect scheringplough share fair value merckscheringplough partnership net asset include intangible inventory reflect table merck share fair value merckscheringplough partnership net asset record connection fair value adjustment merck previously hold equity interest partnership merckscheringplough partnership iprd represent fair value assign incomplete research project time merger reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck determination useful life asset begin amortization inprocess research development goodwill recognize largely attributable anticipate synergy expect arise merger approximately billion goodwill allocate pharmaceutical segment remainder goodwill allocate nonreportable segment goodwill deductible tax purpose order allocate merger consideration company estimate fair value asset liability scheringplough contingent asset liability recognize fair value merger date fair value contingency determine contingent liability record table content extent amount probable reasonably estimable note account financial reporting purpose fair value define price receive sale asset pay transfer liability orderly transaction market participant measurement date market participant assume buyer seller principal advantageous market asset liability additionally fair value measurement asset assume highest good use asset market participant use different estimate judgment yield different result fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain market regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent net cash flow probability adjust appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate inprocess research development connection merger company record fair value human animal health research project approximately billion consideration transfer merger allocate human health iprd project billion allocate animal health iprd project amount capitalize account similar indefinite live intangible asset subject impairment testing completion abandonment project successful completion project merck determination useful life asset begin amortization fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probability adjust future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value discount rate range actual cash flow likely different assumed iprd project subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate significant project include bridion vorapaxar boceprevir phase iii clinical development ezetimibeatorvastatin combination product bridion sugammadex medication design rapidly reverse effect certain muscle relaxant general anesthesia bridion receive regulatory approval european union eu country world date regulatory review market include united states vorapaxar study prevention treatment atherothrombosis boceprevir hepatitis c protease inhibitor currently development ezetimibe combine atorvastatin investigational medication treatment dyslipidemia merckscheringplough partnership consummation merger company obtain control interest merckscheringplough partnership msp partnership own company previously company noncontrolle interest result obtain control interest company require remeasure merck previously hold equity interest msp partnership mergerdate fair value recognize result gain billion earning income expense net conjunction remeasurement company record intangible asset approximately billion include iprd approximately billion stepup inventory table content mergerrelate cost mergerrelate cost expense incur year end december merck incur million transaction cost directly related merger include advisory legal fee million integration cost billion restructuring cost include exit cost connection merger note cost recognize marketing administrative expense restructure cost additionally million interest cost recognize connection debt issue partially fund merger note supplemental pro forma datum scheringplough result operation include new merck financial statement period subsequent completion merger scheringplough contribute revenue billion estimate loss billion new merck period consummation merger december follow unaudited supplemental pro forma datum present consolidated information merger complete january year end december unaudited sale earning attributable merck co inc earning available merck co inc common shareholder basic earning common share available common shareholder earn common share assume dilution available common shareholder unaudite supplemental pro forma datum reflect application follow adjustment consolidation msp partnership own company correspond gain result company remeasurement previously hold equity interest msp partnership additional depreciation amortization expense recognize assume fair value adjustment inventory property plant equipment intangible asset additional interest expense financing cost incur borrowing arrangement loss interest income cash shortterm investment fund merger transaction cost associate merger conversion portion outstanding preferred stock unaudite supplemental pro forma financial information reflect potential realization cost saving relate integration company pro forma datum consider indicative result occur merger relate borrowing consummate january indicative future result restructure merger restructuring program february company announce phase new global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough business merger restructuring program intend optimize cost structure combine company phase merger restructuring program end company expect reduce total workforce approximately area company worldwide company plan eliminate vacant position phase program workforce reduction primarily come elimination duplicative position sale administrative headquarters organization consolidation certain manufacturing facility research development operation company continue hire new employee strategic growth area business period certain action ongoing reevaluation manufacture research development facility table content worldwide complete include later phase merger restructuring program connection merger restructuring program separation cost company exist severance program worldwide record fourth quarter extent cost probable reasonably estimable company record pretax restructuring cost billion primarily employee separation cost relate merger restructuring program fourth quarter phase merger restructuring program expect complete end total pretax cost estimate billion billion cost voluntary program enhancement program record relevant criterion meet company estimate approximately cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest global restructuring program october old merck announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness restructure program company expect eliminate approximately position active employee vacancy area company worldwide end total reduction occur united states restructure program company streamline management layer reduce total number senior midlevel executive globally december approximately position eliminate connection restructuring program comprise employee separation elimination contractor vacant position merck roll new customercentric selling model design provide merck meaningful competitive advantage help physician patient payer improve patient outcome company operate new commercial selling model united states market world company make great use outside technology resource centralize common sale marketing activity consolidate streamline operation merck manufacturing division focus capabilitie core product outsource noncore manufacturing merck continue implement new model basic research global operating strategy legacy merck research laboratory site new model align franchise function align resource disease area priority balance capacity discovery phase allow company act program high probability success additionally disease area priority company strategy design expand access worldwide external science incorporate external research key component company early discovery pipeline order translate basic research productivity latestage clinical success basic research facility pomezia italy tsukuba japan sell operation conduct basic research facility seattle closed merck sell close certain facility sell related asset connection restructure program connection restructuring program separation cost exist severance program worldwide record quarter extent cost probable estimable old merck commence accrue cost relate onetime termination benefit offer employee restructure program fourth quarter necessary criterion meet pretax restructuring cost million million respectively record related restructuring program inception restructuring program december merck record total pretax accumulate cost billion restructuring program expect complete end total pretax cost estimate billion billion company estimate twothird cumulative pretax cost relate cash outlay primarily employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest global restructuring program november old merck announce global restructure program restructuring program design reduce cost structure increase efficiency enhance competitiveness substantially complete end segment report restructuring charge unallocated expense table content follow table summarize charge related merger restructuring program restructuring program activity type cost separation accelerate year end december cost depreciation total merger restructuring program material production research development restructuring cost restructure program material production research development restructuring cost year end december restructuring program material production research development restructuring cost restructure program material production research development restructuring cost year end december restructuring program material production research development restructuring cost separation cost associate actual headcount reduction headcount reduction probable reasonably estimate approximately position eliminate approximately relate restructuring program approximately relate merger restructuring program certain employee anticipate separate plan restructuring action restructure program instead transfer buyer conjunction sale facility accordingly accrual separation cost associate employee reverse result reduction expense approximately position eliminate approximately relate restructuring program relate restructuring program approximately table content position eliminate connection restructure program position elimination comprise actual headcount reduction elimination contractor vacant position accelerate depreciation cost primarily relate manufacture research facility sell close program site continue operate respective closure date future cash flow sufficient recover respective book value merck require accelerate depreciation site asset write immediately site asset include manufacture research facility equipment activity include million million million respectively asset abandonment shutdown relate cost additionally activity include million million million respectively relate curtailment settlement termination charge pension postretirement benefit plan note activity reflect pretax loss result sale facility relate asset million pretax gain sale million adjustment record amount material period follow table summarize charge spend relate merger restructuring program restructuring program activity separation accelerate cost depreciation total merger restructuring program restructure reserve january expense payment receipt net noncash activity restructure reserve december restructure program restructure reserve january expense payment receipt net noncash activity restructure reserve december expense payment receipt net noncash activity restructure reserve december restructure program restructure reserve january expense payment receipt net noncash activity restructure reserve december payment receipt net restructure reserve december cash outlay associate phase merger restructuring program expect substantially complete end cash outlay associate remain restructuring reserve restructuring program expect complete end cash outlay associate remain restructuring reserve restructuring program expect complete end include proceed sale facility connection restructuring action table content legacy scheringplough program prior merger scheringplough commence productivity transformation program design reduce avoid cost increase productivity postmerger period december company record million cost relate program include million employee separation cost include restructuring cost million accelerate depreciation cost include material production cost remain reserve associate program million december approximately position eliminate connection program postmerger period december acquisition research collaboration license agreement december merck avecia investment limited announce definitive agreement merck acquire biologics business avecia group total purchase price million avecia biologic contract manufacturing organization specific expertise microbialderive biologic term agreement merck acquire avecia biologic limit avecia asset include avecias process development scaleup manufacture quality business support operation locate billingham united kingdom transaction close february accordingly result operation acquire business include merck result operation acquisition date september old merck announce enter exclusive agreement csl biotherapie csl subsidiary csl limited market distribute afluria csls seasonal influenza flu vaccine united states flu season term agreement merck assume responsibility aspect commercialization afluria united states csl supply afluria merck retain responsibility marketing vaccine outside united states afluria indicate active immunization person age month old influenza disease cause influenza virus subtype type b present vaccine july old merck portola pharmaceuticals inc portola sign exclusive global collaboration license agreement development commercialization betrixaban mk investigational oral factor xa inhibitor anticoagulant currently phase ii clinical development prevention stroke patient atrial fibrillation return exclusive worldwide license betrixaban old merck pay portola initial fee million closing record research development expense portola eligible receive additional cash payment total million achievement certain development regulatory commercialization milestone doubledigit royalty worldwide sale betrixaban approve merck assume development commercialization cost include cost phase iii clinical trial portola retain option cofund phase iii clinical trial return additional royalty b copromote betrixaban merck united states term agreement commence august terminate early continue remain royalty payment obligation country time agreement expire entirety country agreement terminate party event material uncured breach bankruptcy party agreement terminate merck event party merck decide cease development betrixaban safety efficacy addition merck terminate agreement time day prior write notice portola terminate agreement event merck challenge portola patent cover betrixaban termination agreement depend circumstance party vary right obligation respect continued development commercialization betrixaban case termination cause merck certain royalty obligation april old merck medarex inc medarex massachusetts biologic laboratory mbl university massachusetts medical school announce exclusive worldwide license agreement cda cdb mka know mdxmdx mblcdamblcdb investigational fully human monoclonal antibody combination develop target neutralize clostridium difficile toxin b treatment c difficile infection cda cdb codevelope medarex mbl term agreement merck gain worldwide right develop commercialize cda cdb medarex mbl receive aggregate upfront payment million closing record research development expense potentially eligible receive additional cash table content payment million aggregate achievement certain milestone associate development approval drug candidate cover agreement commercialization medarex mbl eligible receive doubledigit royalty product sale milestone certain sale target meet term agreement commence closing date terminate early continue remain royalty payment obligation country time agreement expire entirety country party terminate agreement uncured material breach party bankruptcy insolvency party merck terminate agreement time provide day prior write notice medarex mbl april old merck santen pharmaceutical co ltd santen announce worldwide licensing agreement tafluprost mk prostaglandin analogue investigation united states tafluprost preserve preservativefree formulation receive marketing approval reduction elevate intraocular pressure openangle glaucoma ocular hypertension european nordic country japan file approval additional european asia pacific market term agreement merck pay fee capitalize amortize material production cost life underlie patent pay milestone royalty payment base future sale tafluprost preserve preservativefree formulation exchange exclusive commercial right tafluprost western europe exclude germany north america south america africa santen retain commercial right tafluprost country eastern europe northern europe asia pacific include japan merck provide promotion support santen germany poland tafluprost approve united states santen option copromote agreement merck santen expire countrybycountry basis occur expiry expire valid patent claim b expiration expire royalty merck terminate agreement time day prior write notice time day prior write notice merck determine product present issue safety tolerability addition merck terminate agreement event enumerate agreement santen coownerlicensor certain intellectual property terminate expire materially adversely affect merck merck santen materially breach agreement fail cure receive notice nonbreache party terminate agreement agreement provide termination noninsolvent party bankruptcy party finally agreement terminate term merck develop commercialize competitive product term define agreement addition april old merck cardiome pharma corp cardiome announce collaboration license agreement development commercialization vernakalant mk investigational candidate treatment atrial fibrillation agreement provide merck exclusive global right oral formulation vernakalant vernakalant oral maintenance normal heart rhythm patient atrial fibrillation provide merck affiliate merck sharp dohme switzerland gmbh exclusive right outside united states canada mexico intravenous iv formulation vernakalant vernakalant iv rapid conversion acute atrial fibrillation normal heart rhythm term agreement old merck pay cardiome initial fee million closing record research development expense addition cardiome eligible receive million payment base achievement certain milestone associate development approval vernakalant product include million submission regulatory approval europe vernakalant iv old merck pay result submission million initiation plan phase iii program vernakalant oral million milestone associate approval subsequent indication intravenous oral formulation cardiome receive tiere royalty payment sale approve product potential receive million milestone payment base achievement significant sale threshold cardiome retain option copromote vernakalant oral merck hospitalbase sale force united states merck responsible future cost associate development manufacturing commercialization candidate merck grant cardiome secure interestbeare credit facility million cardiome access tranches year commence cardiome codevelopment partner north america astellas pharma inc submit nda fda kynapid vernakalant hydrochloride injection december include result pivotal phase iii clinical trial december cardiovascular renal drug advisory committee recommend fda approve vernakalant iv rapid conversion atrial fibrillation table content august fda issue approvable action letter request additional information phase iib doubleblind placebocontrolle randomized doserange clinical trial patient risk recurrent atrial fibrillation show mg dose vernakalant oral significantly reduce rate atrial fibrillation relapse compare placebo agreement continue effect expiration cardiome copromotion right royalty milestone payment obligation agreement terminate event insolvency material uncured breach party additionally collaboration terminate merck event merck determine good faith advisable continue development commercialization vernakalant product result safety issue addition merck terminate agreement time month prior write notice cardiome terminate agreement event merck challenge cardiome patent cover vernakalant termination agreement depend circumstance party vary right obligation respect continued development commercialization vernakalant case continue royalty obligation march old merck acquire insme incs insme portfolio followon biologic therapeutic candidate commercial manufacturing facility locate boulder colorado term agreement old merck pay insme aggregate million cash acquire right boulder facility insmed pipeline followon biologic candidate insmed followon biologic portfolio include clinical candidate mk investigational recombinant granulocytecolony stimulate factor gcsf evaluate ability prevent infection patient cancer receive chemotherapy mk pegylate recombinant gcsf design allow frequent dose transaction account business combination accordingly asset acquire liability assume recorded respective fair value acquisition date determination fair value require management significant estimate assumption connection acquisition substantially purchase price allocate insmed followon biologics portfolio mk mk indefinitelive intangible asset record fair value determine base present value expect future cash flow new product candidate result insmed followon biologics portfolio adjust probability estimate technical marketing success utilize income approach reflect appropriate riskadjuste discount rate ongoing activity relate mk mk expect material company research development expense remain net asset acquire material milestone royalty obligation associate acquisition transaction close march accordingly result operation acquire business include merck result operation begin april september old merck japan tobacco inc jt sign worldwide licensing agreement develop commercialize jtt mk investigational oral osteoanabolic bone growth stimulate agent treatment osteoporosis disease reduce bone density strength result increase risk bone fracture jtt investigational oral calcium sense receptor antagonist currently evaluate jt phase ii clinical trial japan effect increase bone density phase clinical trial outside japan term agreement merck gain worldwide right japan develop commercialize jtt certain related compound jt receive upfront payment million record research development expense eligible receive additional cash payment achievement certain milestone associate development approval drug candidate cover agreement jt eligible receive royalty sale drug candidate receive marketing approval license agreement merck jt remain effect expiration royalty milestone obligation terminate event uncured material breach party agreement terminate merck cause initial commercial sale jtt give month prior notice jt give year prior notice thereof jt license agreement terminate immediately merck merck determine safety andor efficacy concern base available scientific evidence cease development jtt andor withdraw jtt market permanent basis september old merck complete acquisition novacardia inc novacardia privately hold clinicalstage pharmaceutical company focus cardiovascular disease old merck acquire outstanding equity novacardia total purchase price million include million table content cash investment hand closing pay issuance million share old merck common stock novacardia shareholder base old merck average closing stock price day prior closing acquisition connection acquisition old merck record charge million inprocess research development associate rolofylline mk novacardias investigational phase iii compound acute heart failure acquisition date technological feasibility establish alternative future use exist charge deductible tax purpose record research development expense determine base present value expect future cash flow result technology adjust estimate probability technical marketing success time utilize income approach reflect appropriate risk adjusted discount rate remain purchase price allocate cash investment million defer tax asset relate net operating loss carryforward million net asset million novacardia development stage company commence plan principal operation transaction account acquisition asset business combination goodwill record novacardias result operation include merck consolidated financial result acquisition date june old merck announce preliminary result pivotal phase iii study rolofylline show rolofylline meet primary secondary efficacy endpoint old merck terminate clinical development program rolofylline old merck gtx inc gtx enter agreement provide research development global strategic collaboration selective androgen receptor modulator sarm new class drug potential treat agerelate muscle loss sarcopenia musculoskeletal condition merck discontinue internal development mk sarm agreement currently discuss step gtx old merck ariad pharmaceuticals inc ariad enter global collaboration jointly develop commercialize ridaforolimus mk ariad novel mtor inhibitor use cancer collaboration generally continue effect expiration royalty milestone payment obligation collaboration generally terminate event insolvency material uncured breach party additionally collaboration agreement merck gtx terminate merck day notice gtx time december collaboration agreement merck ariad terminate merck failure mk meet certain developmental safety requirement event merck conclude advisable continue development mk use cancer indication addition merck terminate ariad collaboration agreement anniversary effective date provide month prior write notice termination ariad collaboration agreement depend circumstance party vary right obligation respect continued development commercialization mk continue royalty obligation collaborative arrangement company continue strategy establish external alliance complement substantial internal research capability include research collaboration license preclinical clinical compound technology platform drive near longterm growth company supplement internal research aggressive licensing external alliance strategy focus entire spectrum collaboration early research latestage compound new technology broad range therapeutic area arrangement include upfront payment royalty profit share payment contingent occurrence certain future event link success asset development expense reimbursement payment party discuss note january new guidance issue fasb adopt define collaborative arrangement establish reporting requirement transaction participant collaborative arrangement participant arrangement party company review party arrangement determine arrangement scope new guidance arrangement unique nature company significant arrangement discuss table content cozaarhyzaar old merck ei dupont de nemour company dupont agree form longterm research marketing collaboration develop class therapeutic agent high blood pressure heart disease discover dupont call angiotensin ii receptor antagonist include cozaar hyzaar return old merck provide dupont marketing right united states canada prescription medicine sinemet sinemet cr pursuant agreement dupont company exclusive licensing agreement market cozaar hyzaar register trademark dupont return royalty profit share payment dupont patent provide marketing exclusivity cozaar hyzaar expire april addition patent cozaar expire number major european market march hyzaar lose patent protection number major european market february remicadesimponi subsidiary scheringplough enter licensing agreement centocor inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi golimumab fully human monoclonal antibody company exclusive marketing right product outside united states japan certain asian market december scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition scheringplough centocor agree share certain development cost relate simponis autoinjector delivery system october european commission approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille syringe result company marketing right product extend year commercial sale simponi eu follow receipt pricing reimbursement approval eu operating expense subject certain adjustment company entitle receive approximate share profit company distribution company market territory begin share profit change time share profit product share profit remain fixed remainder term company independently develop market simponi crohns disease indication territory option centocor participate note discussion arbitration involve remicadesimponi product right financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment dollarbase research development extent dollar value cash flow diminish result strengthen dollar company ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate functional currency entity objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange decrease dollar value future cash flow derive foreign currency table content denominate sale primarily euro japanese yen achieve objective company partially hedge forecast foreign currency denominate party intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion party intercompany distributor entity sale hedge get close expect date forecast foreign currency denominate sale probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase value anticipate foreign currency cash flow company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow derivative instrument designate cash flow hedge fair value contract record asset gain position liability loss position consolidate balance sheet accordingly effective portion unrealize gain loss contract record aoci reclassify sale hedge anticipate revenue recognize hedge relationship highly effective hedge ineffectiveness de minimis cash flow contract report operating activity consolidate statement cash flow dollar functional currency company foreign subsidiary primary objective balance sheet risk management program protect dollar value foreign currency denominate net monetary asset effect volatility foreign exchange occur prior conversion dollar instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange dollar cash flow derive net asset dollar functional currency company foreign subsidiary merck execute spot trade convert foreign currency dollar base shortterm forecast need dollar proceed invest require company foreign subsidiary merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level foreign currency denominate monetary asset liability remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year applicable company use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate derivative contract designate qualify fair value hedge accordingly change fair value hedge security fluctuation spot rate record income expense net table content offset fair value change forward contract attributable spot rate fluctuation change contract fair value spotforward difference exclude designate hedge relationship recognize income expense net amount hedge ineffectiveness significant year end december cash flow contract report operating activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note eurodenominate term loan designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss eurodenominate debt instrument include foreign currency translation adjustment comprehensive income interest rate risk management december company party seven payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap mature notional amount million effectively convert company million fixedrate note float rate instrument swap mature notional amount million effectively convert million company billion fixedrate note float rate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change benchmark interest rate record interest expense offset fair value change swap contract old merck terminate interest rate swap contract notional amount million terminate interest rate swap contract notional million swap effectively convert billion fixedrate note million fixedrate note variable rate debt result swap termination old merck receive million cash exclude accrue interest material correspond gain relate basis adjustment debt associate terminate swap contract defer amortize reduction interest expense remain term note cash flow contract report operating activity consolidate statement cash flow present table fair value derivative segregate derivative designate hedge instrument designate hedge instrument december f air va lue de rivative dollar balance sheet caption asset liability notional derivative designate hedge instrument foreign exchange contract current defer income taxis current asset foreign exchange contract noncurrent asset foreign exchange contract current accrue current liability interest rate swap noncurrent asset derivative designate hedge instrument foreign exchange contract current defer income taxis current asset foreign exchange contract current accrue current liability table content table provide information location pretax gain loss amount derivative designate fair value hedge relationship ii designate cash flow hedging relationship iii designate hedge relationship year end december pretax pretax gain loss gain loss gain loss gain loss recognize recognize reclassify recognize earning earning aoci oci derivative hedge item earning derivative derivative designate fair value hedge relationship interest rate swap contract foreign exchange contract derivative designate cash flow hedging relationship foreign exchange contract derivative designate hedge relationship foreign exchange contract recognize income expense net recognize sale derivative contract mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate december company estimate million pretax net unrealize loss derivative mature month hedge foreign currency denominate sale period reclassify aoci sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level quote price active market identical asset liability company level asset include equity security trade active exchange market level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability company level asset liability primarily include debt security quote price trade frequently exchangetrade instrument corporate note bond foreign government agency security certain mortgagebacke assetbacked security municipal security commercial paper derivative contract value determine pricing model input observable market derive principally corroborate observable market datum level unobservable input support little market activity financial instrument value determine pricing model discount cash flow methodology similar technique instrument determination fair value require significant judgment estimation company level asset mainly include certain mortgagebacked asset table content back security certain corporate note bond limit market activity december million approximately company investment security categorize level asset pledge certain collateral arrangement note asset classify level december acquire old merck elect redeemedinkind shortterm fix income fund restrict cash redemption describe input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis summarize fair value measu rem ent ing fa ir value urement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total december december assets investment government agency security corporate note bond municipal security mortgagebacke security commercial paper assetbacke security foreign government bond equity security debt security asset security hold employee compensation asset derivative asset purchase currency option forward exchange contract interest rate swap total asset liability derivative liability write currency option forward exchange contract total liability substantially assetbacked security highlyrate standard poor rate aaa moodys investor service rating aaa secure primarily credit card auto loan home equity receivables weightedaverage live primarily year mortgagebacked security represent aaarate security issue unconditionally guarantee payment principal interest government agency asset represent portion pledge collateral discuss note december level asset comprise million assetbacked security million mortgage back security million corporate note bond december level asset comprise million corporate note bond million municipal security million commercial paper million mortgagebacke security million government agency security million assetbacke security fair value determination derivative include assessment credit risk counterpartie derivative companys credit risk effect significant table content december company approximately billion cash equivalent level valuation technique financial asset consider level fair value determine pricing model discount cash flow methodology similar technique significant model assumption input unobservable level financial asset include certain investment security limited market activity determination fair value require significant judgment estimation company level investment security december primarily include certain mortgagebacke assetbacked security certain corporate note bond decrease observability market pricing investment security value primarily pricing model management understand methodology model incorporate transaction detail contractual term maturity timing future cash inflow assumption liquidity credit valuation adjustment marketplace participant december table provide summary change fair value include net transfer andor financial asset measure fair value recur basis significant unobservable input level available forsale debt investment asset total security asset total beginning balance january net transfer level purchase sale settlement net total realize unrealized gain loss include earning comprehensive income end balance december loss record earning level asset hold december transfer level deem occur begin quarter transaction take place amount record income expense net january old merck million invest shortterm fix income fund fund market liquidity condition cash redemption fund restrict result restriction cash redemption old merck consider fund trade active market observable pricing january amount categorize level january old merck elect redeemedinkind fund receive share underlie security fund result majority underlie security transfer level determine security observable market december million investment security associate redemptioninkind classify level security contain significant input unobservable security account entire balance company level asset december level investment aggregate million long pledge collateral reclassify asset availableforsale investment financial instrument measure fair value company financial instrument measure fair value recur basis record amount approximate fair value liquid shortterm nature cash cash equivalent receivables payable table content estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate quote dealer price summary december gross unrealized gain loss availableforsale investment include pledge collateral record aoci follow decem r december fair amortize gross unrealize fair amortize gross unrealized value cost gain loss value cost gain loss government agency security corporate note bond municipal security mortgagebacke security assetbacke security foreign government bond commercial paper debt security equity security december gross unrealized gain gross unrealized loss relate amount pledge collateral note million million respectively december gross unrealized gain gross unrealized loss relate amount pledge collateral million million respectively availableforsale debt security include shortterm investment total million december remain debt security million mature year debt security pledge collateral include current asset december debt security pledge collateral mature year total million letter credit august old merck execute billion letter credit agreement financial institution satisfy certain condition set forth vioxx settlement agreement note old merck pledge collateral financial institution approximately billion pursuant term letter credit agreement asset pledge collateral set letter credit agreement asset hold custody party asset manage old merck old merck consider asset pledge letter credit agreement restrict letter credit require collateral balance decline payment million settlement agreement december billion record deferred income taxis current asset billion classified asset old merck remaining payment vioxx settlement fund pursuant vioxx settlement agreement accordingly letter credit agreement terminate collateral release concentration credit risk ongoing basis company monitor concentration credit risk associate corporate issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty december cash cash equivalent include cash collateral million table content receive counterpartie correspond offset include accrue current liability company advanced cash collateral counterpartie december company large customer mckesson corporation cardinal health inc amerisourcebergen corporation medco health solutions inc represent aggregate approximately onefifth account receivable december company monitors creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale inventory inventory december consist finished good raw material work process supply total approximate current cost reduction lifo cost recognize inventory asset increase inventory primarily merger include billion december remain purchase accounting adjustment inventory adjustment recognize component material production cost relate inventory sell inventory value lifo method comprise approximately inventory december respectively amount recognize asset comprise entirely raw material work process inventory goodwill intangible result merger note company record billion goodwill billion acquire identifiable intangible asset include acquire iprd company record additional billion intangible asset conjunction remeasurement merck previously hold equity interest msp partnership follow table summarize goodwill activity segment pharmaceutical total goodwill balance january goodwill balance december addition goodwill balance december table content intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product product right inprocess research development tradename total identifiable intangible asset amount capitalize inprocess research development account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project company separate determination useful life asset begin amortization aggregate amortization expense million million million estimate aggregate amortization expense year follow billion billion billion billion billion joint venture equity method affiliate equity income affiliate reflect performance company joint venture equity method affiliate comprise follow year end december merckscheringplough astrazeneca lp primarily reflect result merial limited disposition september sanofi pasteur msd johnson johnsonmerck consumer pharmaceutical company merckscheringplough partnership old merck scheringplough collectively partner enter agreement create equallyowne partnership develop market united states new prescription medicine cholesterol management agreement generally provide equal sharing development cost copromotion approve product company cholesterolmanagement partnership expand include country world exclude japan ezetimibe new class cholesterollowere agent launch united states zetia market ezetrol outside united states combination product contain active ingredient zetia zocor approve united states vytorin market inegy outside united states cholesterol agreement provide share operating income generate msp partnership base percentage varied product sale level country market partner share profit zetia vytorin sale equally exception million annual zetia sale scheringplough receive great share profit operating income include expense partner contractually agree share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service ongoing clinical research market support market research market expansion specialty sale force physician education program expense incur support msp partnership share partner market administrative expense include certain sale force cost certain manufacturing cost include equity income affiliate table content cost reflect overall result company certain research development expense generally share equally partner adjust earn milestone result merger note msp partnership own company result msp partnership date merger reflect equity income affiliate activity result sale msp partnership product merger consolidated merck result note information respect litigation involve msp partnership partner relate sale promotion zetia vytorin summarize financial information msp partnership follow period january year end november december sale vytorin zetia material production cost expense net income taxis merck share income taxis december total asset total liability old merck share msp partnership income taxis differ equity income recognize msp partnership primarily time recognition certain transaction old erck msp partnership period present include milestone payment amounts comprise entirely current balance astrazeneca lp old merck enter agreement astra ab astra develop market astra product royaltybeare license old merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami old merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach line old merck astra complete restructure ownership operation joint venture old merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical lp partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca lp azlp astras merger zeneca group plc astrazeneca merger exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner table content certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale current future kbi product revenue billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate reflect table return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent merck share undistribute azlp gaap earning astrazeneca merger trigger partial redemption march old merck interest certain azlp product right redemption old merck receive billion azlp base primarily multiple old merck average annual variable return derive sale astra usa inc product year prior redemption limited partner share agree value old merck record billion pretax gain partial redemption partial redemption old merck interest product right result change old merck limited partnership interest conjunction restructure astra purchase option asset option payment million record deferred income buy old merck interest kbi product exclude gastrointestinal medicine nexium prilosec nonppi products astrazeneca exercise asset option half exercise price million represent net present value march project future pretax revenue receive old merck nonppi product appraise value february astrazeneca notify company exercise asset option old merck right require astra purchase interest appraise value february old merck advise astrazeneca exercise asset option million remain defer recognize asset option consummate addition old merck grant astra option share option buy old merck common stock interest kbi old merck interest nexium prilosec exercisable year astra exercise asset option astra exercise share option combine annual sale product fall minimum provide case long astrazenecas asset option exercise exercise price share option base net present value estimate future net sale nexium prilosec determine time exercise subject certain trueup mechanism astrazeneca merger constitute trigger event kbi restructuring agreement result merger exchange old mercks relinquishment right future astra product exist pende patent time merger astra pay million advance payment advance payment defer remain subject trueup calculation trueup directly dependent fair market value march astra product right retain old merck calculate trueup million return azlp march old merck recognize pretax gain million relate residual advance payment balance provision kbi restructuring agreement trigger event occur sum limit partner share agree value appraise value trueup guarantee minimum billion distribution limited partner share agree value payment trueup result cash receipt old merck billion aggregate pretax gain billion include income expense net astrazeneca purchase old merck interest nonppi product contingent exercise asset option astrazeneca payment appraise value occur march billion outstanding loan astra plus interest redemption date settle result transaction old merck receive net proceed azlp billion table content summarize financial information azlp follow year end december sale material production cost expense net income taxis december current asset noncurrent asset total liability current merial limited old merck rhnepoulenc sa sanofiaventis combine animal health business form merial limited merial fully integrate animal health company standalone joint venture own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie september old merck sell interest merial sanofiaventis billion cash sale result recognition billion gain reflect income expense net connection sale merial old merck sanofiaventis scheringplough sign option agreement term option agreement follow closing merger sanofiaventis option require company combine intervetscheringplough animal health business merial form animal health joint venture own equally company sanofiaventis option agreement value merial fix billion minimum total value receive company contribute intervetscheringplough combine entity billion subject customary transaction adjustment consist floor valuation intervetscheringplough fix minimum billion subject potential upward revision base valuation exercise party additional payment sanofiaventis million base valuation exercise intervetscheringplough customary transaction adjustment merial intervetscheringplough combine payment required pay party joint venture equally own company sanofiaventis payment trueup value contribution equal formation new animal health joint venture sanofiaventis subject customary closing condition include antitrust review united states europe prior closing merger agreement provide old merck certain right terminate option fee million recognition termination fee defer fourth quarter condition trigger payment lapsed reflect income expense net merial sale billion period january september divestiture date billion billion sanofi pasteur msd old merck pasteur mrieux connaught sanofi pasteur sa establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe joint venture vaccine sale billion billion billion johnson johnsonmerck consumer pharmaceutical company old merck form joint venture johnson johnson develop market broad range nonprescription medicine consumer own venture subsequently expand canada significant joint venture product pepcid ac overthecounter form company ulcer table content medication pepcid pepcid complete overthecounter product combine company ulcer medication antacids sale product market joint venture million million million investment affiliate account equity method include joint venture total billion december billion december amount report asset amount joint venture include defer income taxis current asset million december million december summarize information affiliate exclude msp partnership azlp disclose separately follow year end december sale material production cost expense net income taxis december current asset noncurrent asset current liability noncurrent liability include information merial divestiture september loan payable longterm debt commitment loan payable december include million eurodenominate note shortterm foreign borrowing million include loan payable december million longdate note subject repayment option holder begin reclassify longterm debt additionally loan payable december include million longdate note subject repayment option holder annual basis loan payable december include billion commercial paper borrowing million longdate note subject repayment option holder annual basis million shortterm foreign borrowing table content longterm debt december consist eurodenominate note note note note note note note note note note float rate eurodenominate term loan note debenture note debenture note debenture company party interest rate swap contract effectively convert fixedrate note million fixedrate note floatingrate instrument note present table december consist primarily million million borrowing variable rate average respectively borrowing million subject repayment option holder begin year include foreign borrowing vary rate june old merck close underwritten public offer billion senior unsecured note consist billion aggregate principal note billion aggregate principal note billion aggregate principal note million aggregate principal note interest note payable semiannually note series redeemable time company option redemption price specify note associate prospectus proceed note fund portion cash consideration merger connection merger company record longterm debt fair value billion december include million represent remain excess fair value record value debt amortize interest expense remain life underlie debt obligation eurodenominate note eurodenominate note note note note note redeemable merck option time redemption price specify note associate prospectus respect eurodenominate note note note change control trigger event define occur certain circumstance define note associate prospectus holder note right require merck repurchase note cash payment equal aggregate principal note repurchase plus accrue unpaid interest date purchase table content note note subject interest rate adjustment provision event rating assign particular series note moodys investors service inc standard poor rating service drop predetermine level prior merger interest rate adjustment trigger consequently time merger note pay interest rate note pay interest rate follow closing merger rating series note upgrade pursuant term indenture interest rate payable note revert state amount effective december interest rate adjustment provision note long apply connection merger effective november new merck execute unconditional guarantee exist debt old merck old merck execute unconditional guarantee exist debt new merck exclude commercial paper include payment principal interest aggregate maturity longterm debt year follow million billion million billion billion connection merger march old merck enter finance commitment letter jpmorgan chase bank na jp morgan securities inc collectively jpmorgan jpmorgan commit provide billion financing old merck enter billion day senior unsecured interim term loan facility bridge loan facility billion day asset sale revolve credit facility asset sale facility billion day corporate revolve credit facility incremental facility connection billion offering bridge loan facility terminate commitment lender day asset sale facility reduce completion sale merial sanofiaventis note asset sale facility terminate incremental facility available backstop commercial paper general corporate purpose facility draw expire november merck incur commitment fee approximately million associate facility amortize commitment period april old merck amend billion year revolve credit facility mature april allow facility remain place merger company exist billion credit facility mature august remain outstanding facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility rental expense operating lease net sublease income million million million minimum aggregate rental commitment noncancellable lease follow million million million million million company significant capital lease contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision result number factor product liability insurance available cost increase significantly company evaluate risk determine cost obtain product liability insurance outweighs likely benefit table content coverage available insurance certain product liability effective august include liability legacy merck product sell date company continue evaluate insurance need cost availability benefit product liability insurance future vioxx litigation product liability lawsuit previously disclose individual putative class action file old merck state federal court allege personal injury andor economic loss respect purchase use vioxx action file federal court coordinate multidistrict litigation district court eastern district louisiana mdl district judge eldon e fallon number action file state court coordinate separate coordinate proceeding state court new jersey california texas counties philadelphia pennsylvania washoe clark county nevada december company serve aware name defendant approximately pende lawsuit include approximately plaintiff group allege personal injury result use vioxx approximately putative class action allege personal injury andor economic loss action discuss paragraph lawsuit collectively refer vioxx product liability lawsuit lawsuit approximately lawsuit represent approximately plaintiff group slate federal mdl approximately lawsuit represent approximately plaintiff group include coordinate proceed new jersey superior court judge carol e higbee plaintiff group describe currently vioxx settlement program describe december plaintiff group eligible settlement program participate claim remain pende old merck addition claim approximately plaintiff group eligible settlement program remain pende old merck number plaintiff group subject motion dismiss failure comply courtordere deadline december certain plaintiff group dismiss addition claim plaintiff dismiss december vast majority dismiss result settlement process discuss november old merck announce enter agreement settlement agreement law firm comprise executive committee plaintiff steering committee psc federal vioxx mdl representatives plaintiff counsel texas new jersey california state coordinate proceeding resolve state federal myocardial infarction mi ischemic stroke claim file date united states settlement agreement apply legal resident allege mi occur united states settlement agreement provide old merck pay fix aggregate billion fund billion mi claim million claim interim final payment certain qualifying claimant expect remainder billion distribute half company complete make payment settlement fund vioxx product liability lawsuit currently schedule trial old merck previously disclose outcome vioxx product liability lawsuit try prior case go trial mcdarby matter resolve fourth quarter leave unresolved posttrial appeal ernst v merck garza v merck previously report september old merck file notice appeal august jury verdict favor plaintiff texas state court case ernst v merck texas court appeal reverse trial court judgment issue judgment favor old merck court appeal find evidence legally insufficient issue causation plaintiff file motion rehear en banc court appeal june response plaintiff motion rehear court appeal issue new opinion reverse jurys verdict render judgment old merck september plaintiff table content file second motion rehear en banc court appeal deny november december plaintiff file motion rehear court appeal deny plaintiff file petition review supreme court texas february previously report april garza v merck jury state court rio grande city texas return verdict favor family decedent leonel garza jury award total million compensatory damage mr garzas widow son jury purport award million punitive damage texas law case potential punitive damage cap san antonio court appeal reverse judgment render judgment favor old merck december court appeal rehear vacate prior ruling issue replacement new rule court order takenothe judgment old merck design defect claim reverse remand new trial strict liability claim juror misconduct january old merck file petition review texas supreme court texas supreme court grant old merck petition review oral argument hold january lawsuit approximately claim individual private thirdparty payor file new jersey court federal court mdl september old merck announce finalize settlement agreement previously disclose resolve pende lawsuit usbased private thirdparty payor tpps seek reimbursement covering vioxx purchase plan member certain claimant participate resolution agreement provide old merck admit wrongdoing fault settlement agreement old merck pay fix total million include settlement fund divide tpps insurer employee benefit plan union welfare fund participate resolution accordance formula base product volume provision potential payment attorney fee return settling tpp dismiss lawsuit release claim old merck stipulate dismissal settle ttp action file new jersey mdl december old merck record charge million second quarter relate settlement pay million fourth quarter settlement additional tpp case file pende mdl proceeding separately pende court putative class action purportedly bring behalf individual purchaser user vioxx seek reimbursement allege economic loss mdl proceeding class action remain old merck move dismiss master complaint include case mdl court rule motion march new jersey superior court deny plaintiff motion class certification martinkleinman v merck putative consumer class action plaintiff move leave appeal decision new jersey supreme court november january new jersey supreme court deny plaintiff request appellate review denial class certification june missouri state court certify class missouri plaintiff seek reimbursement outofpocket cost relate vioxx plaintiff allege personal injury take vioxx missouri court appeal affirm trial court certification class missouri supreme court deny old merck application review decision september trial set april addition indiana plaintiff file motion certify class indiana vioxx purchaser case pende circuit court marion county indiana discovery case ongoing briefing complete plaintiff motion certify class kentucky vioxx purchaser circuit court pike county kentucky hearing matter hold february judge cook county illinois consolidate putative class action bring vioxx purchaser plaintiff action recently voluntarily dismiss lawsuit plaintiff file class action california state court seek certification class california thirdparty payor enduser trial court deny motion class certification april court appeal affirm rule december january plaintiff file petition review california supreme court table content old merck name defendant twentyone separate lawsuit bring government entity include attorney general thirteen state county city new york private citizen bring qui tam taxpayer derivative suit action allege old merck misrepresented safety vioxx seek recovery cost vioxx purchase reimburse government entity agencies ii reimbursement sum pay government entity agency medical service treatment person injure vioxx iii damage common law theory andor iv remedy state statutory theory include state consumer fraud andor fair business practice medicaid fraud statute include civil penalty thirteen case pende mdl proceed subject conditional order transfer mdl proceed remand state court lawsuit bring county class action file santa clara county california behalf similarly situate california county old merck motion summary judgment grant november case bring attorney general texas schedule trial early texas attorney general appeal michigan attorney general case old merck currently seek appellate review trial court order deny old merck motion dismiss trial court enter stay proceeding include discovery pende result appeal finally attorney general action mdl describe previous paragraph discovery phase louisiana attorney general case currently schedule trial mdl court april shareholder lawsuit previously disclose addition vioxx product liability lawsuit old merck current officer director defendant putative class action individual lawsuit federal security law state security law vioxx security lawsuit vioxx security lawsuit pende federal court transfer judicial panel multidistrict litigation jpml district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx security lawsuit purpose putative class action request damage behalf purchaser old merck stock october allege defendant false misleading statement vioxx violation section b securities exchange act seek unspecified compensatory damage cost suit include attorney fee complaint assert claim section security exchange act certain defendant relate sale old merck stock section security act certain defendant base statement registration statement certain prospectus file connection old merck stock investment plan dividend reinvestment plan april judge chesler grant defendant motion dismiss complaint prejudice plaintiff appeal judge chesler decision court appeal circuit september circuit issue opinion reverse judge chesler order remand case district court old merck file petition writ certiorari united states supreme court january supreme court grant oral argument hold november decision expect half petition certiorari pende plaintiff file consolidated fifth amend class action complaint district court old merck file motion dismiss complaint follow district court proceeding stay pende outcome supreme court appeal motion dismiss district court withdraw prejudice old merck right refile motion pende outcome supreme court appeal october dutch pension fund file complaint district new jersey allege violation federal security law violation state law old merck certain officer pursuant case management order govern shareholder mdl case base allegation vioxx security lawsuit consolidate vioxx security lawsuit defendant motion dismiss pension fund complaint file august september dutch pension fund file amend complaint respond defendant motion dismiss addition new complaint file district new jersey behalf foreign institutional investor allege violation federal security law violation state law old merck certain officer stipulation table content defendant require respond complaint resolution motion dismiss consolidated security action addition previously disclose putative class action file federal court employee retirement income security act erisa old merck certain current officer director vioxx erisa lawsuit vioxx security lawsuit vioxx derivative lawsuit describe vioxx shareholder lawsuit transfer shareholder mdl consolidated purpose consolidate complaint assert claim breach fiduciary duty behalf certain old merck current employee participant certain old merck retirement plan complaint make similar allegation respect vioxx allegation contain vioxx security lawsuit july judge chesler grant deny defendant motion dismiss erisa complaint october plaintiffs move certification class individual participant beneficiary old merck retirement saving plan time october september plan account include investment old merck common stock fund andor old merck common stock february court deny motion certification class count grant motion remain count court exclude class definition individual injure connection investment old merck stock ii execute post separation settlement agreement release claim erisa march judge chesler deny defendant motion judgment pleading judge chesler enter order deny plaintiff motion partial summary judgment certain individual defendant file december previously disclose october individual shareholder demand old merck board legal action mr raymond gilmartin chairman president chief executive officer individual allegedly cause damage old merck respect allegedly improper marketing vioxx december special committee board director retain honorable john martin jr debevoise plimpton llp conduct independent investigation thing allegation set forth demand judge martin report public september base special committee recommendation careful consideration martin report impact derivative litigation old merck board reject demand october shareholder file shareholder derivative lawsuit purportedly old merck behalf state court atlantic county new jersey current officer director old merck plaintiff allege board rejection demand unreasonable improper defendant breach duty old merck allow vioxx market party reach propose settlement february court issue order preliminarily approve settlement require notice propose settlement merck shareholder set hearing consider final approval settlement march february merck notify shareholder propose settlement term propose settlement merck agree certain corporate governance change supplement policy procedure previously establish company agree pay award fee expense plaintiff attorney determined court exceed million addition merck plaintiff individual defendant exchange mutual release claim assert derivative action propose settlement constitute admission liability wrongful conduct merck defendant name action approve court propose settlement resolve federal consolidated shareholder derivative action describe previously disclose shareholder derivative action file federal court transfer shareholder mdl consolidated purpose judge chesler vioxx derivative lawsuit judge chesler grant defendant motion dismiss ground plaintiff fail demonstrate demand excuse deny plaintiff request leave amend complaint plaintiff appeal argue judge chesler err deny plaintiff leave amend complaint document acquire stipulation party july united states court appeal circuit reverse district court decision ground judge chesler allow plaintiff seek leave amend complaint document acquire stipulation remand case district court consideration additional material plaintiff propose amendment table content futile plaintiff file brief support request leave amend complaint propose amend complaint november court deny motion june dismiss case plaintiff appeal judge chesler decision united states court appeal circuit oral argument appeal hold july november decision issue appeal stay pende approval settlement reach derivative action pende new jersey superior court resolve state federal shareholder derivative claim relate vioxx international lawsuit previously disclose addition lawsuit discuss old merck name defendant litigation relate vioxx country collectively vioxx foreign lawsuit europe canada brazil argentina australia turkey israel philippines singapore november superior court quebec authorize institution class action behalf individual quebec consume vioxx suffer damage arise ingestion plaintiff serve introductory motion class action base authorization case remain preliminary stage litigation provincial court queen bench saskatchewan canada enter order certify class vioxx user canada quebec old merck appeal certification order march court appeal grant old merck appeal quash certification order october supreme court canada dismiss plaintiff appeal application decide review judgment saskatchewan court appeal july superior court ontario deny old merck motion stay class proceeding ontario decide certify overlap class vioxx user canada quebec saskatchewan allege negligence entitlement elect waive tort february ontario divisional court dismiss appeal order deny stay ontario court appeal deny leave appeal october supreme court canada dismiss old merck application decide review judgment ontario court appeal court appeal saskatchewan quash multijurisdictional certification order enter province old merck applied ontario court appeal leave appeal ontario certification order leave appeal grant appeal file accordance court decision old merck sought leave appeal divisional court deny december procedural decision canadian litigation address merit plaintiff claim litigation canada remain early stage trial representative action australia commence march federal court australia name plaintiff allege suffer mi seek represent australia ingest vioxx suffer mi thrombotic stroke unstable angina transient ischemic attack peripheral vascular disease march trial judge enter order direct advance issue proceed issue determine trial issue fact law name plaintiff individual case issue fact law trial judge find hear evidence common claim group member name plaintiff allege represent trial representative action conclude june trial judge reserve decision insurance previously disclose company director officer insurance coverage applicable vioxx security lawsuit vioxx derivative lawsuit state upper limit approximately million company fiduciary insurance vioxx erisa lawsuit state upper limit approximately million result previously disclose arbitration additional insurance coverage claim available need upperlevel excess policy provide coverage variety risk dispute insurer availability company insurance coverage claim likely additional dispute amount actually recover policy discuss paragraph state upper limit table content investigation previously disclose old merck receive subpoenas department justice doj request information relate old merck research marketing selling activity respect vioxx federal health care investigation criminal statute investigation include subpoenas witness appear grand jury previously disclose march old merck receive letter attorney office district massachusetts identify target grand jury investigation vioxx previously disclose investigation conduct local authority certain city europe order determine criminal charge bring concern vioxx company cooperate governmental entity respective investigation vioxx investigation company predict outcome inquiry result potential civil andor criminal remedy addition old merck receive subpoena september state california attorney general seek document information relate placement vioxx california medical formulary company cooperate attorney general respond subpoena reserve discuss november old merck enter settlement agreement law firm comprise executive committee psc federal vioxx mdl representatives plaintiff counsel texas new jersey california state coordinate proceeding resolve state federal mi claim file date united states result enter settlement agreement old merck record pretax charge billion represent fix aggregate pay plaintiff qualify payment settlement program vioxx product liability lawsuit trial schedule trial company predict timing trial relate vioxx litigation company believe meritorious defense vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit include settlement program company establish reserve potential liability relate vioxx lawsuit include settlement program reserve establish connection resolution shareholder derivative lawsuit discuss vioxx investigation unfavorable outcome vioxx litigation material adverse effect company financial position liquidity result operation legal defense cost expect incur connection loss contingency accrue probable reasonably estimable december old merck aggregate reserve approximately billion vioxx reserve settlement program future legal defense cost relate vioxx litigation merck spend approximately million aggregate legal defense cost worldwide include approximately million fourth quarter relate vioxx product liability lawsuit ii vioxx shareholder lawsuit iii vioxx foreign lawsuit iv vioxx investigation collectively vioxx litigation addition old merck pay additional billion settlement fund connection settlement program merck record million charge include million fourth quarter solely future legal defense cost vioxx litigation consequently december aggregate vioxx reserve approximately million solely future legal defense cost vioxx litigation significant factor consider review vioxx reserve follow actual cost incur company development company legal defense strategy structure light scope vioxx litigation include settlement agreement expectation certain lawsuit continue pende number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial table content vioxx litigation vioxx reserve december represent company good estimate minimum defense cost incur connection remain aspect vioxx litigation event additional trial vioxx litigation event arise course vioxx litigation affect ultimate defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase vioxx reserve time future base factor set forth believe appropriate product liability litigation fosamax previously disclose old merck defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case include approximately plaintiff group file pende old merck federal state court include case seek class action certification damage andor medical monitoring action plaintiff allege thing suffer osteonecrosis jaw generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax addition plaintiff approximately percent action allege sustain stress andor low energy femoral fracture association use fosamax august jpml order fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax mdl coordinated pretrial proceeding fosamax mdl transfer judge john keenan district court southern district new york result jpml order approximately case judge keenan judge keenan issue case management order amendment thereto set forth schedule governing proceeding focus primarily resolve class action certification motion complete fact discovery initial group case october briefing argument plaintiff motion certification medical monitoring class complete judge keenan issue order deny motion january january judge keenan issue order dismiss prejudice class claim assert class action lawsuit file old merck seek personal injury damage andor medical monitoring relief class wide basis daubert motion file judge keenan conduct daubert hearing july july judge keenan issue rule party respective daubert motion ruling deny plaintiff steering committee motion grant deny old merck motion mdl trial boles v merck begin august end september september mdl court declare mistrial bole person jury reach unanimous verdict consequently bole case set retry june second mdl case set trial fleming v merck schedule start january judge keenan grant old merck motion summary judgment dismiss case november mdl case set trial maley v merck currently schedule start april old merck file motion summary judgment maley mdl court grant deny january result company expect trial commence currently schedule april february judge keenan select new bellwether case judith grave v merck replace fleming bellwether case mdl court dismiss grant summary judgment favor old merck mdl court set grave trial begin september trial alabama currently schedule begin trial florida currently schedule begin june addition july application atlantic county superior court new jersey request fosamax case pende new jersey consider mass tort designation centralize management judge new jersey october new jersey supreme court order pende future action file new jersey arise use fosamax seeking damage exist dental jawrelate injury include osteonecrosis jaw solely seek medical monitoring designate mass tort centralize management purpose judge higbee atlantic county superior court december approximately case pende old table content merck new jersey coordinated proceeding july judge higbee enter case management order amendment thereto set forth schedule contemplate complete fact discovery initial group case february follow expert discovery case project trial date july case try new jersey coordinated proceeding discovery ongoing fosamax mdl litigation new jersey coordinated proceed remain jurisdiction fosamax case pende company intend defend lawsuit december company remain reserve approximately million solely future legal defense cost fosamax litigation company spend approximately million add million reserve consequently december company reserve approximately million solely future legal defense cost fosamax litigation significant factor consider establishment reserve fosamax litigation legal defense cost follow actual defense cost incur far development company legal defense strategy structure light creation fosamax mdl number case bring company anticipate timing progression relate cost pretrial activity fosamax litigation company continue monitor legal defense cost review adequacy associate reserve uncertain nature litigation company unable reasonably estimate cost quarter company establish reserve potential liability relate fosamax litigation unfavorable outcome fosamax litigation material adverse effect company financial position liquidity result operation nuvare begin number complaint file jurisdiction assert claim company subsidiarie organon usa inc organon pharmaceuticals usa inc organon international collectively organon scheringplough arise organon marketing sale nuvare combine hormonal contraceptive vaginal ring plaintiff contend organon scheringplough fail adequately warn allege increase risk venous thromboembolism vte pose nuvare andor downplay risk vte plaintiff seek damage injury allegedly sustain product use include alleged death heart attack stroke majority case currently pende federal multidistrict litigation venue missouri new jersey state court case pende state vetsulin december scheringplough animal health name defendant putative class action lawsuit file district court northern district ohio lawsuit entitle friedman v scheringplough animal health individual plaintiff seek represent class people purchase vetsulin household pet suit allege vetsulin contaminate improperly manufacture vetsulin insulin product administer diabetic dog cat plaintiff seek compensatory punitive damage base theory negligence violation consumer sale practice act breach warranty product liability allegedly defective manufacturing merck intend defend lawsuit vigorously commercial litigation awp litigation investigation previously disclose old merck join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level complaints allege violation federal state law include fraud medicaid fraud consumer protection violation claim outcome litigation investigation include substantial damage imposition substantial fine penalty injunctive administrative remedy jpml order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action expand number manufacturer include like old merck defendant prior pende case court grant old merck motion dismiss consolidated class action dismiss old table content merck class action case old merck pharmaceutical manufacturer defendant similar complaint pende federal state court include case bring individually number county state new york county case consolidate new york state court old merck dismiss suffolk county case new york county case file addition new york county case december old merck defendant state case bring attorney general state defend february kansas attorney general file suit old merck manufacturer awp claim bring attorney general arizona old merck drop court awp case pende hawaii list old merck set trial mid scheringplough reach settlement claim relate awp august scheringplough pharmaceutical company settle claim bring behalf alabama medicaid program combine total million addition july scheringplough reach settlement relator acting behalf united states non intervene awp qui tam action pende federal district court massachusetts states california florida combine total million settlement resolve claim bring behalf medicaid programs states california florida approve district court district massachusetts hold preclusive claim federal share allege medicaid overpayment remain state consistent applicable precedent january district court district massachusetts hold unit scheringplough drug maker overcharge new york city new york county certain generic drug court reserve issue damage penalty future proceeding company continue respond litigation bring certain state private payor investigation initiate department health human services department justice state awp company cooperate investigation centocor distribution agreement centocor wholly own subsidiary johnson johnson deliver scheringplough notice initiate arbitration proceeding resolve result merger centocor permit terminate company right distribute commercialize remicade simponi sale remicade simponi include company result postmerger period million million respectively sale remicade recognize scheringplough prior merger billion arbitration process involve number step include selection independent arbitrator information exchange hearing final decision reach hearing arbitration schedule commence late september unfavorable outcome arbitration material adverse effect company financial position liquidity result operation governmental proceeding previously disclose february old merck enter corporate integrity agreement cia department health human service office inspector general hhsoig fiveyear term cia require thing old merck maintain ethic training program policy procedure govern promotional practice medicaid price reporting require cia old merck retain independent review organization iro conduct system review promotional policy procedure conduct sample basis transactional review old merck promotional program certain medicaid pricing calculation old merck require provide regular report certification hhsoig compliance cia similarly previously disclose scheringplough scheringplough enter cia hhsoig fiveyear term august enter addendum cia effective year requirement old merck scheringplough cia similar identical failure comply cia requirement result financial penalty exclusion participation federal health care program company believe promotional practice medicaid price report meet requirement cia table content vytorinzetia litigation previously disclose legacy company receive letter house committee energy commerce subcommittee oversight investigation oi rank minority member senate finance committee collectively seek combination witness interview document information variety issue relate enhance clinical trial sale promotion vytorin sale stock corporate officer addition previously disclose august old merck scheringplough receive additional letter oi include identical letter date february seek certain information document relate seas clinical trial previously disclose legacy company receive subpoenas new york state attorney general office letter connecticut attorney general seek similar information document july legacy company announce reach civil settlement attorney general represent state district columbia resolve previously disclose investigation group legacy company violate state consumer protection law market vytorin zetia settlement legacy company agree reimburse investigative cost state district columbia total million voluntary assurance compliance relate promotion vytorin zetia include agree continue comply food drug cosmetic act food drug administration amendment act law require truthful nonmisleading marketing pharmaceutical product settlement include admission misconduct liability legacy company furthermore previously disclose september legacy company receive letter civil division doj inform doj investigate conduct relate promotion vytorin cause false claim submit federal health care program company cooperate investigation respond inquiry previously disclose legacy company aware serve approximately civil class action lawsuit allege common law state consumer fraud claim connection msp partnership sale promotion vytorin zetia certain lawsuit allege personal injury andor seek medical monitoring lawsuit old merck scheringplough consolidated single multidistrict litigation docket judge cavanaugh district new jersey vytorinzetia marketing sale practice product liability litigation august old merck scheringplough jointly announce cholesterol joint venture enter agreement resolve total fix million civil class action lawsuit msp partnership record charge second quarter february judge cavanaugh grant final approval settlement previously disclose april old merck shareholder file putative class action lawsuit federal court eastern district pennsylvania allege old merck chairman president chief executive officer richard clark violate federal security law suit withdraw refiled district new jersey consolidate federal security lawsuit caption merck co inc vytorin security litigation amend consolidated complaint file october name defendant old merck merckscheringplough pharmaceutical llc certain company current officer director specifically complaint allege old merck delay release unfavorable result enhance clinical trial efficacy vytorin old merck false misleading statement expect earning know result vytorin study release sale vytorin decline old merck earning suffer december old merck defendant move dismiss lawsuit ground plaintiff fail state claim relief grant september court issue opinion order deny defendant motion dismiss lawsuit october old merck defendant file answer amend consolidated complaint similar consolidated putative class action security lawsuit pende district new jersey file scheringplough shareholder scheringplough chairman president chief executive officer fre hassan caption scheringplough corporationenhance security litigation amend consolidated complaint file september name defendant schere plough merckscheringplough pharmaceutical llc certain company current officer director underwriter participate august public offering scheringplough common prefer stock december scheringplough table content defendant file motion dismiss lawsuit ground plaintiff fail state claim relief grant september court issue opinion order deny defendant motion dismiss lawsuit september defendant file motion reconsideration court september opinion order deny motion dismiss motion reconsideration fully brief october decision remain pende defendant file answer consolidate amend complaint november previously disclose april member old merck erisa plan file putative class action lawsuit old merck certain company current officer director alleging breach fiduciary duty erisa time similar erisa lawsuit file old merck district new jersey lawsuit consolidate caption merck co inc vytorin erisa litigation consolidate amend complaint file february name defendant old merck current member company board director plaintiff allege erisa plan investment old merck stock imprudent old merck earning dependent commercial success cholesterol drug vytorin defendant know know result scientific study cause medical community turn expensive drug cholesterol management april old merck defendant move dismiss lawsuit ground plaintiff fail state claim relief grant september court issue opinion order deny defendant motion dismiss lawsuit november plaintiff move strike certain defendant affirmative defense motion fully brief december pende court similar consolidated putative class action erisa lawsuit currently pende district new jersey file member scheringplough erisa plan schere plough certain current officer director alleging breach fiduciary duty erisa caption scheringplough corp enhance erisa litigation consolidate amend complaint file october name defendant scheringplough current member scheringploughs board director current member committee scheringploughs board director november company defendant file motion dismiss lawsuit ground plaintiff fail state claim relief grant plaintiff opposition motion dismiss file december motion fully brief january decision remain pende november stockholder company file shareholder derivative lawsuit local international brotherhood electrical worker pension fund v clark local district new jersey behalf nominal defendant company shareholder company company certain company officer director allege insider certain predecessor company officer director allege insider allege breach fiduciary duty waste unjust enrichment gross mismanagement similar shareholder derivative lawsuit cain v hassan file scheringplough stockholder currently pende district new jersey amend complaint file scheringplough stockholder behalf nominal defendant scheringplough scheringplough shareholder lawsuit scheringplough scheringplough thencurrent board director certain scheringplough current officer director allege insider plaintiff local cain v hassan allege defendant withhold enhance study result false misleading statement deceive cause harm company scheringplough respectively invest public unjustly enrich insider waste corporate asset defendant local intend dismiss plaintiff complaint defendant cain v hassan move dismiss amend complaint july motion fully brief october decision remain pende company intend defend lawsuit refer section unfavorable outcome result government investigation civil litigation material adverse effect company financial position liquidity result operation table content november individual shareholder previously deliver letter old merck board director demand board legal action responsible individual recover amount pay old merck resolve certain governmental investigation deliver letter board demand board subcommittee thereof commence investigation matter raise civil suit governmental investigation relate vytorin security class action litigation federal security litigation follow scheringploughs announcement february fda conduct inspection manufacture facility new jersey puerto rico issue report cite deficiency concern compliance current good manufacturing practice delay approval clarinex lawsuit file scheringplough certain name officer lawsuit allege defendant violate federal security law allegedly fail disclose material information make material misstatement specifically allege scheringplough fail disclose allege risk new drug application clarinex delay result manufacturing issue allege company fail disclose allege depth severity manufacturing issue complaint consolidate action district court district new jersey consolidated amend complaint file october purport represent class shareholder purchase share scheringplough stock february complaint seek compensatory damage behalf class february court sign order preliminarily approve settlement agreement scheringplough provide settlement fund million resolve claim class fund place escrow time vast majority settlement cover insurance december district court grant final approval settlement settlement consummated expiration appeal period final approval decision erisa litigation march scheringplough serve putative class action complaint file district court new jersey allege scheringplough employee saving plan plan administrator current director certain corporate officer breach fiduciary obligation certain participant plan complaint seek damage loss allegedly suffer plan complaint dismiss june plaintiff appeal august court appeal circuit reverse dismissal district court matter remand district court proceeding september district court enter order grant deny name putative class representative motion class certification scheringplough petition district court appeal circuit leave appeal class certification decision scheringplough petition grant december december circuit vacate district court order remand case proceeding consistent court rule kdur antitrust litigation june january scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upshersmith file abbreviate new drug application follow commencement administrative proceeding united states federal trade commission ftc allege anticompetitive effect settlement resolve scheringploughs favor allege class action suit file federal state court behalf direct indirect purchaser kdur scheringplough upshersmith lederle suit claim violation federal state antitrust law state statutory common law cause action suit seek unspecified damage february special master recommend district court district new jersey dismiss class action lawsuit summary judgment district court judge rule recommendation table content thirdparty payor action discuss july connection settlement investigation doj attorney office eastern district pennsylvania schering plough enter fiveyear cia cia amend august connection million settlement investigation state massachusetts involve certain scheringplough sale marketing clinical trial practice program massachusetts investigation purport class action litigation file follow announcement settlement massachusetts investigation plaintiff action seek damage behalf thirdparty payor result allegation offlabel promotion improper payment physician issue massachusetts investigation action consolidate multidistrict litigation federal district court district new jersey july district court dismiss consolidated class action complaint grant plaintiff leave refile september plaintiff file amend complaint company motion dismiss complaint pende vaccine litigation previously disclose old merck party individual class action product liability lawsuit claim united states involve pediatric vaccine eg hepatitis b vaccine contain thimerosal preservative vaccine december approximately thimerosal relate lawsuit pende old merck defendant vast majority lawsuit currently active defendant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result exposure thimerosal pediatric vaccine case currently schedule trial company defend lawsuit possible unfavorable outcome material adverse effect company financial position liquidity result operation old merck successful case type dismiss stay ground action prohibit national childhood vaccine injury act vaccine act vaccine act prohibit person file maintain civil action state federal court seek damage vaccine manufacturer vaccinerelate injury petition file united states court federal claim hereinafter vaccine court vaccine act file civil action vaccine manufacturer petitioner pursue petition conclusion vaccine court timely file election proceed civil action lieu accept vaccine court adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribe time period old merck party vaccine court proceeding petition bring united states department health human service company aware approximately case pende vaccine court involve allegation thimerosalcontaine vaccine andor mmr ii vaccine cause autism spectrum disorder thimerosalcontaine vaccine involve vaccine court proceeding company vaccine company sole source mmr ii vaccine domestically special master preside vaccine court proceeding hold hearing test case involve theory combination mmr ii vaccine thimerosal vaccine cause autism spectrum disorder february special master issue decision case find theory unsupported valid scientific evidence petitioner case entitle compensation case currently appeal special master hold similar hearing different test case involve theory thimerosal vaccine cause autism spectrum disorder decision issue second set test case special master previously indicate hold similar hearing involve theory mmr ii cause autism spectrum disorder state long intend vaccine court indicate intend use evidence present test case hearing guide adjudication remain autism spectrum disorder case table content patent litigation time time generic manufacturer pharmaceutical product file andas fda seek market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market united states generic forms fosamax nexium singulair emend cancidas respectively prior expiration old mercks astrazenecas case nexium patent concern product addition anda submit fda seek market united states generic form zetia anda submit fda seek market united states generic form vytorin prior expiration scheringplough patent concern product generic company anda generally include allegation noninfringement invalidity unenforceability patent company file patent infringement suit federal court company file andas generic alendronate fosamax montelukast singulair astrazeneca company file patent infringement suit federal court company file andas generic esomeprazole nexium company scheringplough file patent infringement suit federal court company file andas generic version ezetimibe zetia ezetimibesimvastatin vytorin schere corp schering subsidiary company file patent infringement suit federal court generic company file andas generic version temodar integrilin levitra nasonex similar patent challenge exist certain foreign jurisdiction company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product february scheringplough receive notice generic company indicate file anda zetia challenge patent list zetia prior merger company market zetia joint venture msp singapore company llc march scheringplough msp singapore company llc file patent infringement suit glenmark pharmaceuticals inc usa parent corporation glenmark lawsuit automatically stay fda approval glenmark anda october adverse court decision whichever occur early trial matter schedule commence previously disclose february old merck receive notice teva pharmaceuticals inc teva generic company indicate file anda montelukast challenge patent list singulair april old merck file patent infringement action teva trial matter hold february august court issue decision uphold validity old merck singulair patent order tevas anda approve prior expiry old merck exclusivity right august teva appeal decision january teva withdraw appeal trial court decision uphold validity old merck singulair patent addition united states patent trademark office grant petition article partner llc reexamine old merck singulair patent december united states patent trademark office issue notice indicating allow claim company singulair patent product exclusivity accordingly expect maintain august federal court canada trial division issue decision refuse bar approval generic alendronate ground old merck patent weekly alendronate likely invalid decision appeal generic alendronate launch canada june july old merck sue federal court canada apotex corp apotex seek damage lose sale generic weekly alendronate patent proceeding october federal court canada issue decision awarding apotex lose profit generic alendronate product period time hold market old merck lawsuit june trial court decision uphold company seek leave appeal supreme court canada january supreme court canada decline hear appeal leave intact decision apotex entitle damage discrete period time market entry postpone litigation launch old merck table content previously disclose september old merck appeal decision opposition division european patent office epo revoke company patent europe cover onceweekly administration alendronate march board appeal epo uphold decision opposition division revoke patent march epo issue patent europe old merck cover onceweekly administration alendronate term new patent effective july old merck sue multiple party european country assert european patent cover onceweekly dose fosamax decision render netherlands belgium invalidate patent country old merck appeal decision opposition file epo patent hearing hold march opposition division epo issue appealable decision revoke patent old merck appeal decision addition previously disclose japan proceeding file challenging validity old merck japanese patent onceweekly administration alendronate patent office invalidate patent decision appeal october patent dorzolamide cover trusopt cosopt expire old merck experience significant decline sale product company involve litigation proceeding correspond patent canada great britain germany november trial court great britain issue decision find old merck cosopt patent invalid canada trial hold december company canadian trusopt cosopt patent company await decision old merck astrazeneca receive notice october ranbaxy file anda esomeprazole magnesium anda contain paragraph iv challenge patents nexium november old merck astrazeneca sue ranbaxy district court new jersey previously disclose astrazeneca old merck ranbaxy enter settlement agreement provide ranbaxy bring generic esomeprazole product market united states company astrazeneca receive cid ftc july settlement agreement ranbaxy company cooperate ftc respond cid old merck astrazeneca receive notice january ivax pharmaceuticals inc ivax subsequently acquire teva file anda esomeprazole magnesium anda contain paragraph iv challenge patent nexium march old merck astrazeneca sue teva district court new jersey january astrazeneca old merck tevaivax enter settlement agreement provide tevaivax bring generic esomeprazole product market united states addition january old merck astrazeneca sue dr reddys laboratories dr reddys district court new jersey base dr reddys filing anda esomeprazole magnesium trial schedule january respect ivaxs dr reddys andas postpone new trial date set old merck astrazeneca receive notice december sandoz inc sandoz file anda esomeprazole magnesium anda contain paragraph iv challenge patent nexium january old merck astrazeneca sue sandoz district court new jersey base sandozs file anda esomeprazole magnesium addition old merck astrazeneca receive notice september lupin ltd lupin file anda esomeprazole magnesium anda contain paragraph iv challenge patents nexium october old merck astrazeneca sue lupin district court new jersey base lupins file anda esomeprazole magnesium january old merck receive notice sandoz file anda challenge old merck patent list fda orange book emend february old merck file patent infringement suit sandoz lawsuit automatically stay fda approval sandozs anda july adverse court decision whichever occur early case schedule trial december europe old merck aware company seek registration generic losartan active ingredient cozaar hyzaar old merck patent right losartan license ei du pont de nemour table content company du pont old merck du pont file patent infringement proceeding company portugal spain norway finland belgium netherlands austria october old merck receive notice teva parenteral medicine tpm file anda caspofungin acetate challenge patent list fda orange book cancidas november company file patent infringement suit tpm lawsuit automatically stay fda approval tpms anda april adverse court decision whichever occur early november schering receive notice apotex file anda mometasone furoate nasal spray challenge patent list fda orange book nasonex december schering file patent infringement suit apotex lawsuit automatically stay fda approval apotexs anda adverse court decision whichever occur early november scheringplough receive notice mylan file anda ezetimibesimvastatin challenge patent list fda orange book vytorin december scheringplough file patent infringement suit mylan lawsuit automatically stay fda approval mylans anda adverse court decision whichever occur early july schering licensor cancer research technology limited crt receive notice barr laboratories barr subsidiary teva barr file anda temodar challenge crt patent temozolomide july schering crt file patent infringement action barr january court issue decision find crt patent unenforceable ground prosecution lache inequitable conduct schere crt process appeal decision january schering licensor millennium receive notice teva file anda eptifibatide challenge millennium patent list fda orange book integrilin february schering millennium file patent infringement action teva lawsuit automatically stay fda approval tevas anda august adverse court decision whichever occur early schere bayer schering pharma ag bayer healthcare pharmaceutical receive notice teva file anda vardenofil challenging bayer patent list fda orange book levitra june schering bayer file patent infringement action teva lawsuit automatically stay fda approval tevas anda november adverse court decision whichever occur early legal proceeding relate merger connection merger separate class action lawsuit bring old merck scheringplough challenge merger seek form relief previously disclose lawsuit settle pende court approval settlement approve court resolve release claim brought shareholder old merck scheringplough challenging aspect propose merger include merger disclosure claim litigation french matter base complaint french competition authority competitor france pursuant court order french competition authority obtain document french subsidiary company relate subutex product subsidiary market sell resolution matter adverse french subsidiary result imposition civil fine injunctive administrative remedy july juge des libert et de la dtention order annulment search seizure procedural ground july french authority appeal order french supreme court french supreme court overturn annulment remand case paris court appeal table content basis juge des libert et de la dtention examine document assess seize lawfully seize case pende paris court appeal april competitor request interim relief portion grant french competition authority december interim relief require company french subsidiary publish specialized newspaper information include generic quantitative qualitative composition pharmaceutical form substitutable subutex february paris court appeal confirm decision french competition authority january french supreme court confirm decision french competition authority legal proceeding principally product liability intellectual property suit involve company pende feasible predict outcome proceeding proceeding discuss note opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company proceeding separate assessment provide note environmental matter company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability de minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party previously disclose approximately plaintiff file amend complaint old merck defendant district court eastern district california assert claim clean water act resource conservation recovery act negligence nuisance suit seek damage personal injury diminution property value medical monitoring allege real personal property damage associate groundwater soil contamination find site old merck subsidiary merce california old merck intend defend claim management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year table content equity accordance new merck certificate incorporation share common stock share prefer stock authorize authorize share prefer stock series share designate mandatory convertible preferred stock mandatory convertible preferred stock prior merger august scheringplough issue share scheringplough preferred stock connection merger holder schere plough preferred stock receive preferred stock right substantially similar right scheringplough prefer stock accordance new merck restate certificate incorporation result merger prefer stock subject makewhole acquisition provision prefer stock effective november makewhole acquisition conversion period end november prefer stock convertible makewhole conversion rate share prefer stock convert period holder receive cash new merck common share holder receive dividend makewhole payment depend date conversion total share prefer stock convert share new merck common stock cash payment approximately million holder convert addition makewhole dividend payment million holder convert represent present value remain future dividend payment conversion date mandatory conversion date august discount rate stipulate preferred stock designation december share prefer stock remained issue outstanding outstanding share automatically convert common share company cash august pursuant provision new merck restate certificate incorporation holder elect convert time prior august prefer stock million december classify current liability conversion settle combination cash common stock additionally certain condition company elect cause conversion merck prefer stock outstanding preferred stock accrue dividend annual rate share outstanding dividend cumulative date issuance extent company legally permit pay dividend board director declare dividend payable company pay dividend dividend payment date remain dividend payment date february august capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january issuance share connection merger issuance share connection acquisition novacardia inc issuance purchase treasury stock cancellation treasury stock balance december issuance primarily reflect activity sharebase compensation plan pursuant merger agreement certain old merck treasury share cancel table content noncontrolle interest connection restructure ami old merck assume billion par value prefer stock obligation dividend rate annum carry kbi include noncontrolle interest small portion prefer stock carry kbi convertible kbi common share prefer security convertible company common share include common share issuable purpose compute earning common share assume dilution available common shareholder note sharebased compensation plan company sharebase compensation plan employee nonemployee director employee certain company equity method investee grant option purchase share company common stock fair market value time grant addition stock option company grant performance share unit psus restrict stock unit rsus certain management level employee plan approve company shareholder result merger scheringplough stock incentive plan scheringplough sip amend restate sharebased compensation instrument remain available future grant scheringplough sip new merck employee employee scheringplough prior merger outstanding sharebased compensation instrument sharebase compensation instrument available future grant old merck new merck incentive plan result merger certain sharebased compensation instrument previously grant scheringplough sip legacy scheringplough incentive plan exchange new merck replacement awards awards relate precombination service payable cash addition certain stock option scheringplough legacy incentive plan contain lockin feature award holder elect receive cash payment stock option fix base price scheringplough common stock day prior merger liability associate provision million december expiration exercise period associate lockin feature reclassify liability equity fair value replacement award attributable precombination service million include calculation consideration transfer note significant portion legacy scheringplough award vest opening balance sheet time merger scheringplough sharebased compensation instrument immediately vest completion merger exchange new merck replacement award generally vest basis original grant scheringplough legacy incentive plan immediately vest employee terminate company year merger certain circumstance fair value new merck replacement award attribute postcombination service recognize compensation cost subsequent merger requisite service period award december million share collectively authorize future grant company sharebase compensation plan prior merger employee share base compensation award settle primarily treasury share subsequent merger award settle newly issue share employee stock option grant purchase share company stock fair market value time grant award generally vest onethird year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest nonforfeitable dividend equivalent fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price fair value stock option rsu psu replacement award determine fix time merger psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize table content base ultimate number share issue rsu psu distribution share company stock end vest performance period generally year subject term applicable award total pretax sharebase compensation cost record million million million respectively relate income tax benefit million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield riskfree interest rate volatility term option expect dividend yield base historical pattern dividend payment riskfree rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represents expect time option grant expect outstanding base historical forecast exercise behavior weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term value balance january grant replacement award exercise forfeited outstanding december exercisable december additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option fair value stock option vest exclude fair value option vest result merger attributable precombination service table content summary nonveste rsu psu activity share thousand follow rsus psus weighted weight average average number grant date number grant date share fair value share fair value nonveste january grant replacement award vest forfeited nonveste december december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expenses pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary pension benefit united states base formula consider final average pay year credit service addition company provide medical dental life insurance benefit principally eligible retiree similar benefit dependent postretirement benefit plan company use december yearend measurement date pension plan postretirement benefit plan net cost pension postretirement benefit plan consist follow component p ostretir em ent pension benefit benefit year end december service cost interest cost expect return plan asset net amortization termination benefit curtailment settlement net pension postretirement cost net pension postretirement benefit cost total million million million increase compare primarily million cost associate scheringplough benefit plan date merger december net pension cost attributable plan include table million million million connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity net curtailment gain record curtailment loss record pension plan net curtailment gain record postretirement benefit plan table content addition settlement loss record certain domestic international pension plan employee benefit plan exception recognition fair value measurement principle business combination employee benefit plan obligation recognize measured accordance exist authoritative literature accounting benefit plan fair value accordingly company remeasure benefit plan sponsor scheringplough recognize asset liability fund status plan merger date summarize information change plan asset benefit obligation fund status amount record december follow pen io n benef post r et irement b enefit fair value plan asset january actual return plan asset company contribution scheringplough merger effect exchange rate change benefit pay fair value plan asset december benefit obligation january service cost interest cost scheringplough merger actuarial loss gain benefit pay effect exchange rate change plan amendment curtailment termination benefit benefit obligation december fund status december recognize asset accrue current liability defer income taxis noncurrent liability fair value pension plan asset include precede table billion billion pension project benefit obligation plan include table billion billion increase fair value pension project benefit obligation plan primarily relate merger approximately company pension project benefit obligation relate international define benefit plan individual plan significant relative total benefit obligation table content december accumulate benefit obligation billion billion respectively pension plan december accumulate benefit obligation pension plan billion billion respectively pension plan benefit obligation excess plan asset december fair value plan asset billion billion respectively benefit obligation billion billion respectively plan accumulate benefit obligation excess plan asset december fair value plan asset billion million respectively accumulate benefit obligation billion million respectively discuss note december company adopt new authoritative guidance issue fasb revise disclosure requirement plan asset define pension postretirement plan amend guidance require disclosure investment allocation decision major category plan asset input valuation technique measure fair value plan asset effect fair value measurement significant unobservable input level change plan asset period significant concentration risk plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level quote price active market identical asset liability plan level asset primarily include register investment company mutual fund equity security level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability plan level asset primarily include investment commoncollective trust certain fix income investment government agency security corporate obligation level unobservable input support little market activity financial instrument value determine pricing model discount cash flow methodology similar technique instrument determination fair value require significant judgment estimation plan level asset primarily include investment insurance contract real estate fund value methodology management understand plan level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique plan level investment real estate generally value market appraisal infrequent nature december million approximately company pension investment categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument table content fair value companys pension plan asset december asset category follow f air value sureman ts quote price significant active significant market observable unobservable identical asset input input level level level total asset cash cash equivalent security lending collaterial shortterm investment equity security large cap smallmid cap nonus develop market emerge market fix income security government agency obligation corporate obligation mortgage asset back security fix income obligation type investment insurance contract real estate derivative liability liability return collateral security loan table provide summary change fair value include net transfer andor financial asset measure fair value significant unobservable input level company pension plan asset actual ur n plan sset relate begin asset end balance hold relate purchase schere balance january december asset sell sale plough december settlement net merger insurance contract real estate total table content fair value company postretirement benefit plan asset december asset category follow fair value e asurement u sing quote price significant active significant market observable unobservable identical asset input input level level level total asset cash cash equivalent securite lend collateral shortterm investment equity security large cap smallmid cap nonus develop market emerge market fix income security corporate obligation government agency obligation mortgage asset back security fix income obligation total investment liabilitie liability return collateral security loan total pension postretirement benefit plan asset exclude fair value hierarchy include shortterm payable receivables relate purchase sale investment respectively company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline contribution pension plan postretirement benefit plan expect approximately million million respectively table content expect benefit payment follow pension postretirement benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee follow amount reflect component comprehensive income p ostretire ent pension plan benefit plan year end december net gain loss arise period prior service cost credit arise period net loss amortization include benefit cost prior service cost credit amortization include benefit cost estimate net loss prior service cost credit amount amortize aoci net pension postretirement benefit cost million million respectively pension plan million million respectively postretirement benefit plan table content company reassesse benefit plan assumption regular basis weight average assumption determine pension plan pension postretirement benefit plan information follow u pensi ther postretirement pension plan benefit plan december net cost discount rate expect rate return plan asset salary growth rate benefit obligation discount rate salary growth rate net cost rate precede table include cost associate scheringplough benefit plan date merger december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determined country basis develop expect rate return country longterm historical return datum consider actual return plan asset capital market experience reference information longterm return expectation asset category weight average expect return countrys target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate company expect rate return range compare range pension postretirement benefit plan health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate percentage point change health care cost trend rate follow effect e percentag e point increase decrease effect total service interest cost component effect benefit obligation company maintain define contribution saving plan unite states include plan assume connection merger company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively table content income expense net year end december interest income interest expense exchange gain loss net decline interest income compare primarily result low interest rate change investment portfolio mix cash shorterdate security anticipation merger increase interest expense largely million commitment fee incremental interest expense relate financing merger include net billion gain result recognize merck previously hold equity interest msp partnership fair value result obtain control msp partnership merger note include net billion gain sale old merck interest merial note million investment portfolio recognize net gain million charge relate settlement vioxx thirdparty payor litigation united states include net aggregate gain distribution azlp billion note gain million relate sale remain worldwide right aggrastat million expense contribution merck company foundation million investment portfolio recognize net loss million charge relate resolution investigation old merck violate state consumer protection law respect sale marketing vioxx fluctuation exchange loss gain primarily high cost foreign currency contract low interest rate unfavorable impact periodtoperiod change foreign currency exchange rate net long net short foreign currency position consider net monetary asset relate foreign currency contract change net primarily reflect aggregate gain azlp billion impact million charge relate resolution certain civil governmental investigation gain million relate sale remain worldwide right aggrastat partially offset million expense contribution merck company foundation high investment portfolio recognize net loss million million charge relate resolution investigation old merck violate consumer protection law respect sale marketing vioxx interest pay million million million respectively exclude commitment fee table content tax income reconciliation effective tax rate statutory rate follow tax rate tax rate tax rate statutory rate apply income taxis differential arise gain equity investment foreign earning tax rate change state tax settlement foreign tax credit utilization amortization purchase accounting adjustment restructure state taxis inprocess research development include tax effect contingency reserve research credit export incentive miscellaneous item tax rate reconciliation percentage foreign earning reflect change mix foreign domestic earning primarily result billion vioxx settlement agreement charge income loss taxis consist year end december domestic foreign taxis income consist year end december current provision federal foreign state defer provision federal foreign state table content defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation unremitte foreign earning equity investment pension postretirement benefit compensation relate vioxx litigation reserve unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize deferred income taxis current asset asset income taxis payable deferred income taxis noncurrent liability increase defer tax asset relate pension postretirement benefit compensation relate net operating loss tax credit carryforward increase defer tax liability relate intangible unremitte foreign earning primarily reflect impact defer taxis record conjunction merger company net operating loss nol carryforward jurisdiction december significant nol carryforward approximately million united states begin expire million netherlands expire unused company tax credit carryforward research development tax credit foreign tax credit federal alternative minimum tax amt credit carryforward december company million research development credit carryforward begin expire million foreign tax credit carryforward begin expire million amt credit carryforward indefinite life valuation allowance primarily relate foreign entity nol carryforward result primarily loss generate restructuring action income taxis pay million billion billion respectively stock option exercise reduce income taxis pay million stock option exercise significant impact taxis pay table content january new authoritative guidance issue fasb accounting report uncertain tax position adopt reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position additon relate merger scheringplough reduction tax position prior year settlement lapse statute limitation balance december reflect settlement internal revenue service discuss company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion unrecognized tax benefit change month primarily anticipate closure tax examination company estimate change result reduction unrecognized tax benefit approximately million interest penalty associate uncertain tax position amount benefit expense million million million liability accrue interest penaltie billion billion december respectively previously disclose internal revenue service irs complete examination old merck tax return year result examination old merck aggregate payment billion february payment offset tax refund million receive amount previously pay matter ii federal tax benefit approximately million related interest include payment result net cash cost old merck approximately billion impact year subsequent item review examination include payment year remain open respect close irs examination material impact old merck result operation amount previously accrue old merck report result irs adjustment year state tax authority result additional tax interest penalty payment million million respectively million million respectively equivalent reduction balance unrecognize tax benefit accrue interest penalty october irs auditor assert interest rate swap scheringplough enter unrelated party recharacterize loan affiliate company result additional tax liability tax year september scheringplough payment irs million income taxis million interest scheringplough file refund claim taxis interest irs december follow irss denial scheringplough claim refund schering plough file suit district court district new jersey refund taxis interest scheringplough tax reserve adequate cover mention payment decision favor government announce august scheringplough file motion retrial motion grant scheringplough intend file appeal rd circuit previously disclose october canada revenue agency cra issue old merck notice reassessment contain adjustment relate certain intercompany pricing matter february old merck cra negotiate settlement agreement regard matter accordance settlement old merck pay additional tax approximately million dollar interest approximately million dollar additional amount penalty assessment settlement account quarter old merck previously establish reserve table content matter significant portion taxis pay expect creditable tax purpose resolution matter material effect old merck financial position liquidity respect associate collateral discuss addition july november cra propose additional adjustment respectively relate intercompany pricing matter adjustment increase canadian tax approximately million dollar plus million dollar interest december possible cra propose similar adjustment later year company disagree position take cra believe merit company intend contest assessment cra appeal process court necessary management believe resolution matter material effect company financial position liquidity connection appeal process matter discuss old merck pledge collateral financial institution provide guarantee cra quebec ministry revenue represent portion tax interest assess result settlement note guarantee require appeal dispute reduce eliminate approximately million associate collateral release certain cash investment continue collateralized guarantee require appeal canadian tax dispute collateral include defer income taxis current asset asset consolidate balance sheet total approximately million billion december respectively irs examine old merck federal income tax return addition state foreign tax examination progress significant tax jurisdiction state foreign company income tax return open examination period second quarter irs complete examination scheringplough federal income tax return company seek resolution issue raise examination irs administrative appeal process july scheringplough payment million irs pertain examination company income tax return remain open irs tax year irs commence examination federal income tax return examination expect complete significant tax jurisdiction state foreign company income tax return open examination period december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning addition company subsidiary operate puerto rico singapore tax incentive grant begin expire earning share discuss note effective january new guidance issue fasb adopt clarifie unvested sharebased payment award contain nonforfeitable right dividend dividend equivalent pay unpaid consider participate security shall include computation earning share pursuant twoclass method provision new guidance retrospective prior period restate twoclass method earning allocation formula determine earning share common stock participate security accord dividend declare participation right undistribute earning method earning distribute undistributed allocate common share participate security base respective right receive dividend rsus certain psus grant certain management level employee note participate dividend basis common share nonforfeitable holder result rsus psus meet definition participate security table content calculation earning share twoclass method follow year end december basic earning common share net income available merck co inc common shareholder income allocate participate security net income allocate common shareholder average common share outstanding earning common share assume dilution net income available merck co inc common shareholder income allocate participate security net income allocate common shareholder average common share outstanding common share issuable average common share outstanding assume dilution issuable primarily sharebased compensation plan million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive table content comprehensive income component comprehensive income loss follow year end december pretax tax tax net unrealize loss derivative net loss realization derivative net unrealized gain investment net gain realization investment benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment year end december net unrealized gain derivative net gain realization derivative net unrealized loss investment net loss realization investment benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment year end december net unrealized loss derivative net loss realization derivative net unrealized gain investment net gain realization investment benefit plan net gain loss prior service cost credit net amortization cumulative translation adjustment increase cumulative translation adjustment merger amount represent cumulative translation adjustment relate equity investee component accumulate comprehensive loss follow december net unrealized loss gain derivative net unrealized gain investment pension plan net loss postretirement benefit plan net loss pension plan prior service cost postretirement benefit plan prior service cost cumulative translation adjustment table content include cumulative translation adjustment gain million postmerger period eurodenominate debt designate effective economic hedge net investment foreign operation segment reporting company operation principally manage product basis comprise reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sell center disease control prevention vaccine child program fund government company animal health operation discover develop manufacture market animal health product include vaccine additionally company consumer health care operation develop manufacture market otc foot care sun care products united states canada segment composition reflect certain managerial change implement segment disclosure prior period recast comparable basis include nonreportable segment include animal health consumer health care revenue company relationship azlp accounting policy segment describe describe note revenue profit segment follow pharmaceutical total year end december segment revenue segment profit include segment profit equity income affiliate depreciation amortization year end december segment revenue segment profit include segment profit equity income affiliate depreciation amortization year end december segment revenue segment profit include segment profit equity income affiliate depreciation amortization segment profit comprise segment revenue certain element material production cost operating expense include component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker merck allocate production cost standard cost research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit table content sale company product follow million pharmaceutical bone respiratory immunology dermatology singulair fosamax propecia remicade arcoxia nasonex clarinex asmanex cardiovascular vytorin zetia integrilin diabetes obesity januvia janumet infectious disease isentress primaxin cancidas invanz crixivanstocrin pegintron avelox rebetol mature brand cozaarhyzaar zocor vasotecvaseretic proscar claritin rx proventil neuroscience ophthalmology maxalt cosopttrusopt remeron subutexsuboxone oncology emend temodar caelyx intron vaccines proquadmmr iivarivax gardasil rotateq pneumovax zostavax womens health endocrine follistimpuregon nuvare pharmaceutical segment revenue total segment revenue sale legacy scheringplough product reflect result postmerger period december sales msp partnership product zetia vytorin represent sale postmerger period december prior merger sale zetia vytorin primarily recognize msp partnership result old merck interest msp partnership record equity income affiliate sale zetia vytorin reflect old merck sale product latin america msp partnership amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily include sale human pharmaceutical product include product franchise list separately reflect nonreportable segment include animal health consumer health care revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively revenue primarily comprise miscellaneous corporate revenue thirdparty manufacture sale sale relate divested product business supply sale include segment result table content consolidated revenues geographic area derive follow year end december united states europe middle east africa japan reconciliation total segment profit consolidate income taxis follow year end december segment profit profit adjustment unallocate interest income interest expense equity income affiliate depreciation amortization research development amortization purchase accounting adjustment gain related msp partnership gain merial divestiture gain distribution astrazeneca lp vioxx settlement agreement charge expense net profit primarily comprise miscellaneous corporate profit operating profit relate divested product business supply sale adjustment represent elimination effect double count certain item income expense equity income affiliate include taxis pay joint venture level portion equity income report segment profit expense net include expense corporate manufacturing cost center miscellaneous income expense net property plant equipment net geographic area locate follow december united states europe middle east africa japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director shareholders merck co inc opinion accompany consolidated balance sheet relate consolidated statement income equity cash flow present fairly material respect financial position merck co inc subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion merck maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso merck management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report item responsibility express opinion financial statement merck internal control financial reporting base integrated audits conduct audits accordance standard public company accounting oversight board united states standard require plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respect audits financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion discuss note consolidated financial statement merck change manner account unrecognized tax benefit discuss note note consolidated financial statement merck change manner account business combination discuss note consolidated financial statement merck change manner account noncontrolle interest companys internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company ii provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp florham park new jersey february table content b supplementary datum select quarterly financial datum contain condense interim financial datum table condense interim financial datum unaudite million share amount th q rd q nd q st q sale material production cost market administrative expense research development expense restructure cost equity income affiliate income expense net income taxis net income available common shareholder basic earning common share available common shareholder earning common share assume dilution available common shareholder sale material production cost market administrative expense research development expense restructure cost equity income affiliate income expense net income taxis net income available common shareholder basic earning common share available common shareholder earning common share assume dilution available common shareholder amount include gain fair value adjustment merck previously hold interest msp partnership note fourth quarter tax provision reflect favorable impact foreign exchange rate change benefit relate research development tax credit amount fourth quarter fourth quarter include impact additional vioxx legal defense reserve note amount quarter second quarter quarter include impact additional fosamax legal defense reserve note amount include gain sale old merck interest merial limited note amount reflect favorable impact tax settlement amount include gain distribution astrazeneca lp note gain related sale remain worldwide right aggrastat realization foreign tax credit expense contribution merck company foundation amount include impact merger include amortization intangible asset mergerrelate cost note amount include impact restructuring action note table content item change disagreement accountant account financial disclosure prior merger old merck historical financial statement audit pricewaterhousecooper llp pwc scheringplough historical financial statement audit deloitte touche llp deloitte closing date merger board director company dismiss deloitte company independent register public accounting firm audit report deloitte financial statement scheringplough fiscal year end december contain adverse opinion disclaimer opinion qualify modify uncertainty audit scope accounting principle scheringplough fiscal year end december scheringploughs subsequent interim period january closing date merger date dismissal deloitte regard financial statement refer disagreement deloitte matter accounting principle practice financial statement disclosure auditing scope procedure disagreement resolve deloitte satisfaction cause deloitte reference subject matter disagreement connection report ii reportable event type describe item av regulation sk item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule ae de securities exchange act amend act effective management responsible establish maintain adequate internal control financial reporting term define rule af act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission coso base evaluation management conclude internal control financial reporting effective december effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear november merck co inc scheringplough corporation complete plan merger entity period lead merger change companys internal control financial report reasonably likely material effect postmerger period management maintain operational integrity company legacy control financial reporting addition management design test new control financial reporting support accuracy financial presentation merge company operation support business integration plan process evaluate address necessary change control environment financial reporting adopt old merck previously disclose process multiyear implementation enterprise wide resource planning system company intend implement system united states implementation plan revision address combine company requirement old merck entity implement worldwide employee datum management system implementation system include modification design operation control validate component employee master datum management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement table content prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice company periodically conduct management stewardship program key management financial personnel program reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear richard clark chairman president peter n kellogg chief executive officer executive vice president chief financial officer item b information table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion item election director company proxy statement annual meeting shareholder hold information executive officer set forth document page require information compliance section security exchange act incorporate reference discussion head section beneficial ownership report compliance company proxy statement annual meeting shareholder hold company adopt code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer code conduct available company website wwwmerckcomaboutuspdf company intend post website amendment waivers code conduct print copy send charge stockholder request write chief ethic officer merck co inc merck drive whitehouse station nj require information identification audit committee audit committee financial expert incorporate reference discussion head board committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity awards fiscal yearend table option exercise stock vest table retirement plan benefit relate pension benefit table nonqualifie defer compensation relate table potential payment termination changeincontrol include discussion subheading separation separation plan payment benefit estimate table individual agreement change control change control payment benefit estimate table footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate director compensation table schedule director fee table company proxy statement annual meeting shareholder hold require information heading compensation committee interlock insider participation compensation benefit committee report incorporate reference company proxy statement annual meeting shareholder hold item security ownership certain beneficial owner management relate stockholder matter information respect security authorize issuance equity compensation plan incorporate reference discussion head equity compensation plan information company proxy statement annual meeting shareholder hold information respect security ownership certain beneficial owner management incorporate reference discussion head security ownership certain beneficial owner management company proxy statement annual meeting shareholder hold table content item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion audit committee beginning caption preapproval policy service independent register public accounting firm fee companys proxy statement annual meeting shareholder hold iv item